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ABSTRACT 
 
Corticosteroids are widely used in the treatment of chronic inflammatory diseases. 
However, in patients with chronic obstructive pulmonary disease (COPD), cystic 
fibrosis and a subset of patients with severe asthma, corticosteroids fail to improve 
the underlying inflammation. Recent advances in the cellular and molecular basis of 
the pathology in asthma and COPD have revealed several biological targets that 
may contribute to the relative corticosteroid insensitivity observed in these diseases. 
These targets include impaired glucocorticoid receptor (GR) nuclear translocation, 
reduced histone deactylase (HDAC)-2 activity and heightened pro-inflammatory 
transcription factor activity. 
 
Although in vitro and in vivo data support a role for impaired GR nuclear 
translocation as a potential mechanism of corticosteroid insensitivity in asthma, as of 
yet, no published data has confirmed this in COPD patients. Furthermore, the 
mechanisms that govern GR nuclear translocation are mostly unknown. There is 
growing evidence that excess reactive oxygen species (ROS) generated by 
inflammatory and immune cells of the lung leads to oxidative stress, which plays a 
crucial role in the amplification of redox-sensitive pro-inflammatory transcription 
factors that leads to corticosteroid insensitivity.  
 
In this PhD, I investigated the role of GR nuclear trafficking in oxidative stress-
induced corticosteroid insensitivity. In a monocytic cell line, U937 cells, we showed 
that hydrogen peroxide (H2O2), an oxidant, induced intracellular and mitochondrial 
oxidative stress. This increase in oxidative stress was associated with enhanced IL-
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1β-induced NFB activity and IL-1β-induced CXCL8 release, pro-inflammatory 
markers shown to be elevated in COPD. Pre-treatment with H2O2 significantly 
reduced corticosteroid induced GR nuclear import for budesonide (BUD) and 
fluticasone propionate (FP). This reduction in GR nuclear import was associated with 
reduced suppression of CXCL8. In our ex vivo study in patients with severe asthma 
and COPD, we observed similar findings, where BUD was unable to induce GR 
binding to glucocorticoid response elements (GRE) in patients with severe asthma 
and also, BUD at a low concentration was unable to suppress CXCL8 release in 
patients with COPD. The degree of corticosteroid insensitivity observed in our 
patients with severe asthma and COPD was limited to the above mentioned 
observations. We then investigated the nuclear transport receptors that govern 
nucleocytoplasmic shuttling of macromolecules in U937 cells and revealed that 
importin-7 is essential for corticosteroid-induced GR nuclear import. Further 
experiments identified that RanGTP, an essential co-factor for importin-7 mediated 
GR nuclear import, was reduced in our oxidative stress-induced corticosteroid 
insensitivity model. This novel finding suggests that the importin-7-RanGTP complex 
may be a potential target to overcome corticosteroid insensitivity in COPD patients. 
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 Introduction: 
Asthma and chronic obstructive pulmonary disease (COPD) are common chronic 
inflammatory lung diseases that are each characterised by different types of 
inflammation. Interestingly, some patients with asthma that smoke share a similar 
pathology to patients with COPD. Differences in the inflammatory patterns between 
these lung diseases are predominantly determined by the type of immune and 
inflammatory cells involved. These cells drive the inflammatory cascade that gives 
rise to the distinct patterns of structural changes between these diseases. Structural 
changes in the respiratory tract result in airways obstruction and airflow limitation, 
which is usually reversible in asthma, but is progressive and mainly irreversible in 
COPD.  
 
Corticosteroids are widely used in the management of asthma and COPD to treat the 
underlying inflammation. However, in sharp contrast to patients with asthma, they 
are less effective in COPD patients. These differences in corticosteroid response 
between asthma and COPD may be partly due to pathological differences at the 
cellular and molecular level. Recent evidence suggests several molecular 
mechanisms may contribute to corticosteroid insensitivity in COPD patients. These 
include reduced histone deacetylase-2 (HDAC2) activity, impaired glucocorticoid 
receptor (GR) nuclear translocation and heightened pro-inflammatory transcription 
factor activity. Recent evidence in corticosteroid-resistant asthmatic patients 
26 
 
suggests GR nucleocytoplasmic shuttling, essential for corticosteroid activity, may 
also be impaired. The purpose of this work is to determine the role of GR nuclear 
trafficking in corticosteroid insensitivity.  
 
1.2 COPD Definition 
The Global initiative for chronic Obstructive Lung Disease (GOLD) defines COPD as 
a common preventable and treatable disease, which is characterised by persistent 
airflow limitation that is usually progressive and associated with an enhanced 
inflammatory response in the airways and the lung to noxious particles and gases. 
Exacerbations and co-morbidities contribute to the overall severity in individual 
patients (GOLD).  
 
1.3 Burden of disease 
COPD is the fourth most common cause of mortality, and projected to rank fifth in 
global burden of disease according to the World Health Organization (Barnes, 2007, 
Rabe et al., 2007). The general prevalence of COPD is 10%, although there are 
reports of a much higher disease prevalence (Mannino and Buist, 2007). Prevalence 
surveys conducted in numerous countries suggest approximately one quarter of 
adults aged over 40 years may have COPD (Menezes et al., 2005, Chapman et al., 
2006, Lopez et al., 2006b). Approximately one in four individuals during their lifetime 
are likely to be diagnosed with COPD. In addition, 50% of smokers who reach 80 
years of age will develop COPD (Gershon et al., 2011). Furthermore, a meta-
analysis of several studies conducted in 28 countries revealed that the prevalence of 
COPD was considerably greater amongst smokers and ex-smokers than in non-
smokers (Halbert et al., 2006).  
27 
 
 
COPD is a major global cause of morbidity and mortality. In the year 2000, there 
were approximately 8 million outpatient and 1.5 million emergency department 
COPD visits, with more than 600,000 hospitalisations in the US. In most parts of the 
world, outpatient COPD consultations considerably outnumbered those for asthma, 
lung cancer, pneumonia and tuberculosis (Schellevis et al., 1994). The increasing 
epidemic of smoking and changing population demographics has projected COPD to 
become the third leading cause of death worldwide by 2020. The increasing burden 
of COPD has also presented a major economic and social burden where, in the 
European Union, COPD accounts for more than 50% (>€38 billion Euros) of the total 
costs of respiratory disease (Loddenkemper et al., 2003). Furthermore, with 
increasing severity of COPD disease; the cost of care has been shown to increase 
considerably (Rabe et al., 2007).   
 
1.4 Risk Factors 
Globally, cigarette smoke is the most common risk factor and cause of COPD. 
Smokers have a higher prevalence of respiratory symptoms and lung function 
abnormalities than non-smokers (Rabe et al., 2007, Eisner et al., 2005). Moreover, 
passive exposure to cigarette smoke can also lead to the development of COPD, 
due to an increase in total burden of inhaled particles and gases in the lungs (Dayal 
et al., 1994, Eisner et al., 2005). In a study involving 4,197 never-smoking adults, 
individuals subjected to passive smoking had an elevated risk of dyspnoea and 
wheezing and, an increased risk of symptoms associated with chronic bronchitis. 
Furthermore, the risk of these respiratory symptoms was elevated with increased 
passive smoking exposure (Leuenberger et al., 1994).  
28 
 
 
In developing countries, exposure to indoor pollution due to the burning of biomass 
fuels is also associated with the development of COPD (Torres-Duque et al., 2008). 
COPD is a polygenic disease and risk factors for its development mainly arise from a 
gene-environment interaction and due to differences in genetic predisposition to 
COPD. Where, one individual with a similar smoking history may develop COPD and 
the other may not (Sadeghnejad et al., 2007).  
 
1.5 Pathology 
Clinically, the hallmark of COPD is progressive airflow limitation that is not fully 
reversible, which manifests itself primarily as dyspnoea and exercise limitation. 
These physiological symptoms arise from pathological and structural changes that 
take place in the proximal and peripheral airways, lung parenchyma and pulmonary 
vasculature (Hogg et al., 2004). Biologically, COPD is an inflammatory disease of the 
lungs, characterised by an abnormal inflammatory response to noxious particles and 
gases, where the extent of the pulmonary inflammation correlates to COPD disease 
severity (Turato et al., 2002). Inhaled cigarette smoke, and other noxious particles 
which are rich in reactive oxygen species (ROS), cause lung inflammation and this is 
amplified in COPD patients (GOLD).  
 
Oxidative stress is an important feature in COPD, where an imbalance between the 
production of harmful ROS and the ability to repair the resulting damage is believed 
to be important (Lee and Yang, 2012, Rahman, 2005). It is also recognised there are 
significant extra-pulmonary effects and co-morbidities in COPD patients that 
contribute to the severity of the disease (GOLD). However, most clinical trials have 
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shown that existing medications do not reverse the decline in lung function, which is 
the key feature of the disease (Barnes, 2000a, Suissa and Barnes, 2009). According 
to the GOLD guidelines, patients with COPD should be treated with bronchodilators 
at all stages of the disease, with the addition of inhaled corticosteroids (ICS) in 
severe (stage III) to very severe (stage IV) COPD patients (Rabe et al., 2007).   
 
The cellular composition of the chronic inflammation in COPD is characterised 
principally by macrophages, neutrophils and T-lymphocytes. These inflammatory 
cells are found in elevated levels in the bronchial tree, small airways and lung 
parenchyma from COPD patients (Hogg et al., 2004). They release a variety of 
chemotactic factors, pro-inflammatory cytokines and growth factors that further 
amplify the abnormal inflammatory response in COPD patients (Barnes et al., 2003).  
Of the cells identified, macrophages play an important role in the pathogenesis of 
COPD, and are derived from circulating monocytes that migrate in response to 
chemoattractants such as CCL1 and CCL2. Macrophages are markedly increased in 
the alveolar space and lungs of patients with COPD. Macrophages release a 
plethora of inflammatory proteins that further drive the chronic inflammation 
observed in COPD and give rise to many of the structural changes characteristic of 
COPD (Barnes, 2004). Historically it has been shown that alveolar macrophages 
from COPD patients show a degree of corticosteroid insensitivity (Barnes, 2004, 
Keatings et al., 1997).  
 
In addition to an elevated number of macrophages, COPD patients also have 
elevated levels of neutrophils and mediators such as tumour necrosis factor-alpha 
(TNF-) and chemokine (C-X-C motif) ligand 8 (CXCL8) secretions compared to 
smoking and non-smoking subjects. Levels of CXCL8 but not TNF- have been 
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shown to be significantly higher in sputum from COPD patients compared to patients 
with asthma (Keatings et al., 1996, Hodge et al., 2011). CXCL8 is a chemoattractant 
for neutrophils which acts on the CXCCR2 receptor that predominantly resides on 
neutrophils (Pignatti et al., 2005).  
 
Similar to observations in patients with asthma, the transcription factor nuclear 
factor-B (NF-B) is found in elevated levels in COPD patients and regulates the 
secretion of many of the inflammatory mediators. In a study involving 11 active 
smokers with moderate COPD, p65 (a subunit of NF-B) nuclear expression in 
sputum macrophages, was found to be markedly elevated during clinical 
exacerbations of the disease compared to baseline levels (Caramori et al., 2003). 
The activation of NF-B is regulated by the IB kinase (IKK) complex. In peripheral 
blood mononuclear cells (PBMCs) of COPD patients, the expression and activation 
of the alpha isoform of IB kinase (IKK) was higher than in asthmatics. Both 
asthmatics and COPD patients had greater levels of the beta isoform of IKK than 
controls. Fluticasone propionate (FP) inhibited IKKbeta to a greater extent than 
IKKalpha (Gagliardo et al., 2011). These differences in the regulation of NF-B in 
asthmatics and COPD patients may partly explain the different responses to 
corticosteroids in these patients (Barnes, 2010b).  
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Fig. 1.5 The cellular and molecular profile of COPD (Barnes, 2008).  
 
1.6 Comparison between Asthma & COPD 
Chronic inflammation in asthma and COPD is characterised and orchestrated by 
distinct inflammatory cells, cytokines, chemokines, adhesion molecules, enzymes 
and receptors. The inflammation in asthma is often described as eosinophilic-led, 
whereas the disease in COPD is described as neutrophilic-led inflammation. Recent 
advances in the underlying immunopathology of asthma and COPD have highlighted 
the importance of different subsets of T cells that may initiate different inflammatory 
profiles and consequently different structural changes (Brusselle et al., 2011, Lloyd 
and Hessel, 2010).  
 
However, there are shared similarities in the inflammatory profile and clinical 
features between these diseases and this has led to the development of the Dutch 
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hypothesis that proposes asthma and COPD are different forms of the same disease 
(Postma and Boezen, 2004). In contrast, based on the very distinct cellular and 
inflammatory profiles observed between the diseases, an opposing hypothesis, the 
British hypothesis, proposes they are separate entities (Kraft, 2006, Barnes, 2006a). 
Moreover, asthma is mainly a disease of the large conducting airways, although 
involvement of the smaller airways in severe forms is well documented, whereas 
COPD is characteristically a disease of the small airways and lung parenchyma 
(Barnes, 2000b, Jeffery, 2000). It is important to note that a sub-population of 
patients with asthma are corticosteroid-insensitive. These corticosteroid-insensitive 
patients with asthma can resemble some aspects of the inflammatory profile 
observed in COPD (Wenzel and Busse, 2007, Jatakanon et al., 1999).  
 
In a prospective study over 7.5 years in patients with severe asthma, the annual 
decline in post-bronchodilator FEV1 was far greater than the decline in pre-
bronchodilator FEV1 (indicating loss in reversibility) and this was strongly associated 
with an influx of CD8+ T cells (r= 0.39, p= 0.032) (Kurashima et al., 2006, van 
Rensen et al., 2005, Cho et al., 2005). Interestingly, it has also been observed that 
asthmatic patients who smoke also exhibit a degree of corticosteroid resistance and 
have a similar pathology to COPD patients (Table 1.1). Bronchial biopsies in 
asthmatic patients who smoke have shown remodelling of the bronchial mucosa, 
squamous cell metaplasia, and increased expression of subepithelial neutrophil 
elastase, IFN- and intraepithelial CXCL8, similar to that observed in patients with 
COPD (St-Laurent et al., 2008). Recently, increased expression of arginase I, which 
is involved in the regulation of airway smooth muscle tone, has also been shown in 
the airways of smoking asthmatics, which may also contribute to the COPD-like 
airway changes observed in this disease group (Bergeron et al., 2007).  
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Cell type Asthma 
(mild-to-moderate) 
COPD Smoking Asthmatics 
Neutrophils - ++ + 
Eosinophils + -  
Macrophages + +++ ++ 
T-lymphocytes Th2++ Tc1+ ++ 
Chemokines CXCL8 CXCL8+ CXCL8+ 
Cytokines IL-4, IL-5 & IL-13 TNF- TNF- 
Oxidative stress - ++ ++ 
Steroid response ++++ - - 
 
Table 1.1 Comparison of the airway inflammation in patients with asthma, COPD and 
in smoking asthmatics (St-Laurent et al., 2008, Saetta et al., 2001, Barnes, 2008).  
 
1.7 Oxidative stress 
The major environmental risk factor for developing COPD is cigarette smoke, which 
contains abundant ROS. Cigarette smoke induces oxidative stress in the lungs of 
smokers and COPD patients, which subsequently leads to amplification of the 
underlying inflammation (Rahman, 2005). Neutrophils of smokers and COPD 
patients during exacerbations release more of the free radical superoxide anion (O2
.-)  
(Rahman et al., 1996). Furthermore, the lungs of COPD patients have elevated 
levels of 4 hydroxy-2-nonenal (4-HNE), a highly reactive product of lipid peroxidation 
and a key mediator of oxidant-induced cell signalling. In a study involving 23 current 
or ex-smokers with COPD, 4-HNE levels were higher in airway and alveolar 
epithelial cells, and neutrophils (Rahman et al., 2002). It was clearly noted that the 
elevated levels of 4-HNE inversely correlated with FEV1. Another product of lipid 
peroxidation, 8-isoprostane, a very biologically active mediator, is also found in 
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elevated levels in the plasma and bronchoalveolar lavage of patients with COPD and 
in chronic smokers compared to healthy subjects (Montuschi et al., 2000). Auto-
antibodies against carbonyl-modified protein, as a result of oxidative stress, are also 
elevated in COPD (Kirkham et al., 2011). This suggests oxidative stress may also 
drive an autoimmune response in COPD.   
 
Fundamentally, the lungs are exposed to either cellular- or environmental-derived 
ROS (Rahman, 2005, Lopez et al., 2006a). Cellular-derived ROS are enzymatically 
produced by epithelial and inflammatory cells, under normal physiological conditions 
of the inflammatory-immune response towards an irritant or pathogen (Rochelle et 
al., 1998). Cellular-derived ROS is predominantly generated from nicotinamide 
adenine dinucleotide phosphate oxidase (NAPDH oxidase) and mitochondria. In 
contrast, environmental sources of ROS include airborne particulate matter from 
diesel car exhausts, cigarette smoke and oxidant gases, and nitrogen dioxide 
(Rahman, 2005). 
 
1.7.1 Cellular-derived ROS 
In the airspace of COPD patients, activation by inflammatory mediators and 
subsequent infiltration of inflammatory cells results in the release of intracellular 
ROS, such as O2
.-, which plays an important role as a catalyst for the generation of 
further cell damaging ROS. Superoxide dismutase (SOD) rapidly converts O2
.- into 
hydrogen peroxide (H2O2). The highly damaging hydroxyl ion (OH
.) is formed in the 
presence of Fe2+. Cellular-derived ROS can be generated from several intracellular 
sources; mitochondrial respiration, the NADPH oxidase system, and 
xanthine/xanthine oxidase (XO).  
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Mitochondria play a crucial role in the pathological generation of ROS in disease 
(Pacher et al., 2007, Kirkham and Rahman, 2006, Al Ghouleh et al., 2011). In a 
study involving 152 samples from patients who underwent surgical resection for 
various pulmonary diseases, the frequency of the 4,839 base pair (bp) mitochondrial 
DNA deletion correlated positively with smoking pack-years history, with current 
smokers having significantly greater rates of incidence and proportion of the 
mitochondrial DNA mutation than non-smokers. Moreover, changes in mitochondrial 
DNA in smokers in comparison to non-smokers were associated with increased 
levels of lipid peroxidation. Multiple regression analysis revealed smoking history, 
lung tissue lipid peroxidation, and the FEV1/FVC ratio correlated positively with the 
level of the mitochondrial DNA mutation (Fahn et al., 1998). Abnormal mitochondria 
function has also been reported in mitochondria in muscle biopsies of the vastus 
lateralis and external intercostalis from COPD patients (Puente-Maestu et al., 2009), 
where it has been noted that muscle fatigue and weakness worsens with disease 
(Polkey, 2003). 
 
1.7.2 Environmental-derived ROS 
Each puff of cigarette smoke contains more than 1015 oxidants. In this myriad, 
oxidants may have a short half-life such as O2˙
- or a relatively long half-life such as 
tar-semiquinone, which can lead to ·OH and H2O2 generation (Church and Pryor, 
1985, Nakayama et al., 1989). Consequently, H2O2 in the presence of Fe
2+ can lead 
to the production of the highly damaging ·OH via the Fenton reaction. It has been 
shown that smokers have significantly higher levels of iron in their lungs than non-
smokers, potentially predisposing them to increased ROS burden (Ghio et al., 1997).       
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The oxidant H2O2 and other biomarkers of oxidative stress, such as 8-isoprostane, 
are found in elevated levels in exhaled breath condensate, sputum and in the 
systemic circulation of patients with COPD (Makris et al., 2008, Dekhuijzen et al., 
1996). Furthermore, COPD patients during exacerbations have increased levels of 
oxidative stress. In the study by Dekhuijzen and colleagues it was observed that 
patients with stable COPD had significantly higher levels of exhaled H2O2 
(0.205±0.054μM) compared to healthy volunteers (0.029±0.012μM) which was 
further raised in patients with an exacerbation (0.6±0.075μM, p< 0.01) (Dekhuijzen et 
al., 1996). Elevated levels of H2O2 may also be partly derived from the increased 
release of O2˙
- from alveolar macrophages, and this has been shown by Rahman 
and colleagues where, elevated levels of H2O2 were observed from circulating 
neutrophils from COPD patients during exacerbations (Rahman and MacNee, 1996, 
Rahman et al., 1996).  
 
1.7.3 ROS-activated inflammation in COPD 
Inhaled cigarette smoke and other noxious particles acutely induce pulmonary 
inflammation through the activation of pro-inflammatory redox-sensitive transcription 
factors such as NF-B and activator protein-1 (AP-1) and, through signalling 
pathways such as p38 mitogen-activated protein kinases (p38 MAPK) and 
phosphoinositide-3-kinase (PI3K) (Di Stefano et al., 2002, Lee et al., 2012, Isajevs et 
al., 2011). In a clinical study to compare patterns of inflammation between the large 
and small airways in patients with COPD, it was shown that both the large and small 
airways had greater levels of NF-B expression than non-smokers and smokers 
without COPD (Isajevs et al., 2011). This was associated with higher levels of 
macrophages, CD8+ T lymphocytes and neutrophils. It was also observed that the 
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small airways of COPD patients had fewer macrophage numbers than the large 
airways, whereas more neutrophils were present in the small airways.  In a separate 
study in PBMCs from patients with asthma and COPD, Gagliardo and colleagues 
observed that different isoforms of IKK, which drives the NF-B activation, 
dominated in asthma and COPD (Gagliardo et al., 2011). NF-B has been shown to 
upregulate the transcription of many inflammatory genes, such as CXCL8, TNF- 
and IL-6, which are highly expressed in COPD patients (Keatings et al., 1996).  
 
The sputum of COPD patients have been shown to have significantly higher levels of 
TNF- and CXCL8 than smokers and non-smokers (Keatings et al., 1996). 
Furthermore, Rusznak and colleagues noted that bronchial epithelial cells from 
COPD patients had greater levels of the pro-inflammatory mediator IL-1β than 
smokers upon cigarette smoke exposure (Rusznak et al., 2000). This increase in 
inflammatory mediators leads to activation and induction of non-specific 
inflammatory cells, macrophages and neutrophils, and adaptive immune cells, T-
lymphocytes, in the bronchial mucosa and small airways.  
 
The increased burden of inhaled oxidants is enhanced by activated macrophages 
and neutrophils in the lungs of smokers (Rahman and MacNee, 1996, Saetta et al., 
1993). In retinal pigment epithelial cells, cigarette smoke increased mitochondrial 
membrane potential which was associated with an increase in superoxide levels  
(Bertram et al., 2009). Macrophages and neutrophils generate O2˙
- which is rapidly 
converted to H2O2 by SOD. This abnormal inflammatory response to noxious 
particles and gases, orchestrated by a cascade of inflammatory cells and mediators, 
leads to narrowing and structural changes of the small airways and destruction of the 
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lung parenchyma; the latter is a characteristic of the pathological and radiological 
findings of emphysema. These structural changes include increased bronchial wall 
thickness and smooth muscle tone, mucus hypersecretion and loss of elastic 
structure (Roche et al., 2011) and it is these pathological changes of the lungs that 
lead to progressive airflow limitation, which is the hallmark of COPD (Usmani and 
Barnes, 2012). 
 
1.8 Corticosteroids 
Inhaled corticosteroids (ICS) are widely used in the treatment of COPD patients. 
However, in sharp contrast to asthmatic patients they provide little clinical benefit 
(Barnes, 2010a). The addition of corticosteroids is recommended for severe COPD 
patients at GOLD stage III (Rabe et al., 2007) (Fig. 1.8). However, corticosteroids fail 
to prevent disease progression or mortality in COPD patients (Suissa and Barnes, 
2009, Barnes, 2000a). In a two-year double-blind, randomized, placebo controlled 
trial, high dose ICS had no effect on the decline in the forced expiratory volume in 
one second (FEV1) in COPD patients (Renkema et al., 1996).  
 
More recently, several long-term clinical studies in COPD patients have shown that 
high dose ICS had no effect on the annual decline in FEV1, in comparison to placebo 
(Pauwels et al., 1999, Burge et al., 2000). In a randomised three-year, placebo-
controlled study conducted by Vestbo and colleagues, high dose budesonide had no 
effect on respiratory symptoms and no significant reduction in the number of disease 
exacerbations in 145 COPD patients. Of the 316 exacerbations that occurred during 
the study, 155 exacerbations were in the budesonide-treated group with the 
remaining 161 in the placebo-treated group (Vestbo et al., 1999). In contrast, a 
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reduction in the number of disease exacerbations has been observed in two studies. 
In a six-month randomised, double blind, placebo controlled study involving 13 
European countries, New Zealand and South Africa, patients with COPD receiving 
fluticasone propionate 500 micrograms twice daily had significantly less moderate or 
severe exacerbations compared to a placebo group, 86% vs 60%, respectively 
(Paggiaro et al., 1998). However, there was no difference in the primary endpoint; 
the number of patients who had at least one exacerbation by the end of treatment. A 
meta-analysis of six long term studies involving 3571 COPD patients, where the rate 
of decline in FEV1 was the primary endpoint, failed to show any effect of ICS on the 
rate of FEV1 decline (Highland et al., 2003). In a more recent review of 55 studies 
involving 16,154 subjects, the long-term use of inhaled corticosteroids did not 
consistently reduce the rate of decline in FEV1 in patients with COPD (Yang et al., 
2012).  
 
The Toward a Revolution in COPD Health (TORCH) study investigated all-cause 
mortality as its primary endpoint between four treatment arms of; fluticasone 
propionate alone, salmeterol alone, salmeterol in combination with fluticasone 
propionate and, placebo (Vestbo, 2004). Post-hoc analysis showed a small but 
significant reduction of 13 ml (millilitres)/year (95% CI, 5- 22; p= 0.003) in the annual 
rate of FEV1 decline by fluticasone propionate compared to placebo (Celli et al., 
2008). However, meta-analysis of all these studies, involving more than 13,000 
COPD patients has revealed no significant effect of ICS on the rate of FEV1 decline, 
although the number of disease exacerbations are reduced by approximately 25% 
(Yang et al., 2007).  
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Fig. 1.8 Pharmacotherapy management of COPD (Rabe et al., 2007). Definition of 
abbreviation: FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity. 
 
1.8.1 Inhaled corticosteroid and long-acting 2-agonist combination therapy 
In patients with asthma, the addition of long acting 2-agonists (LABA) to low dose 
ICS have been shown to be more clinically beneficial than the use of high dose ICS, 
allowing a reduction in ICS dose and minimising adverse side effects of 
corticosteroids (Greening et al., 1994, Pauwels et al., 1997, Juniper et al., 1999). 
Subsequent biological studies have been undertaken to understand the cellular 
mechanisms of this complementary interaction (Usmani et al., 2005b, Roth et al., 
2002). In the management of patients with COPD, combination therapy with ICS and 
LABA is considered for severe diseased patients at GOLD stage III & IV and those 
with frequent exacerbations (Rabe et al., 2007).  
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Several clinical studies investigating the combination of corticosteroid and LABA in 
patients with COPD have shown beneficial effects on symptoms and lung function in 
comparison to corticosteroid alone. However, the improvement in disease 
exacerbations of COPD with combination therapy have not been statistically greater 
than the effects of LABA treatment alone (Calverley et al., 2007, Mahler et al., 2002, 
Calverley et al., 2003, Kardos et al., 2007). A 2x2 factorial study analysis of the 
TORCH study, where the corticosteroid was fluticasone propionate used in 
combination with the LABA salmeterol, showed that the reduction in all-cause 
mortality in the combination treatment group was entirely due to the LABA 
component of salmeterol (Suissa et al., 2008, La Vecchia and Fabbri, 2007). 
  
A recent Cochrane database meta-analysis of eleven studies reviewed the effect of 
the two combination therapies of fluticasone propionate/salmeterol and 
budesonide/formoterol on disease exacerbations, mortality and pneumonia. This 
showed that COPD disease exacerbations were less frequent compared to placebo 
(Nannini et al., 2007). Furthermore, the analysis showed an overall reduction in 
mortality, which did not quite reach statistical significance (p=0.052), and this 
outcome was greatly influenced by the results of the TORCH study where a 
reduction in all-cause mortality was shown with fluticasone propionate/salmeterol. Of 
note, however, in a post-hoc analysis of the TORCH study, there was an observed 
increased risk of pneumonia with combination therapy, primarily associated with ICS 
use (Crim et al., 2009). 
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1.9 Molecular mechanisms of corticosteroids 
Corticosteroids exert their anti-inflammatory effects primarily through binding and 
subsequent activation of the glucocorticoid receptor (GR), a ligand-inducible 
transcription factor. GR is a member of the superfamily of steroid receptors and is 
fundamental for the regulation of many physiological and metabolic processes. 
These processes include inflammatory and immune responses, cell proliferation and 
metabolic homeostasis (Beato and Klug, 2000, Whitfield et al., 1999). Like many 
transcription factors, GR undergoes nucleocytoplasmic shuttling upon activation 
(Deroo et al., 2002). GR is made up of three major functional domains, the N-
terminal domain (BTD), the central DNA-binding domain (DBD) and the C-terminal 
ligand-binding domain (LBD) (Fig. 1.9a), that facilitate GR nucleocytoplasmic 
shuttling and binding to DNA promoter regions. Furthermore, a ligand-dependent 
transcriptional activation function (AF)-2 is located in the LBD. A hinge junction 
between DBD and LBD also facilitates GR nuclear translocation (Vandevyver et al., 
2012).  
 
 
 
 
 
 
 
Fig. 1.9a Ligand binding domain of the glucocorticoid receptor (GR) (Veleiro et al., 
2010). The ligand bound to the active site of GR is dexamethasone.  
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In the resting state, the inactive GR is bound to a protein complex that includes heat 
shock protein (hsp)-90, acting as molecular chaperones to prevent the nuclear 
localisation of unoccupied GR. Upon activation, GR translocates into the nucleus 
where it affects gene transcription via DNA-binding dependent and independent 
mechanisms (Fig. 1.9b). The DNA-binding dependent mechanism occurs via direct 
binding to the promoter regions of corticosteroid-sensitive genes, at glucocorticoid 
response elements (GRE). The consensus GRE sequence is 5-
AGAACAnnnTGTTCT-3 (Strahle et al., 1987), which may vary among different 
promoters (Meijsing et al., 2009). Recently global chromatin immunoprecipitation 
(ChIP)-sequencing data has revealed that GR binds to DNA mostly via the 
aforementioned consensus sequence (Voss et al., 2011). Binding of activated GR to 
GRE leads to the transcriptional induction of anti-inflammatory genes such as dual 
specificity protein phosphatase 1 (DUSP1) (Tchen et al., 2010). Whilst the DNA-
binding independent mechanism involves activated GR binding to transcription 
factors and coactivators, which in turn bind to DNA (Muzikar et al., 2009). Binding of 
activated GR to AP-1 and NF-B may lead to gene transrepression of genes 
regulated by these transcription factors (McKay and Cidlowski, 1998, De Bosscher et 
al., 2003, Heck et al., 1994).  Recent evidence suggests that activated GR may form 
a multi-protein repression complex with the enzyme O-linked β–N–
acetylglucoasmine transferase (OGT), which leads to the suppression of NF-B 
transcriptional activity (Li et al., 2012). In this study, depletion of OGT abolished GR 
repression of NF-B transcriptional activity, whereas overexpression potentiated it. 
   
Activated GR may also lead to the recruitment of histone deacetylase-2 (HDAC2) to 
the p65 subunit of NF-B bound to the promoters of several inflammatory genes and 
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inhibit the transcription of a wide range of pro-inflammatory cytokines, by preventing 
local histone acetylation (Fig. 2.0) (Barnes, 2006b, Barnes, 2011, Garside et al., 
2004). By this process of transrepression by tethering, corticosteroids reduce pro-
inflammatory cytokines such as TNF- and CXCL8 in asthmatic patients, whereas 
they are far less effective in COPD patients (Barnes, 2008). Furthermore, activated 
GR is deacetylated by HDAC2 to enable binding to the NF-κB complex that leads to 
the subsequent suppression of NF-κB induced genes. A reduction in HDAC2 activity 
has been shown to increase GR acetylation, which prevents GR from associating 
with the p65 subunit of NF-κB and thereby less inhibition of NF-κB induced 
inflammation (Ito et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.9b Corticosteroid suppression of pro-inflammatory genes. In the resting state, 
inactive glucocorticoid receptor (GR) is bound to a complex of molecular chaperones. Upon 
corticosteroid binding, activated GR translocates into the nucleus where it affects gene 
transcription via DNA-binding dependent and –independent mechanisms. 
 
1.9.1 GR nuclear translocation 
Nucleocytoplasmic shuttling of proteins across the nuclear pore complex (NPC) is a 
dynamic process regulated by nuclear import and export complexes requiring 
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several sequential steps. These steps involve retrograde movement through the 
cytoplasm, recognition of nuclear localisation signals (NLS) on cargo proteins by 
nuclear import proteins, docking to the nuclear pore, translocation across the nuclear 
compartment, binding to and release from nuclear sites of action, recognition of 
nuclear export signals (NES) on cargo proteins by nuclear export proteins and finally, 
anteretrograde cytoplasmic movement (Galigniana et al., 2010).  
 
Nuclear importin and exportin receptors, containing a Ran-GTP binding domain, 
mediate RanGTPase-dependent transport across the nuclear envelope (Nakielny 
and Dreyfuss, 1999, Strambio-De-Castillia et al., 2010). The RanGTPase system is 
composed of a Ran gradient across the NPC, where RanGDP is predominantly 
found in the cytoplasm, whereas RanGTP mainly resides in the nucleus. This 
gradient is maintained by 2 enzymes; cytoplasmic RanGTPase-activating protein 
(RanGAP) which hydrolyses RanGTP to RanGDP and the nuclear RanGDP/GTP-
activating protein (RANGEF) which hydrolyses RanGDP to RanGTP (Poon and 
Jans, 2005, Wagstaff and Jans, 2009).  
 
Although the mechanisms that govern GR nucleocytoplasmic shuttling remain largely 
unknown, evidence over the previous decade suggests that specific nuclear import 
and export receptors may mediate GR nucleocytoplasmic shuttling, essential for 
corticosteroid regulation of gene transcription (Freedman and Yamamoto, 2004, 
Vandevyver et al., 2012). In 1999, a group of researchers discovered two distinct 
nuclear localisation signals, NLS1 and NLS2, located on GR. The NLS1 is located 
within the DBD, whereas NLS is located in the LBD (Savory et al., 1999). In this 
study NLS1 was responsible for rapid GR nuclear translocation (4-6 min) and NLS2 
mediated relatively slower GR nuclear translocation (45 min to 1h) (Savory et al., 
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1999). Importantly, nuclear localisation of fusion proteins containing either the full-
length receptor or the NLS2 alone was hormone-dependent. Furthermore, the rates 
of hormone induced nuclear localisation of both the full-length receptor and NLS2 
were similar (Picard and Yamamoto, 1987, Cadepond et al., 1992).  
 
More recently, several nuclear importin receptors, importins-7, -8, -13 and the -/ 
heterodimer have been shown to interact with, and mediate, GR nuclear 
translocation (Freedman and Yamamoto, 2004, Vandevyver et al., 2012). In a study 
investigating the role of importins on GR trafficking, importin-7 fused to glutathione 
S-transferase (GST) bound directly to the GR purified from rat liver. Furthermore, 
immunoprecipitation of the S-methionine-labelled fragments of GR in reticulocyte 
lysate, revealed that importin-7 binds to both NLS1 and NLS2, suggesting multiple 
sites for importin-7 binding on GR. Finally, importin-7 and GR binding was impaired 
by RanQ69L, a GTPase-deficient Ran mutant (Freedman and Yamamoto, 2004). It 
is not known whether these different importins interact in combination with each 
other or individually to facilitate GR nuclear translocation. It would be important to 
characterise the role of importin-7 on GR nucleocytoplasmic shuttling in inflammatory 
cells following corticosteroid challenge.  
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Fig. 1.9.1a Potential mechanism of glucocorticoid receptor (GR) nuclear import. 
Corticosteroid-induced GR nuclear translocation is essential for corticosteroid-mediated 
suppression of pro-inflammatory mediators. Importin-7 binds to and mediates nuclear 
translocation of the GR. Once in the nucleus, nuclear RanGTP binds to importin-7 resulting 
in the dissociation of the importin-7 and GR complex. Consequently, the GR is able to move 
through the nucleus and either binds to glucocorticoid response elements on corticosteroid-
inducible genes or recruits histone deacetylase (HDAC)-2 to prevent the gene transcription 
of pro-inflammatory mediators. Activated GR may also prevent gene transcription by binding 
as a monomeric unit to other transcription factors.  
  
Similarly, nuclear export of proteins is also regulated by the RanGTPase system. A 
nuclear export signal (NES) located on the cargo protein is recognised by exportins. 
Recognition of the NES of a protein results in the formation of the exportin-cargo 
protein complex and subsequent nuclear export of the complex. Some studies have 
shown several nuclear export pathways may be implicated in GR nuclear export. Of 
the nuclear export pathways studied, exportin-1 (CRM-1) is the best characterized. 
Leptomycin B (LMB), a specific inhibitor of CRM-1 mediated nuclear export, has 
been shown to inhibit GR nuclear export, leading to enhanced unliganded and 
hormone-treated GR nuclear localisation (Savory et al., 1999). However, other 
studies have suggested GR nuclear export is governed by a pathway other than the 
CRM-1 mediated transport mechanism, namely the nuclear export receptor 
calreticulin (CRT).  
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Similar to exportin receptors, CRT-mediated nuclear export is Ran-GTPase-
dependent and forms a trimeric CRT-cargo protein-RanGTP complex (Galigniana et 
al., 2010). Using a combination of microinjection and transfection approaches, 
Holaska and colleagues have shown that CRT induced GR nuclear export.  CRT 
binds to a 15 amino acid sequence located between the two zinc fingers of the GR 
DBD which contains the GR NES (Holaska et al., 2001). Subsequently, the same 
group reported that this effect of CRT on binding to the GR DBD and induction of GR 
nuclear export was Ca2+ dependent (Holaska et al., 2002). These differences in 
pathways that govern GR nuclear export may be cell specific. It would be important 
to characterise the role of CRM-1 mediated transport on GR nuclear export in 
inflammatory cells important in asthma and COPD. Unravelling the mechanisms that 
govern GR nuclear export would allow one to potentially increase the 
pharmacokinetic profile of a corticosteroid, as well as more importantly, the duration 
of the anti-inflammatory effects of the corticosteroid.  
49 
 
 
Figure 1.9.1b Potential mechanism for glucocorticoid receptor (GR) nuclear export 
(Vandevyver et al., 2012). Calreticulin (CRT) and exportin-1 (CRM-1) are two potential 
nuclear export receptors that may govern GR nuclear export.   
 
1.10 Corticosteroid resistance  
As highlighted above, unlike mild-to-moderate asthmatics, subsets of severe 
asthmatics and asthmatic patients who smoke show a degree of corticosteroid 
resistance similar to that observed in COPD patients (Table 1.1) (Suissa and Barnes, 
2009, Thomson and Spears, 2005, Barnes, 2010a). Asthmatic patients who smoke 
as well as those patients with severe asthma, require high doses of ICS or even oral 
corticosteroids to achieve relative control of their disease, which still remains 
suboptimal on treatment (Thomson and Spears, 2005). COPD patients are also 
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recommended high dose ICS, despite lack of their clinical benefit (Suissa and 
Barnes, 2009). Corticosteroid resistance persists even after smoking cessation and 
markers of oxidative stress and inflammation continue to be elevated in COPD 
patients (Gamble et al., 2007).  
 
1.10.1 Why do inhaled corticosteroids fail in COPD? 
There are several well established clinical trials which have shown that high doses of 
ICS fail to suppress markers of inflammation in sputum and bronchial biopsies from 
COPD patients compared to asthmatics (Keatings et al., 1997, Culpitt et al., 1999, 
Hattotuwa et al., 2002). In a two-week clinical study in 13 patients with severe 
COPD, inhaled budesonide 800mg twice daily did not suppress the expression of 
TNF- and CXCL8 which play pivotal roles in propagating the inflammatory response 
(Keatings et al., 1997). Additionally, there was no improvement in lung function or 
symptom scores. This group also investigated whether this effect could be due to 
poorly inhaled drug delivery not reaching the distal airways in COPD patients, yet 
similarly observed, that systemically delivered oral prednisolone also did not 
suppress inflammatory markers (Keatings et al., 1997) . In a double-blind, placebo-
controlled study involving 30 COPD patients, fluticasone propionate 500 micrograms 
twice daily did not suppress inflammatory markers in bronchial biopsies including 
CD8+ cells, CD68+ cells or neutrophil levels, which are highly expressed in COPD 
(Hattotuwa et al., 2002).  
 
Better understanding of the mechanism(s) that may cause corticosteroid insensitivity 
are greatly needed to effectively control the underlying causes of COPD and 
symptoms of the disease. Additionally, drug development in COPD has been rather 
slow due to several factors. Traditionally, the high incidence of co-morbidities and 
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inadequate information on biomarkers to monitor the short and long-term potential of 
new treatments (Usmani and Barnes, 2012), as well as discrepancies between 
animal models of COPD and patients, has made it difficult for drug development in 
COPD (Barnes, 2010c). Also, there has been difficulty in targeting inhaled therapies 
to the lower airways of the lungs (De Backer et al., 2010, Usmani et al., 2005a).  
 
However, recent advances in the cellular and molecular mechanisms of COPD have 
revealed several potential targets that may reverse some components of the 
pathology of COPD, as well as reverse corticosteroid insensitivity (Barnes, 2008). 
Potential mechanisms in severe asthmatics and COPD patients that may give rise to 
corticosteroid insensitivity include reduction in HDAC2 activity, impaired GR nuclear 
translocation, and increased pro-inflammatory transcription factors (Barnes, 2011). 
Profiling of the gene expression in primary lymphocytes identified bone 
morphogenetic protein receptor (BMPRII) as a potential modulator of corticosteroid 
insensitivity (Donn et al., 2007). 
 
1.11 Potential mechanisms for corticosteroid resistance 
1.11.1 Histone Deacetylase-2  
The expression of the enzyme HDAC2, which is recruited by corticosteroid activated-
GR to switch off the transcription of pro-inflammatory genes, is reduced in patients 
with COPD (Lin, 2005). In the lung tissue of COPD patients, reduced HDAC2 activity 
correlated with the severity of COPD disease. Furthermore, mRNA and protein 
expression of HDAC2 were significantly lower in COPD patients (Ito et al., 2005). In 
a preclinical study using BEAS-2B lung epithelial cells, H2O2 reduced HDAC2 activity 
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(Ito et al., 2004). The investigators showed that the reduction in HDAC2 activity was 
associated with tyrosine nitration status. 
 
In mice exposed to cigarette smoke, phosphoinositide-3-kinase- (PI3K) dead 
knock-in mice had reduced HDAC2 tyrosine nitration compared to wild type mice 
(Marwick et al., 2009). In PI3K knockout mice exposed to smoke, HDAC2 and 
corticosteroid activity were not reduced in comparison to the wild type group. In 
PBMCs from COPD patients, it has been shown corticosteroid insensitivity and 
reduced HDAC2 activity were reversed by a non-selective PI3K inhibitor theophylline 
(To et al., 2010). Furthermore, theophylline also inhibited PI3K which was up-
regulated in COPD patients. This suggests PI3K inhibition may serve as a potential 
therapeutic target to overcome corticosteroid insensitivity due to cigarette smoke. 
 
Upon activation, GR is deacetylated by HDAC2 to enable binding to the NF-B 
complex that leads to the subsequent suppression of NF-B-induced genes. A 
reduction in HDAC2 activity has been shown to increase GR acetylation, which 
prevents GR from associating with the p65 subunit of NF-B and thereby less 
inhibition of NF-B-induced inflammation (Ito et al., 2006). In alveolar macrophages 
of COPD patients, HDAC2 knockdown by RNA interference resulted in reduced 
dexamethasone suppression of IL-1-induced GMCSF (Ito et al., 2006). This 
reduction in dexamethasone suppression was not associated with reduced GR 
nuclear translocation or binding to DNA promoter regions of corticosteroid-sensitive 
genes, but via impaired association between GR and NF-B. Site directed 
mutagenesis of GR to decrease GR acetylation, reduced the ability of HDAC2 to 
inhibit transcription of NF-B sensitive genes. Therefore, a reduction in HDAC2 
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activity plays a pivotal role in corticosteroid insensitivity through reduced suppression 
of NF-B induced pro-inflammatory mediators (Ito et al., 2006). A recent study in 
alveolar macrophages from patients with COPD demonstrated that nitrosylation of 
HDAC2 was increased, which led to corticosteroid insensitivity (Malhotra et al., 
2011). In this study, treatment with sulphorophane, a small activator of nuclear factor 
erhthroid 2-related factor 2 (Nrf2), reduced nitrosylation of HDAC2 which was 
associated with restored dexamethasone sensitivity.  
 
1.11.2 Defective GR binding and nuclear translocation 
The data on impaired HDAC2 activity in COPD is extensive and supported by 
several clinical trials. Unfortunately, not much is known about whether GR 
nucleocytoplasmic shuttling, essential for HDAC2 recruitment and subsequent 
downregulation of pro-inflammatory gene transcription, is impaired under oxidative 
stress and whether it contributes to corticosteroid insensitivity in COPD patients. 
There is some published data in corticosteroid resistant asthmatics to suggest GR 
nucleocytoplasmic shuttling is impaired. In a study involving corticosteroid resistant 
asthmatic patients, reduced dexamethasone suppression of TNF- was associated 
with impaired GR nuclear translocation in PBMCs (Matthews et al., 2004). In another 
study in PBMCs from severe asthma patients, GR ligand-binding affinity was 
reduced in the nucleus (Irusen et al., 2002). Furthermore, the combination of the 
cytokines interleukin (IL)-2 and IL-4, which show increased expression in the airways 
of corticosteroid resistant asthmatics, led to a reduction in GR nuclear translocation 
and ligand-binding affinity. This reduced GR nuclear translocation was restored with 
a p38 MAPK inhibitor (Mercado et al., 2012). Greater degree of p38 MAPK activation 
in corticosteroid insensitive asthma patients supports the role of p38 MAPK in 
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corticosteroid insensitivity. It has been postulated that p38 MAPK phosphorylates 
GR, which may alter its binding and nuclear translocation (Barnes, 2010b).  
 
At the in vitro level, it has been shown GR nuclear translocation is redox sensitive. In 
human GR-expressing CHOpMTGR cells, H2O2 inhibited GR nuclear translocation, 
in addition to partially inhibiting ligand-dependent dissociation of Hsp90 from GR. GR 
nuclear translocation was reversed with N-acetyl-L-cysteine (Okamoto et al., 1999). 
Another potential mechanism that may contribute to defective GR nuclear 
translocation is increased expression of GR. It has been shown that knockdown of 
GR in alveolar macrophages of asthma patients resulted in increased GR nuclear 
translocation, the GR isoform that corticosteroids bind to, and increased 
corticosteroid response (Goleva et al., 2006).  
 
Nucleocytoplasmic shuttling of proteins has also been shown to be sensitive to 
oxidative stress (Kodiha and Stochaj, 2012). H2O2 at exceptionally high 
concentrations has been shown to impair importin--mediated nuclear translocation; 
importin- being a member of the same family as importin-7. In growing yeast 
Saccharomyces cerevisiae cells, heat, shock and H2O2 significantly impaired 
classical nuclear import of NLS fused to green fluorescent protein (NLS-GFP). This 
was associated with a redistribution of the small GTPase, Gsp1p, from the nucleus 
into the cytoplasm (Stochaj et al., 2000). In HeLa cells, several components of the 
classical nuclear import pathway were affected by extremely high concentrations of 
H2O2. This resulted in the redistribution and degradation of RanGTP, essential for 
nuclear import of cargo proteins, and relocalisation of importin-, resulting in 
impaired nuclear import (Kodiha et al., 2004). 
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1.12 Hypothesis 
As described above, unlike mild-to-moderate asthmatics who respond well to ICS, 
ICS fail to control the underlying inflammation and reverse the decline in lung 
function in COPD patients. Several mechanisms have been shown to contribute or 
be associated to corticosteroid insensitivity in COPD patients and corticosteroid-
resistant asthmatics. Of these, impaired HDAC2 function is the best studied. Another 
postulated mechanism is impaired GR nuclear translocation, which is essential for 
corticosteroid activity. The mechanisms that regulate GR nucleocytoplasmic shuttling 
are mostly unknown.  
 
Recent evidence in an in vitro setting, suggests nuclear importin receptors 7, 8, 13 
and β may facilitate GR nuclear translocation. Amongst these, importin-7 is one of 
the least characterised in its role in inflammatory cells and under oxidative stress. 
Additionally, another member of the nuclear importin receptor family, Importin-β 
mediated transport has been shown to be impaired under oxidative stress.  
 
I propose oxidative stress associated with heightened inflammation may cause 
corticosteroid insensitivity and this may be partly due to impaired GR nuclear 
translocation. Furthermore, I believe importin-7 may contribute to GR nuclear 
translocation and under conditions of oxidative stress it may be impaired 
leading to corticosteroid insensitivity. Two potential targets I propose that may 
be degraded under oxidative stress and lead to corticosteroid insensitivity are 
1) cytoplasmic importin-7 and 2) nuclear RanGTP levels, both essential for 
nuclear import of cargo protein (Fig 1.12).  
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Figure 1.12 Potential mechanisms of reduced glucocorticoid receptor (GR) nuclear 
translocation. Corticosteroid-induced GR nuclear translocation is essential for 
corticosteroid-mediated suppression of pro-inflammatory mediators. Importin-7 binds to and 
mediates nuclear translocation of the glucocorticoid receptor (GR). Once in the nucleus, 
nuclear RanGTP binds to importin-7 resulting in the dissociation of the importin-7 and GR 
complex. Consequently, the GR is able to move through the nucleus and either binds to 
glucocorticoid response elements on corticosteroid-inducible genes or recruits histone 
deacetylase (HDAC)-2 to prevent the gene transcription of pro-inflammatory mediators. 
Activated GR may also prevent gene transcription by binding as a monomeric unit to other 
transcription factors. Under conditions of oxidative stress, importin-7 or nuclear RanGTP 
levels may be reduced leading to reduced GR nuclear translocation and consequently 
corticosteroid insensitivity.  
1 2 
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CHAPTER 2 
MATERIALS AND METHODS 
 
2.1 U937 Cell culture 
The U937 cell line (American Tissue Culture Collection, Rockville, MD) was 
established from malignant cell lines obtained from the pleural effusion of a 37 year 
old Caucasian male with diffuse histiocytic lymphoma. U937 cells express many of 
the monocytic-like characteristics exhibited by cells of histocystic origin and exhibit 
macrophage-like characteristics.  
U937 cells were grown in full RPMI-1640 media (containing 1% L-glutamine and 
10% foetal calf serum (FCS, Invitrogen Ltd, Paisley, UK)) and split every 2-3 days. 
Cells were serum starved in minimal RPMI-1640 media (1% L-glutamine and 0.5% 
FCS) to reduce endogenous steroid content and drive cells towards cell cycle 
synchronisation before experiments. 
 
2.2 Compounds 
Fluticasone furoate (FF), salmeterol (SLM) and vilanterol trifenatate (VI) were 
obtained from GlaxoSmithkline (Greenford, UK). Fluticasone propionate (FP) and 
budesonide (BUD) were purchased from Sigma-Aldrich (Sigma-Aldrich, Poole, UK). 
Stock concentrations of BUD, FP, FF & VI were made up in dimethylsulfoxide 
(DMSO; Sigma, UK) and SLM in ethanol at a concentration of 10-2M. Subsequent 
dilutions were made in medium to yield the final chosen concentrations. Final 
concentrations of DMSO used were 0.25%. All chemicals/reagents were purchased 
from Sigma-Aldrich unless otherwise stated. 
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2.3 (MTT) assay  
The MTT assay was performed on U937 cells (200µl/well of 0.5x106cells/ml) seeded 
in 96-well plates. 125µl of supernatant was removed and 10µl of MTT stock solution 
(5mg/ml; Sigma) was added to the remaining solution, before incubation for 2hr at 
37ºC. Thereafter, DMSO (150µl) was added to each well for 15min at room 
temperature, before the optical density was determined at 550nm.  
 
2.4 MitoSOX Red fluorescence (Mitochondrial ROS) 
U937 monocytes were seeded in low serum media at 2ml of 0.5x106cells/ml per well 
in 6-well plates (Sigma-Aldrich).  Following 3h serum starvation, cells were treated 
with 200μM of H2O2 for 90min followed by 1ng/ml of IL-1 for 30mins. Thereafter, 
cells were washed and resuspended in 5μM MitoSOX Red (M360008, Invitrogen) 
diluted in hanks buffered salt solution (HBSS, Invitrogen), containing calcium (Ca2+) 
and magnesium (Mg2+), and incubated in the dark at 37°C for 30mins. Cells were 
then centrifuged at 1200rpm for 3mins, washed and then resuspended in HBSS 
(containing Ca2+ and Mg2+) in a sterile flow cytometry (FACS) tube at a concentration 
of 0.5x106cells/ml. Antimycin A (AntaA) was used as a positive control for superoxide 
production and cells were incubated for 30min at room temperature (RT) in the dark. 
Mitochondrial superoxide levels were measured by FACS with a 510/580 excitation 
emission.  At least 5,000 events in each sample were collected. Cell debris with low 
forward scatter (FSC) and side scatter (SSC) were excluded from analyses. 
Histogram plots of mean fluorescence intensity for each sample were generated.  
   
2.5 DCF assay 
U937 monocytes were seeded at 100μl of 1x106 cells/ml in a 96-well collagen-coated 
plate 1 day before treatment. The next day, cells were centrifuged (1200rpm at 4°C 
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for 3mins) and washed with KRH buffer (118mM NaCl, 4.8mM KCl, 1.2mM MgSO4, 
2.5mM CaCl2, 10nM HEPES, pH 7.4). Cells were then incubated with 100μM 2, 7-
dichlorofluorescin diacetate (DCFH-DA) in low serum media at 5% CO2/95% air at 
37°C for 30mins. After 30min DCFH-DA incubation, cells were washed and 
incubated with KRH buffer with stimulants, H2O2 and IL-1β, for indicated time points. 
Fluorescence was measured using a plate reader (Synergy HT, Biotek, Winooski, VT 
USA), with an excitation filter set at 485nM and the emission filter set at 530nM.  
 
2.6 Western blotting 
2.6.1 Cytoplasmic and nuclear extraction 
Nuclear and cytoplasmic fractions were extracted using a Nuclear Extraction kit 
(Active Motif, Carlsbad, CA). U937 Cells (9ml of 0.5 x106/ml) were washed 2x with 
ice-cold HBSS and collected by pipetting up and down. Cells were pelleted by 
centrifugation (1500rpm, 5min, 4ºC), resuspended in hypotonic buffer (200µl), 
vortexed and incubated on ice for 15min. Detergent (8µl) was added, the suspension 
vortexed and centrifuged (14000rpm, 30sec, 4ºC), and the supernatant (cytoplasmic 
fraction) collected. The remaining nuclear pellets were resuspended via scraping on 
a metal tube rack, in complete lysis buffer (25µl) containing the protease inhibitors 
and 10mM DTT, and incubated on ice for 30min. The suspension was centrifuged 
(14000rpm, 10min, 4ºC) and the supernatant (nuclear fraction) was collected.  
 
2.6.2 Bradford assay 
Bradford’s reagent (BioRad Laboratories, Hemel Hempstead, Hertfordshire, UK) was 
used to determine cytoplasmic and nuclear protein concentrations. A set of 6 
different final protein concentrations of BSA standard solution (1, 2, 4, 6, 8 & 10µg) 
were added to a 96-well plate in duplicate. Unknown concentrations of nuclear and 
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cytoplasmic (2µl) protein fractions were also added in duplicate. To each well, Biorad 
buffer (200µl) was added. After 5min, absorbance at 595nm was measured using a 
plate reader. A standard curve of absorbance vs. concentration was plotted, and 
used to determine concentrations of nuclear and cytoplasmic fractions.  
 
2.6.3 Polyacrylamide gel electrophoresis 
NuPAGE 4-12% Bis-Tris Pre-Cast gels (Invitrogen) were used under reducing 
conditions to separate proteins of different molecular weights. Gels were firstly rinsed 
with deionised water before being assembled into the gel tank. NuPAGE MOPS 
Running Buffer (Invitrogen) was added into the central compartment, before the 
remaining external compartments were filled, to ensure no leakage. All ten wells of 
the gel were washed with running buffer before adding nuclear or cytoplasmic 
fractions and rainbow marker (Amersham Biosciences, Little Chalfont, UK). 
Corresponding volumes of NuPAGE LDS sample buffer (4X) were added to each 
cytoplasmic and nuclear fraction. These were heated (5min, 95ºC) to denature 
proteins, followed by brief centrifugation. Finally, cytoplasmic and nuclear fractions 
were loaded onto the gels and electrophoresis was performed at 200V and 90A for 
35min. 
 
2.6.4 iBlot dry Western transfer 
After electrophoresis, the polyacrylamide gel was removed from the tank and 
opened. The gel was kept wet at all times and cut with a clean scalpel, removing 
wells and the bottom segment of the gel. The gel was then placed on top of the 
nitrocellulose membrane in the iBlot Western detection bottom stack. Pre-wetted 
filter paper was placed on top of the gel and any bubbles were removed using the 
blotting roller. The Western detection top stack was placed over the filter paper with 
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the electrode side facing up. Finally, the iBlot disposable sponge was positioned so 
that the metal contact was at the upper right corner of the lid, and electro-transfer 
using the iBlot device was performed for 7mins. 
 
2.6.5 Protein immunodetection  
Following the dry Western transfer, the nitrocellulose membrane was removed and 
blocked in 5% non-fat milk TBS-Tween 20 (Sigma) at room temperature for 20min. 
This was removed and 10ml of primary antibody (GR H-300, 1:500, Santa Cruz 
Biotechnology, Santa Cruz, CA) diluted in 5% blocking solution was added and 
incubated overnight at 4ºC on a rocking platform. Thereafter the nitrocellulose 
membrane was washed with TBS-Tween (3x for 5min). 
 
Subsequently, the membranes were incubated with 10ml horseradish peroxidase 
(HRP)-conjugated secondary antibody (goat anti-rabbit, 1:2000, Dako, Cambridge, 
UK) diluted in the blocking solution for 1h on a rocking platform (room temperature). 
Three Washes at 5min with TBS-Tween 20 were repeated, before the antigen-
antibody reactions were detected with the chemiluminescence detection kit 
(Amersham Biosciences). Protein loading control was determined with the use of 
TATA binding protein (TATA BP) and -actin antibodies (Dako). 
 
2.6.6 Band quantification  
The GelDoc Imaging System (UVP, Upland, CA, USA) was used to measure band 
density on the exposed X-ray film. This was standardised against the loading 
controls and compared to untreated cells. Nuclear levels of protein were 
standardised against TATA binding protein (TATA BP; TATA is a conserved DNA 
sequence).  
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2.6.7 Primary and secondary antibodies 
Primary antibody Company Secondary antibody 
GR (H-300) Santa Cruz Goat anti-rabbit 
GR (E-20) Santa Cruz Goat anti-rabbit 
Importin-7 (H-78) Santa Cruz Goat anti-rabbit 
Importin-7 (C-12) Santa Cruz Rabbit anti-goat 
-actin HRP-
conjugated 
Santa Cruz N/A 
TATA BP Abcam Goat anti-mouse 
Anti-Ran Cell Biolabs Goat anti-mouse 
 
Table 2.1 Primary and secondary antibodies. 
 
2.7 Enzyme-linked immunosorbent assay (ELISA)  
Extracellular concentrations of CXCL8 and IL-6 were measured with human CXCL8 
and IL-6 Duoset ELISA kits (R&D Systems Europe, Abingdon, UK) according to the 
manufacturer’s instructions (see below).  
 
2.7.1 CXCL8 and IL-6  
96 well plates were pre-coated with capture antibody (mouse anti-human CXCL8, 
4ug/ml) overnight at room temperature. Each well was aspirated and washed three 
times with wash buffer after incubation with each solution (3X200µl, 0.05% Tween 20 
in PBS). After washing, cells were incubated for 1h with 300µl of blocking buffer per 
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well (1% BSA in PBS). Diluted supernatants (1:2, 100µl, in 0.1% BSA, 0.05% Tween 
20 and Tris-buffered saline (20mM Trizma base, 150mM NaCl)) and standards were 
added to corresponding wells for 2h at room temperature. After the 2h incubation, 
detection antibody (biotinylated goat anti-human, 100µl, 20ng/ml in 0.1% BSA, 
0.05% Tween 20 and Tris-buffered saline) was added and incubated for a further 2h 
at room temperature. This was followed by another wash with washing buffer, before 
incubating for 20min with streptavidin-HRP (1:200 dilution, 100l) at room 
temperature. The remaining steps were conducted in the dark. This was followed by 
the last wash and addition of substrate solution (1:1 mixture of Color Reagent A 
(H202) and Color Reagent B (Tetramethylbenzidine)) for 20min. Finally, 50µl of Stop 
Solution (2N H2SO4) was added to each well before determining optical density using 
a microplate reader set to 450nm (wavelength correction set at 540nm).   
 
2.8 DNA promoter binding assays 
2.8.1 GR-GRE Assay  
The TransAM GR kit (Active Motif) was used to determine GR binding to DNA. 96-
well plates consisting of 8-well strips coated with streptavidin were immobilised with 
biotinylated DNA oligonucleotides (GRE sequence, GGTACAnnnTGTTCT). Nuclear 
and cytoplasmic extracts (15µg in 20µl complete lysis buffer) were incubated with 
complete binding buffer (30µl) for 1h at room temperature on a gently rocking 
platform. Thereafter, the wells were washed with wash buffer. Followed by 
incubation with an anti-GR antibody (100µl, 1:1000) and an HRP-conjugated anti-
rabbit antibody (100µl, 1:1000), for 1h each, at room temperature. After washing, 
developing solution (100µl) was added to each well in the dark for 10min, before 
terminating the reaction with stop solution (100µl). Finally, the colour change was 
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determined using a microplate reader set at 450nm (wavelength correction set at 
655nm). 
 
2.8.2 Nrf2 DNA binding assay  
The TransAM Nrf2 kit (Active Motif) was used to determine Nrf2 binding to DNA. 96-
well plates consisting of 8-well strips coated with streptavidin were immobilised with 
biotinylated DNA oligonucleotides (ARE sequence, 
GTCACAGTGACTCAGCAGAATCTG). Nuclear and cytoplasmic extracts (10µg in 
10µl complete lysis buffer) were incubated with complete binding buffer (40µl) for 1h 
at room temperature on a gently rocking platform. Thereafter, the wells were washed 
with wash buffer. Followed by incubation with an anti-Nrf2 antibody (100µl, 1:1000) 
and an HRP-conjugated anti-rabbit antibody (100µl, 1:1000), for 1h each, at room 
temperature. After washing, developing solution (100µl) was added to each well in 
the dark for 10min, before terminating the reaction with stop solution (100µl). Finally, 
the colour change was determined using a microplate reader set at 450nm 
(wavelength correction set at 655nm). 
 
2.8.3 p65 (NF-B) DNA binding Assay 
The TransAM p65 (NF-B) kit (Active Motif) was used to determine p65 (NF-κB) 
binding to DNA. 96-well plates consisting of 8-well strips coated with streptavidin 
were immobilised with biotinylated DNA oligonucleotides (sequence, 
GGGACTTTCC). Nuclear extracts (5µg in 20µl complete lysis buffer) were incubated 
with complete binding buffer (30µl) for 1h at room temperature on a gently rocking 
platform. Thereafter, the wells were washed with wash buffer. Followed by 
incubation with an anti-p65 antibody (100µl, 1:1000) and an HRP-conjugated anti-
rabbit antibody (100µl, 1:1000), for 1h each, at room temperature. After washing, 
65 
 
developing solution (100µl) was added to each well in the dark for 5min, before 
terminating the reaction with stop solution (100µl). Finally, the colour change was 
determined using a microplate reader set at 450nm (wavelength correction set at 
655nm). 
 
2.9 Quantitative real time reverse transcription polymerase chain reaction (RT-
qPCR) 
2.9.1 mRNA extraction 
mRNA extraction was performed using the RNeasy kit (Qiagen, Crawley, East 
Sussex, UK). Briefly, cells were centrifuged at 4500 rpm at 4°C for 5mins and 
resuspended in 350μl RLT buffer, cell lysis buffer. Ensure all medium is removed 
before resuspending in RLT buffer to prevent incomplete cell lysis. Cells were then 
homogenized in RLT buffer using a QIAshredder spin column by centrifuging for 
2min at 8,000xg. An equal volume of 70% ethanol was mixed with the homogenized 
lysate. 700μl of homogenized lysate in ethanol was transferred to an RNeasy spin 
column and centrifuged for 15sec at 8,000xg. Flow-through was discarded after the 
centrifugation and 700μl of buffer RW1 was added to the RNeasy spin column. Once 
again, the RNeasy spin column was centrifuged for 15sec at 8,000xg to wash the 
spin column and the flow-through was discarded. Next, 500μl of buffer RPE was 
added to the RNeasy spin column and centrifuged for 15sec at 8,000xg. This was 
repeated again; however this time the spin column was centrifuged for 2min to 
ensure no ethanol is carried over during RNA elution. Flow through was discarded 
and RNeasy spin column was placed in a new 1.5ml collection tube. Finally, 30μl of 
RNase-free water was added to the RNeasey spin column and centrifuged for 1min 
at 8,000xg to elute the RNA. RNA was stored at -80°C for future use. The 
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concentration and purity of RNA was evaluated by spectrophotometery using a 
Nanodrop (NanoDrop Technologies, Wilmington, Delaware, USA).  
 
2.9.2 Reverse transcription 
Reverse transcriptase was performed using the Qiagen Quantitect kit (Qiagen). 
mRNA samples were thawed on ice. 20μ l eppendorfs were pre-labelled and 1μg of 
corresponding mRNA samples and 2μl of gDNA Wipeout buffer were added. The 
remaining volume was made up to 14μl with RNase-free water (see Table 2.2). 
Eppendorfs were then incubated for 2min at 42°C and immediately placed on ice 
thereafter. 
 
Component Amount 
gDNA Wipeout Buffer, 7X 2 μl 
Template mRNA 1μg 
RNase-free water Variable 
Total volume 14 μl 
Table 2.2 Genomic DNA elimination components 
 
During the 2 min incubation period, the reverse-transcription master mix was 
prepared on ice for cDNA synthesis (see Table 2.3). 
 
Component Amount 
Reverse Transcriptase 1μl 
RT buffer, 5X 4μl 
RT Primer Mix 1μl 
Total 6μl 
     Table 2.3 Reverse-transcription master mix components 
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6μl of reverse-transcription master mix was added to 14μl of template mRNA and 
then incubated for 15min at 42°C. Finally, samples were incubated for a further 3min 
at 95°C to inactivate the reverse transcriptase.  
 
2.9.3 Quantitative RT-PCR 
mRNA levels of DUSP-1 and 18S were quantified by real-time qPCR using TaqMan 
Universal master mix (Applied Biosystems, Foster City, CA, USA). The TaqMan 
probes are based on the 5-3 exonuclease activity of the Taq DNA polymerase which 
leads to cleavage of fluprescent dye-labelled probes during PCR. Each transcript 
was analysed by delta () CT method and corrected to the CT values of the 18S 
reference gene. Cycle parameters were 95°C for 15min to activate HotStarTaq DNA 
Polymerase, followed by annealing and extension for 50 cycles at 94°C for 15sec, 
followed by 60°C for 25sec and finally 72°C for 25sec. mRNA expression levels of 
DUSP-1 was normalised to reference gene 18S. 
 
Gene name Assay ID 
DUSP-1 Hs00610256_g1 
18S Hs99999901_s1 
 
Table 2.4 List of assay probes used  
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2.10 Transfection (importin-7 knockdown) 
Transfection of U937 monocytes was performed in 6-well plates and 96-well plates 
for analysis of intracellular protein and extracellular pro-inflammatory mediators, 
respectively. Cells were washed with hanks buffer and carefully resuspended in 
100μl Nucleofector solution per sample, at a concentration of 1x106 cells/100μl. 
Immediately, 200nM of human importin-7 ON-TARGETplus SMARTpool small-
interfering RNA (siRNA) or negative siRNA control, ON-TARGETplus Non-Targeting 
pool (Thermo Fisher Scientific, Epsom, UK) was added to cells. Cells were 
transferred immediately into certified cuvettes, avoiding bubbles. The cuvette was 
immediately inserted into the Nucleofector Cuvette holder and an electrical current 
was passed through the cells. Post-transfection, 500μl of the pre-equilibrated 
complete RPMI-1640 media (1% L-glutamine and 10% FCS) was added immediately 
to the cells to neutralise the effects of the Nucleofector solution. The cells were 
diluted further with complete RPMI-1640 media in a final volume of 3ml/well in a 6-
well plate. Subsequently, cells were incubated for 36h at 37°C and 5% CO2, 
followed by serum starvation for 3h in minimal media before treatment.         
 
2.11 Ran activation assay 
Intracellular levels of RanGTP were measured with Ran activation assay kit (Cell 
Biolabs, San Diego, CA, USA). The procedure is detailed below. 
 
2.11.1 Cell lysates 
Serum starved U937 monocytes were seeded at a density of 0.5x106 cell/ml in large 
flasks. Cells were treated with H2O2 for 90min, followed by IL-1β for a further 30min. 
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Cells were washed with ice-cold PBS and resuspended in ice-cold 1X Assay/Lysis 
Buffer. Lysates were centrifuged for 10min at 14,000xg at 4°C.  
 
2.11.2 GTPˠS/GDP (Positive and Negative Controls) 
0.5-1ml of each cell lysate was made up to 1ml with 1X Assay Lysis Buffer, followed 
by, the addition of 20μl of 0.5M EDTA. 10μl of 100X GTPˠS was added to the 
positive control tube and 10μl of 100X GDP was added to the negative control tube. 
Positive and negative controls were incubated for 30min at 30°C with agitation. Then 
65μl of 1M MgCL2 was added to stop the reaction. Tubes were placed on ice.  
 
2.11.3 Ran Pull-Down Assay 
In separate eppendorfs, 40μl of thoroughly resuspended RanBP1 PBD Agarose 
beads were added to 1ml of cell lysate made up with 1X Assay Lysis Buffer. Cell 
Lysates were incubated with gentle agitation for 1h at 4°C followed by 10sec 
centrifugation at 14,000xg. Supernatant was carefully discarded and bead-pellet 
conjugate was washed 3 times with 0.5ml of 1X Assay Buffer. Thereafter, the bead 
pellet was resuspended in 40μl of 2X reducing SDS-PAGE sample buffer and boiled 
for 5min, finally followed by centrifugation at 14,000xg for 10sec. Positive and 
negative control samples (see section 2.11.2) were treated in a similar manner 
before separation by SDS-PAGE.    
 
2.11.4 Western blotting 
See sub-sections 2.6.4-2.6.6. 
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Antibody Dilution 
Primary Mouse Anti-Ran antibody  1:1000 
Secondary Goat Anti-Mouse IgG 1:2000 
Table 2.5 Details of anti-Ran antibody 
 
2.12 Blood monocyte extraction 
80ml of whole blood was collected from each patient. 15ml of Ficoll-Paque solution 
(GE Healthcare, Chalfont St Giles, UK) was added to 4x 50ml conical flasks. 20ml of 
blood was carefully pipetted over the Ficoll-Paque solution, followed by 
centrifugation for 30min at 400xg at room temperature with the brake off. The top 
layer, plasma, was carefully discarded from the 50ml falcon tubes. The cloudy layer, 
containing all the PBMCs, was gently collected using a Pasteur pipette and 
transferred into a newly labeled 50ml falcon tube. The remaining 50ml volume was 
made up with PBS and centrifuged at 200xg for 10min with the brake on. PBMCs 
were seeded at a density of 2x106 cells/ml in complete media for 2h at 37°C and 5% 
CO2. The supernatant was carefully aspirated off and adherent cells, monocytes, 
were washed and resuspended in minimal media with relevant stimulants. 
 
2.13 Replicate experiments and statistical analysis  
At least three independent experiments were performed, with each sample reported 
as the mean of duplicate or triplicate analysis. For most experiments, due to the 
numbers we assumed a non-Gaussian distribution and analysed data using non-
parametric tests. For comparison of one group to a hypothetical value or comparison 
of two paired groups we used the Wilcoxon test. Comparison of two unpaired groups 
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was determined by the Mann-Whitney test, whereas analysis of three or more 
unmatched groups was initially analysed by Kruskal-Wallis ANOVA prior to specific 
non-parametric comparisons. Results were considered significant if p<0.05. 
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CHAPTER 3 
COMPARISON OF THREE CORTICOSTEROIDS ON 
GLUCOCORTICOID RECEPTOR FUNCTION AND 
ACTIVITY 
 
3.1 Introduction 
Corticosteroids are widely used in the treatment of asthma as monotherapy and, in 
both asthma and chronic obstructive pulmonary disease (COPD) in combination with 
bronchodilators. As previously discussed, corticosteroids exert their effects by 
binding to the glucocorticoid receptor (GR), causing GR nuclear translocation, where 
activated GR either upregulates transcription of anti-inflammatory genes or 
downregulates the transcription of pro-inflammatory genes. Activated GR may bind 
directly to the promoter regions of genes that encode pro-inflammatory proteins via 
GREs or negative GREs. GR binding to the palindromic promotor induces the 
transcriptional induction of anti-inflammatory genes such as DUSP1 and secretory 
leukocyte protease inhibitor (SLPI). In contrast, activated GR recruits HDAC2 to NF-
B complexes, which inhibits a range of pro-inflammatory mediators. By this process 
of transrepression, corticosteroids suppress pro-inflammatory mediators such as 
TNF- and CXCL8 in mild-to-moderate asthmatic patients whereas they are far less 
effective in COPD patients (Barnes, 2006b, Barnes, 2011).  
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Better understanding of the structure activity relationships of inhaled corticosteroids 
has led to the development of new corticosteroids with higher therapeutic ratios and 
lower systemic bioavailabilities. Fluticasone propionate (FP) has been shown to have 
high affinity and selectivity for GR and low systemic absorption (Phillipps, 1990). GR 
affinity of FP and mometasone furoate (MF) is estimated to be about 12 and 5 times 
of dexamethasone and BUD, respectively (Crim et al., 2001). Recently, fluticasone 
furoate (FF), a novel new longer-acting ICS, under development as once-daily 
treatment in combination with the LABA, vilanterol trifenatate (VI), for asthma and 
COPD, has been shown to have a greater affinity for GR than FP. Valotis and 
Hogger have shown, FF has a very fast association and a slow dissociation from 
human GR binding kinetics, with a relative receptor affinity (RRA; relative to 
dexamethasone (RRA: 100)) of 2,988, in comparison with other corticosteroids, 
which have a much lower receptor affinity: MF, 2,244; FP, 1775; and BUD, 855 
(Valotis and Hogger, 2007). This may be partly due to better H-bonding and van der 
Waals interaction of the 17-α ester group of FF with the ligand-binding site of GR, 
giving rise to a prolonged duration of action as seen in dose ranging studies in 
asthmatics, where FF had at least 23 hours duration of efficacy (Woodcock et al., 
2011, Oliver et al., 2012).  
 
FP and FF are structurally related; however their chemical and pharmacological 
properties are different. These differences in physiochemical properties, may 
contribute to a favourable efficacy profile for FF. FF was identified after chemical 
changes on the 17- ester group of FP. Based on these pharmacodynamic and 
pharmacokinetic differences between these corticosteroids it would be important to 
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determine whether they have an impact on corticosteroid-induced GR nuclear 
translocation and subsequent downstream events, such as transactivation and 
suppression of pro-inflammatory mediators.  
 
The combination of corticosteroids and LABA has been shown to improve clinical 
effectiveness and anti-inflammatory properties in asthma (Juniper et al., 1999, 
Woolcock et al., 1996). The addition of LABA to low dose corticosteroids has been 
shown to be more clinically beneficial in asthma than the use of high dose inhaled 
corticosteroids, allowing a reduction in the dose of corticosteroid and minimising 
adverse side effects related to corticosteroid therapy. Corticosteroids such as BUD, 
beclomethasone dipropionate (BDP) and FP have been used in combination with 
LABA such as FORM and SLM. These combination treatments are established in 
International  Guidelines for treating patients with asthma (GINA, 2011) and also, 
COPD (Rabe et al., 2007).  Evidence suggests that LABA enhance GR function in 
vitro. In an asthmatic study, the combination of SLM and FP was as effective as high 
dose FP on GR activation, gene transactivation and transrepression (Usmani et al., 
2005b). The LABA SLM and FORM and recently indacaterol are the only licensed 
LABA for clinical use as monotherapy in COPD and in combination with 
corticosteroid for both asthma and COPD. FORM is used in combination with BUD, 
or in combination with BDP, whereas salmeterol is used in combination with FP. 
LABA may interact and bind with the 2-adrenergic receptor (2-AR) in different 
ways, and may elicit different responses (Coleman et al., 1996). For example, in 
bronchial tissue preparations FORM acts as a nearly full 2-AR agonist, whereas 
SLM acts as a partial 2-AR agonist (Kallstrom et al., 1994, Scott et al., 1999). 
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Increased potency may lead to greater phosphorylation of GR via increased MAPK 
activation (Adcock et al., 2002, Miller et al., 2005). Phosphorylation of GR may alter 
its nuclear translocation (Weigel and Moore, 2007). Based on this evidence, it would 
be important to investigate the effects of LABA in combination with their clinically co-
administered corticosteroids in comparison to the newer and longer-acting 
combination of FF and VI, which are currently under development.   
 
Differences in the chemical structure and physiochemical properties of 
corticosteroids, as well as their affinity for GR may determine their duration of action 
(Valotis and Hogger, 2007, Crim et al., 2001). Together, these factors will control and 
affect the clearance of inhaled drug from the lungs. Processes that govern drug 
clearance in the lungs are mostly absent in the in vitro setting. In order to mimic lung 
clearance and thereby to better model the in vivo environment, I have incorporated a 
20h washout step, following 4h corticosteroid incubation in my experiments.   
 
The duration of action of a corticosteroid will affect its efficacy. Increasing the 
duration of corticosteroid-induced GR nuclear translocation may improve the 
corticosteroid’s duration of action. GR nuclear translocation is a dynamic process 
governed by nuclear import and export receptors. A nuclear export signal (NES) 
located on the cargo protein is recognised by exportins. Recognition of the NES of a 
protein results in the formation of an exportin-cargo protein complex and subsequent 
nuclear export of the complex. Several studies have suggested that the nuclear 
exportin pathway CRM-1 may govern GR nuclear export. In an in vitro study, 
leptomycin B (LMB), a specific inhibitor of CRM-1 mediated nuclear export, inhibited 
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GR nuclear export, which led to enhanced unliganded and hormone-treated GR 
nuclear localisation (Savory et al., 1999). It would be important to characterise the 
role of CRM-1 mediated transport on GR nuclear export in inflammatory cells 
important in asthma and COPD. Unravelling the mechanisms that govern GR 
nuclear export would allow one to potentially increase the pharmacokinetic profile of 
a corticosteroid, as well as more importantly, the duration of the anti-inflammatory 
effects of the corticosteroid.  
 
The alveolar macrophage is predominantly found in the alveolar spaces of the lung 
and in the small conducting airways and has been linked to the pathogenesis of 
asthma and COPD (Peters-Golden, 2004). As there are no human macrophage cell 
lines available, we used a well established model of monocytic U937 cells, which has 
similar phenotypes to macrophages (Harris and Ralph, 1985).  
 
 
 
 
 
 
 
          IC50                          5.4±3.0x10
-10M          1.2±3.0x10-10M           2.3±3.1x10-11M                                
      (Suppression of IL-1β 
    -induced CXCL8 (Fig. 3.3.2.1))  
 
Fig. 3.1 Comparison of the structures and GR affinities of budesonide, fluticasone 
propionate and fluticasone furoate. 
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3.2 Experimental protocols 
3.2.1 GR nuclear translocation  
Following 3h serum-starvation, U937 cells (20ml of 0.5x106 cells/ml) were incubated 
with different corticosteroids for different time points. Cells were immediately washed 
with HBSS and extraction of cytoplasmic and nuclear fractions was performed 
(section 2.6.1). A pilot in vitro study was conducted to determine the optimal 
concentration of each corticosteroid to be used (The final concentration of DMSO 
(0.25%) used to dissolve the corticosteroid had no effect on GR subcellular 
localisation (Fig. 3.2.1.1). As seen in Figure 3.2.1.2, FF-induced GR nuclear 
localisation in a concentration-dependent manner with a sub-maximal effect being 
seen with 10-9M FF.  This sub-maximal concentration was used to compare the 
activity and function of each corticosteroid for all future experiments.   
                                   Cytoplasm                   Nucleus 
    
  
   Loading control 
(β-actin and TATA BP)   
 
Fig. 3.2.1.1 Effect of DMSO (0.25%) on GR nuclear translocation. Serum-starved U937 
monocytes were incubated with DMSO (0.25%).  
 
 
 
 
GR 
Basal       DMSO Basal       DMSO 
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Fig. 3.2.1.2 Effect of varying concentrations of fluticasone propionate (FF, 10-11-10-7M) 
on GR nuclear localisation. Serum-starved U937 monocytes were incubated with FF for 
4h. Nuclear fractions were immediately isolated followed by Western blot analysis of GR. GR 
levels were normalised to levels of TATA binding protein (TATA BP). Results represent the 
mean±SEM of 3 independent experiments. *p<0.05 vs. basal. 
 
3.2.2 CXCL8 ELISA  
Serum-starved U937 cells (200µl/well, 0.5x106 cells/ml) were seeded in 96-well 
plates and treated with a range of IL-1 concentrations (0.1-100ng/ml) in order to 
determine the sub-maximal concentration of IL-1 required to stimulate CXCL8 
release from these cells after 16h.  As shown in Figure 3.2.2, IL-1β increased 
extracellular CXCL8 secretion in a concentration-dependent manner. IL-1β at 1, 10 
and 100ng/ml increased CXCL8 secretion by 290±28, 350±27 and 480±23ng/ml 
respectively, with no significant difference seen between 1 and 10ng/ml.  All future 
experiments were conducted with the sub maximal concentration of IL-1β (1ng/ml). 
Nuclear GR 
TATA BP 
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In subsequent experiments, serum-starved U937 cells (200µl/well, 0.5x106 cells/ml) 
seeded in 96-well plates were treated with corticosteroid (BUD, FP or FF) and LABA 
(FORM, SLM or VI), alone and in combination, following 30min stimulation with IL-1β 
(1ng/ml). 16 h post IL-1β stimulation, the cell supernatant was collected to determine 
CXCL8 secretion levels.  
 
 
 
 
 
  
Fig. 3.2.2 Effect of IL-1β on CXCL8 secretion in U937 monocytes. Serum-starved U937 
monocytes were stimulated with varying concentrations of IL-1β for 16 h. Results represent 
the mean±SEM of 3 independent experiments. *p<0.05 vs. basal 
 
3.2.3 DUSP1 mRNA expression 
Serum-starved U937 cells seeded in 24-well plates, as 0.5x106 cells/ml were treated 
with corticosteroids for 3h. DUSP1 mRNA expression was quantified by RT-qPCR 
(see section 2.9).    
 
3.2.4 Corticosteroid washout  
Serum-starved U937 cells were seeded at 20ml of 0.5x106 cells/ml in flasks and 
200μl of 0.5x106 cells/ml in 96-well plates for GR nuclear localisation and CXCL8 
ELISA, respectively. Cells were treated with corticosteroid for 4h followed by 20h 
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washout. In addition, U937 cells seeded in 96-well plates were also pre-treated with 
IL-1β (1ng/ml).  
 
3.3 Results 
3.3.1 Comparison of BUD-, FP- and FF-induced GR nuclear translocation 
GR nuclear translocation is essential for corticosteroid action. We explored whether 
differences in the physiochemical properties and binding affinities of corticosteroids 
would impact on the level of GR nuclear translocation. GR nuclear translocation post 
corticosteroid incubation was examined at 2h and 24h. At 2h continual exposure, 
BUD, FP and FF (all at 10-9M) significantly induced GR nuclear localisation by 
2.96±0.74-, 6.06±0.95- and 7.3±1.48-fold, respectively, relative to basal levels 
(*p<0.05 vs. basal). FF-induced GR nuclear localisation was significantly greater 
than BUD (#p<0.05 vs. BUD 10-9M), but similar to that for FP. There was a 
corresponding decrease in cytosolic GR levels of 43.1±6.43% (BUD), 70.9±5.0% 
(FP) and 80.5±6.14% (FF), relative to basal levels (*p<0.05 vs. basal) (Fig. 3.3.1a). 
Additionally, levels of GR nuclear translocation 2h post BUD, FP and FF challenge 
were maintained with 24h continual exposure. Continual exposure for 24h to BUD, 
FP and FF at 10-9M significantly induced GR nuclear localisation by 3.0±0.61, 
5.6±0.88 and 6.3±0.84-fold, respectively (*p<0.05 compared to unstimulated 
controls). Similarly, FF-induced GR nuclear localisation was significantly greater than 
BUD, but comparable to that achieved with FP, as was observed during the 2h 
continual exposure experiments. Once again, there were corresponding decreases 
in cytosolic GR post corticosteroid treatment (Fig. 3.3.1b).  
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Figure 3.3.1a Effect of budesonide (BUD), fluticasone propionate (FP) and fluticasone 
furoate (FF), all at 10-9M, on GR nuclear translocation. U937 monocytes were incubated 
in low-serum media to reduce endogenous steroid content and to drive cells towards 
synchrony. U937 monocytes were then incubated with BUD, FP and FF for 2h. Results 
represent the mean±SEM of 3 independent experiments. *p<0.05 vs. basal. #p<0.05 vs. 
BUD 10-9M. 
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Fig 3.3.1b Effect of budesonide (BUD), fluticasone propionate (FP) and fluticasone 
furoate (FF), all at 10-9M, on GR nuclear translocation. U937 monocytes were incubated 
in low-serum media to reduce endogenous steroid content and to drive cells towards 
synchrony. U937 monocytes were then incubated with BUD, FP and FF for 24h. Results 
represent the mean±SEM of 3 independent experiments. *p<0.05 vs. basal.  
 
3.3.2 Cytokine secretion 
3.3.2.1 Corticosteroids suppress CXCL8 secretion with varying potencies 
Next we undertook to determine whether the differences seen in BUD-, FP- and FF-
induced GR nuclear translocation would result in different levels of IL-1β-induced 
CXCL8 suppression. Briefly, U937 cells were stimulated with the sub-maximal 
concentration of IL-1β (1ng/ml) for 30min, followed by incubation with BUD, FP and 
FF. 16h post IL-1β stimulation, supernatant was collected and CXCL8 levels were 
measured. BUD, FP and FF suppressed CXCL8 in a concentration-dependent 
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manner, with IC50 values of 5.4±3.0x10
-10M (BUD), 1.2±3.0x10-10M (FP) and 
2.3±3.1x10-11M (FF) (Fig. 3.3.2.1). There was more than a 10-fold increase in the 
concentration required to give 50% inhibition between FF and BUD, which reflects 
the differences seen in levels of GR nuclear translocation. Additionally, the maximal 
inhibition of CXCL8 achieved by BUD, FP and FF were 69.1±19.8% (BUD), 
85.1±12.2% (FP) and 81.7±5.3% (FF) with no significant difference seen between all 
three corticosteroids. At 10-11M, BUD only inhibited CXCL8 secretion by 19.3±2.3%, 
whereas the corresponding concentrations of the more potent FP and FF 
suppressed CXCL8 secretion by significantly greater levels (41.6±7.1% and 
54.2±7.4% respectively, p<0.05 vs. BUD 10-9M). 
 
 
 
 
 
 
 
 
Fig. 3.3.2.1 Effect of budesonide (BUD), fluticasone propionate (FP) and fluticasone 
furoate (FF) on IL-1β-induced CXCL8. Serum-starved U937 monocytes were incubated 
with IL-1β for 30min, followed by incubation with (a) BUD, (b) FP or (c) or FF. 16h post IL-1β 
stimulation, supernatant was collected for CXCL8 analysis. Results represent the 
mean±SEM of a minimum of 3 independent experiments. 
 
3.3.2.2 LABA enhance corticosteroid suppression of CXCL8 
Next we explored the effects of different concentrations of corticosteroid (10-11 and 
10-9M) alone, and in combination with LABA (10-9M) on IL-1β-induced CXCL8 
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secretion. BUD, FP and FF at 10-11M significantly suppressed IL-1β-induced CXCL8 
by 25.0±5.5%, 34.0±4.9% and 35.0±5.2%,respectively.  The suppression seen with 
both FP and FF being significantly greater than that seen for BUD. In contrast, none 
of the LABA tested (FORM, SLM and VI, all at 10-9M) had any effect on IL-1β-
induced CXCL8.  However, the addition of LABA (FORM, SLM and VI all at 10-9M) to 
their respective corticosteroids (BUD, FP and FF all at 10-11M) resulted in greater 
suppression of IL-1β-induced CXCL8 release to 46.8±11.1%, 43.0±7.0 and 
52.9±7.86% of control levels respectively (Fig. 3.3.2.2). However, although the 
combination of FP (10-11M) with SLM (10-9M) further enhanced FP-induced 
suppression of CXCL8 by 9.29±4.88% this was not statistically significant. In 
contrast, FORM and VI (both at 10-9M) significantly enhanced BUD and FF (both at 
10-11M)-induced suppression of CXCL8 secretion by 22.0±11.0 and 18.0±7.9% 
respectively, relative to BUD (10-11M) and FF (10-11M) alone (*p<0.05). Furthermore, 
BUD (10-11M) in combination with FORM (10-9M) was as effective as the higher 
concentration of BUD (10-9M). In contrast, FF (10-11M) in combination with VI (10-9M) 
was not as effective as the higher concentration of FF (10 -9M).   
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Fig. 3.3.2.2 Effect of budesonide (BUD), fluticasone propionate (FP) and fluticasone 
furoate (FF), alone and in combination with their respective LABAs on IL-1β-induced 
CXCL8 release. Serum-starved U937 monocytes were incubated with IL-1β for 30min, 
followed by incubation with corticosteroids (BUD, FP and FF all at 10-11M) and LABAs 
(formoterol; FORM, salmeterol; SLM and vilatenerol trifenatate; VI all at 10-9M) alone and in 
combination. 16h post IL-1β stimulation, supernatant was collected for CXCL8 analysis. 
Results represent the mean±SEM of a minimum of 3 independent experiments. *p<0.05 vs. 
corticosteroid (10-11M) alone. 
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3.3.3 DUSP1 expression 
So far we have established that FF-induced GR nuclear translocation and 
suppression of IL-1β is significantly greater than that of BUD, but similar to that 
observed with FP, when corticosteroids are used at 10-9M. We next wanted to 
determine whether this was also true for corticosteroid-induced gene transactivation. 
We investigated the effects of BUD, FP and FF (all at 10-9M) on DUSP1 mRNA 
expression (Fig. 3.3.3). BUD-, FP- and FF-induced DUSP1 mRNA expression by 
6.7±1.3-, 4.0±1.7- and 4.9±1.7-fold respectively relative to basal levels (*p<0.05 vs. 
basal). Interestingly, unlike GR nuclear translocation and suppression of IL-1β-
induced CXCL8, FF was not superior to BUD. In fact, BUD caused a greater 
increase in DUSP1 mRNA expression, compared to both FP and FF, although this 
did not reach statistical significance. 
 
 
 
 
 
 
 
 
Fig. 3.3.3 Effect of budesonide (BUD), fluticasone propionate (FP) and fluticasone 
furoate (FF) on DUSP-1 mRNA induction. Serum-starved U937 monocytes were 
incubated with BUD, FP and FF for 3h. mRNA extraction was performed immediately. 
Results represent the mean±SEM of 3 independent experiments. (*p<0.05 vs. basal). 
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3.3.4 Corticosteroid washout 
3.3.4.1 FF maintains GR nuclear localization following 20h washout 
BUD, FP and FF all induced sustained GR nuclear translocation over a 24h period in 
a constant drug contact setting. However, in the lungs, ICS are exposed to drug 
clearance; that is, as inhaled drug reaches the airways it becomes exposed to a 
variety of mechanisms that clear the drug from the airways. In order to determine 
whether the differences in the physiochemical properties between these three 
corticosteroids and their binding affinities for GR affect corticosteroid duration of 
action, I introduced a 20h corticosteroid washout model following a 4h pre-
incubation.  In the 20h washout experiments, there was a similar level of GR nuclear 
translocation seen with FF (10–9M) treatment at 24h (4+20h) as seen with continual 
FF exposure (5.4±1.0- versus 6.3±0.84-fold increase, p=ns). However, FP- and 
BUD-induced GR nuclear translocation was dramatically reduced back to basal 
levels in the 20h washout model (Fig. 3.3.4.1).  
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Fig. 3.3.4.1 Effects of budesonide (BUD), fluticasone propionate (FP) and fluticasone 
furoate (FF) on GR nuclear localisation. Serum-starved U937 monocytes were incubated 
with BUD, FP and FF for 4h, followed by a 20h washout. Nuclear extraction was conducted 
immediately and nuclear levels of GR were determined by Western blot. Results represent 
the mean±SEM of a minimum of 3 independent experiments. #p<0.05 vs. 24h BUD 10-9M 
contact. *p<0.05 vs. 24h FP 10-9M contact. 
 
3.3.4.2 FF maintains IL-1β-induced CXCL8 suppression during 20h washout 
Similarly, FF (52±6.4 vs. 69±6.6%, p=ns)-mediated suppression of IL-1β-induced 
CXCL8 was not affected in the 20h washout model. In contrast, BUD (2.2±2.2 vs. 
45.9±7.7%, #p<0.05) and FP (38.2±9.0 vs. 69.0±5.1%, *p<0.05)-mediated 
suppression of IL-1β-induced CXCL8 was significantly reduced. 
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Fig 3.3.4.2 Effects of budesonide (BUD), fluticasone propionate (FP) and fluticasone 
furoate (FF) on IL-1β-induced CXCL8. Serum-starved U937 monocytes were firstly 
stimulated with IL-1β for 30min followed by 4h BUD, FP or FF incubation. After 4h, 
corticosteroid was washed out, IL-1β was replaced and cells further incubated for another 
20h. Results represent the mean±SEM of a minimum of 3 independent experiments. #p<0.05 
vs. 24h BUD 10-9M contact. *p<0.05 vs. 24h FP 10-9M contact. 
 
3.3.5 LMB enhances FF-induced GR nuclear localisation 
So far, we have shown that a 20 h washout leads to reduced FP- and BUD-induced 
GR nuclear import. GR nucleocytoplasmic shuttling is a dynamic process, a balance 
between GR nuclear import and export. Inhibiting GR nuclear export may shift the 
balance towards GR nuclear import and therefore lead to increased retention of 
corticosteroid-induced GR nuclear localisation. We therefore explored the effects of 
inhibition of exportin-1 on corticosteroid-induced GR nuclear localisation. Nuclear 
export inhibitor, LMB (10nM) alone, had no effect on GR subcellular localisation (Fig. 
3.3.5.1). I pre-treated cells with LMB (10nM) for 30 min, followed by incubation with 
FF (10-7M) for 2h. I observed that FF-induced GR nuclear localisation in a 
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concentration dependent manner with a 4.7±0.54- and 6.2±0.65-fold increase seen 
at 10-9 and 10-7M respectively (both *p<0.05 vs. basal levels) (Fig. 3.3.5.2). More 
importantly, pre-treatment with LMB (10–8M) significantly enhanced FF (10–7M)-
induced GR nuclear localisation at 2h by a further 1.4-fold (8.8±0.90 vs. 6.2±0.65; 
#p<0.05). 
                                      Cytoplasm                   Nucleus 
 
 
Fig. 3.3.5.1 Effect of leptomycin B (LMB) on glucocorticoid receptor (GR) subcellular 
localisation. Serum-starved U937 cells were incubated with LMB (10nM) for 4 h. 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 3.3.5.2 Effect of leptomycin B (LMB) on fluticasone fuorate (FF)-induced GR 
nuclear localisation. Serum-starved U937 cells were stimulated with LMB (10nM) for 30min 
followed by FF for 4h. Results represent the mean±SEM of 3 independent experiments. 
*p<0.05 vs. basal levels. #p<0.05 vs. FF (10-7M).  
GR  
TATA BP 
GR 
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3.3.6 LMB enhances corticosteroid induced GR-GRE binding 
GR nuclear translocation is essential for activated GR to bind to GRE on 
corticosteroid-inducible genes. FF significantly induced GR-GRE binding in a 
concentration-dependent manner with the highest concentration of FF (10 -7M) 
increasing GR-GRE binding by more than 4-fold in comparison to basal nuclear 
levels (3.2±0.43 vs. 0.84±0.30, *p<0.05) (Fig. 3.3.6). Furthermore, pre-treatment with 
LMB for 30min further enhanced FF (10-7M)-induced GR-GRE binding (4.7±0.38- vs. 
3.2±0.43-fold increase, #p<0.05). 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3.6 Effect of leptomycin B (LMB) on fluticasone fuorate (FF)-induced GR-GRE 
binding. Serum-starved U937 cells were stimulated with LMB (10nM) for 30min followed by 
FF for 2h. Results represent the mean±SEM of 3 independent experiments. *p<0.05 vs. 
basal levels. #p<0.05 vs. FF (10-7M).  
 
3.3.7 LMB enhances BUD-induced GR nuclear localisation 
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So far, we have shown LMB (10nM) enhances FF-induced GR nuclear localisation 
and GR-GRE binding. In Fig. 3.3.4.1, we showed that BUD- and FP-induced GR 
nuclear localisation were significantly reduced post 20h corticosteroid washout, 
whereas FF-induced GR nuclear localisation was not affected. We next investigated 
whether LMB could reduce the loss in nuclear GR post 20h BUD washout. We first 
examined the effects of LMB on 4h continual BUD incubation. As seen with FF, pre-
treatment with LMB (10nM) for 30min significantly enhanced BUD (10 -9M)-induced 
GR nuclear localisation in comparison to BUD (10-9M) alone (6.4±1.4- vs. 3.0±0.43-
fold increase, #p<0.05) (Fig. 3.3.7.1).  
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Fig. 3.3.7.1 Effect of leptomycin B (LMB) on budesonide (BUD)-induced GR nuclear 
localisation. Serum-starved U937 cells were stimulated with LMB (10nM) for 30min 
followed by incubation with BUD (10-9M) for 4h. Results represent the mean±SEM of 3 
independent experiments. *p<0.05 vs. basal levels. #p<0.05 vs. BUD (10-9M).  
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3.3.7.2 Drug washout 
We next investigated whether we could restore BUD-induced GR nuclear import 
following 20 h BUD washout. Cells were treated with either continual 24h BUD 
treatment, 4h BUD followed by 20h washout, or 30 min LMB followed by 4h BUD 
treatment followed by 20h BUD washout. As seen previously, BUD (10 -9M)-induced 
GR nuclear localisation was reduced back to basal levels (3.0±0.61- vs. 1.2±0.25-
fold increase, #p<0.05) after 20h BUD washout (Fig. 3.3.7.2). In contrast to continual 
BUD incubation, LMB (10-9M) did not reduce the loss of BUD-induced GR nuclear 
localisation post 20h BUD washout (1.2±0.37 vs. 1.2±0.25, p=ns). 
 
  
 
 
 
 
 
 
 
 
 
Fig. 3.3.7.2 Effect of leptomycin B (LMB) on budesonide (BUD)-induced GR nuclear 
localisation post 20h washout. Serum-starved U937 cells were stimulated with LMB 
(10nM) for 30 min, followed by incubation with BUD (10-9M) for 4h. Following 4h incubation, 
cells were washed and incubated for a further 20h in the presence of LMB. Results 
represent the mean±SEM of 4 independent experiments. *p<0.05 vs. basal levels. p=ns.  
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3.4 Discussion 
Corticosteroids are recommended in the treatment of patients with asthma and 
COPD. Since their use in the early 20th Century in respiratory diseases, drug 
development has been focused on developing corticosteroids with better 
pharmacodynamic and pharmacokinetic profiles to improve patient compliance and 
minimise adverse effects. Recently, FF, a new longer-acting corticosteroid under 
development for asthma and COPD, has been shown to have superior affinity and a 
slower rate of dissociation from GR than FP (Salter et al., 2007). Furthermore, X-ray 
crystallography has revealed the superior affinity of FF maybe due to the furoate 
group of FF in combination with other functional groups on the corticosteroid 
backbone, allowing better hydrogen-bonding and generation of van der Waal’s 
forces with the amino acids within the GR ligand binding site (Valotis and Hogger, 
2007).  
 
We demonstrated that FF at 2h and 24h induced GR nuclear translocation to a 
greater extent than BUD (section 3.3.1). Additionally, FF suppressed IL-1β-induced 
CXCL8 to a greater extent than BUD (Fig. 3.3.2.1). In addition, both BUD and FP, 
maintained similar levels of GR nuclear translocation at 2h and 24h (section 3.3.1). 
Determining the duration of action of corticosteroids in the in vitro setting is very 
difficult due to the absence of parameters that dictate ICS clearance from the lungs. 
However, the introduction of a 20h corticosteroid washout period in our experiments 
allowed us to better model the in vivo environment, as well as better represent the 
differences in the PK profiles of BUD, FP and FF that have been observed in several 
studies (Woodcock et al., 2011, Valotis and Hogger, 2007).  In the 20h drug washout 
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experiments, following 4h corticosteroid incubation, FF not only maintained its level 
of GR nuclear localisation and suppression of IL-1β-induced CXCL8, it was also far 
superior to both BUD and FP. Whereas, in contrast, BUD- and FP-induced GR 
nuclear translocation were significantly reduced to basal levels following a 20h 
washout. In addition, BUD-mediated suppression of IL-1β-induced CXCL8 was 
completely abolished and FP-mediated suppression of IL-1β-induced CXCL8 was 
reduced significantly.  The longer duration of action of FF in the drug washout 
experiment can be explained by its enhanced affinity for GR and slower rate of 
dissociation. In freshly isolated human lung tissue, FF was retained for longer than 
FP (Valotis and Hogger, 2007). Further studies using higher concentrations of Bud 
and FP will determine whether the effect of FF can be replicated with other 
corticosteroids when used at equipotent concentrations. 
 
Inhibiting GR nuclear export may shift the balance towards GR nuclear import and 
therefore lead to increased retention of corticosteroid-induced GR nuclear 
localisation. We found, in the continual drug contact setting, pre-treatment with LMB 
(10nM) for 30 min considerably enhanced BUD- and FF-induced GR nuclear 
localisation at 2h. However, LMB failed to prevent loss of BUD-induced GR nuclear 
localisation post 20h BUD washout. Our data is consistent with the findings of 
Savory et al, who showed in an in vitro study in Cos7 cells, 200nM of LMB for 1h 
promoted the movement of wild-type (WT) GR from the cytoplasm into the nucleus 
(Savory et al., 1999). Additionally, they showed LMB failed to promote GR nuclear 
translocation in Cos7 cells expressing GR lacking the NL1 fragment, suggesting that 
the effects of LMB on WT GR were NLS dependent (Savory et al., 1999). In contrast, 
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Holaska and colleagues showed that GR nuclear export is insensitive to LMB. In 
their study they demonstrated that GR nuclear export was governed by the nuclear 
export receptor calreticulin (CRT) (Holaska et al., 2001). They demonstrated that 
CRT mediated GR nuclear export using cell permeabilisation, microinjection and 
transfection assays. 
 
The reported differences in the pathways that may regulate GR nuclear export 
clearly seem contradictory. Several groups have demonstrated multiple sites  on GR 
may be implicated in GR nuclear import and export (Galigniana et al., 2010, 
Freedman and Yamamoto, 2004, Tao et al., 2006). This suggests that GR 
nucleocytoplasmic shuttling maybe governed by more than one pathway, which may 
explain why GR nuclear export maybe sensitive in some cases but not others to 
LMB. This may also partially explain why LMB failed to prevent loss of nuclear GR 
post 20h BUD washout, despite enhancing BUD-induced GR nuclear localisation in 
the drug contact setting at 2h. It is likely that different mechanisms regulate GR 
nuclear shuttling in the presence and absence of ligand, and these mechanisms may 
be time-dependent. For example, Savory et al showed, rapid nuclear import of GR (4 
to 6min) was mediated through the NL1 fragment of GR, whereas slow GR nuclear 
import (45 to 60min) was NL2 mediated (Savory et al., 1999). 
 
We also compared the effects of combination treatment of corticosteroid and LABA 
compared to corticosteroid alone. We found FORM and VI respectively, enhanced 
BUD- and FF-mediated suppression of IL-1β-induced CXCL8. However, SLM had no 
statistically significant effect on FP-mediated suppression of IL-1β-induced CXCL8. 
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Furthermore, FORM enhanced BUD mediated suppression of IL-1β-induced CXCL8 
by an additional 22±11%, which was not different to the additional suppression 
achieved with VI in combination with FF, 18±8%. This is interesting, as FORM is a 
full β2-agonist, whereas VI, similar to SLM, is a partial β2-agonist. This suggests that 
VI, a partial agonist, is as effective as the full agonist, FORM, in relation to 
suppression of the pro-inflammatory mediator, CXCL8, in combination with a 
corticosteroid. A full concentration-response curve for each LABA in combination 
with their respective corticosteroid used in these experiments may provide additional 
information. A full β2-agonist will induce greater receptor activation and down-stream 
signal transduction than a partial β2-agonist (Lotvall, 2001). One would assume, 
therefore a full β2-agonist, like FORM, would have a greater effect on corticosteroid-
mediated suppression of pro-inflammatory mediators than a partial β2-agonist, like 
VI.   
 
There is growing evidence for the molecular rationale of the complementary 
interactions and effects between corticosteroids and LABA both in vitro (Mak et al., 
1995, Eickelberg et al., 1999, Papakonstantinou et al., 2012) and in vivo (Usmani et 
al., 2005b, Orsida et al., 2001, Li et al., 1999), where studies have demonstrated that 
LABA increase GR nuclear translocation and corticosteroids up-regulate β2-
receptors. In primary human lung fibroblasts and vascular smooth muscle cells, 
Eickelberg and colleagues observed that both SLM- and salbutamol-induced GR 
nuclear translocation in the absence of the corticosteroid. This induction of GR 
nuclear translocation was shown to be protein kinase A (PKA) dependent 
(Eickelberg et al., 1999). The biological and therapeutic effects of all β2-agonists are 
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exerted via the cell surface β2-adrenoceptors (β2-A), a member of the G-protein-
coupled receptor family. Upon β2-agonist binding, the associated α-component 
dissociates and activates adenylate cyclase, which then leads to the enzymatic 
production of cyclic adenosine monophosphate (cAMP). Subsequently, PKA is 
activated, which then phosphorylates intracellular proteins (Johnson, 2004). An 
investigation in human embryonic kidney cells demonstrated that stimulation of the 
β2-receptor by SLM resulted in the activation of the mitogen-activated protein kinase 
(MAPK) pathway (Daaka et al., 1997, McDonnell et al., 1998). Activation of MAPK 
may lead to GR phosphorylation at a number of serine residues (Adcock et al., 
2002). This molecular basis may explain the complementary effects of β2-agoinsts 
on corticosteroids in improving lung function, symptoms, disease exacerbations in 
both asthma and COPD (Woolcock et al., 1996, Greening et al., 1994, Pauwels et 
al., 1997, Juniper et al., 1999, Calverley et al., 2007). Comparisons between VI and 
FORM effects on down-stream signalling pathways such as PKA induction and 
MAPK activation for example across a range of concentrations will provide further 
evidence for the mechanism of ICS-LABA cross-talk in these cells. 
 
Finally, we also compared BUD-, FP- and FF-driven induction of DUSP1 mRNA 
expression. As expected BUD-, FP- and FF-induced DUSP1 mRNA expression, with 
no difference in levels of induction between all three corticosteroids. This is in clear 
contrast to GR nuclear translocation and suppression of CXCL8 release, where FF 
was superior to BUD. This may be explained by the use of a concentration of 
corticosteroid that resulted in saturated levels of DUSP1 mRNA expression, as the 
regulation of DUSP1 mRNA expression maybe very sensitive to corticosteroids. 
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Therefore, it would be important to perform a full concentration response of 
corticosteroids on DUSP1 mRNA expression.  In addition, experiments to detail the 
effects of LABA on GR-induced DUSP1 mRNA would prove interesting in delineating 
the mechanisms for GR-LABA cross-talk. Oxidative stress, as detailed in the 
Introduction, can affect inflammatory gene expression and corticosteroid function. 
The next chapter therefore examines the effect of oxidative stress on corticosteroid 
function in these cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
100 
 
CHAPTER 4 
OXIDATIVE STRESS-INDUCED CORTICOSTEROID 
INSENSITIVITY 
 
4.1 Introduction 
In COPD, a key pathophysiological trait central to the disease pathogenesis is a 
heightened inflammatory response to oxidative stress (Lee and Yang, 2012, 
Rahman, 2005). Hydrogen peroxide (H2O2) and other biomarkers of oxidative stress, 
such as 8-isoprostane, are found in elevated levels in exhaled breath condensate, 
sputum and in the systemic circulation of COPD patients (Dekhuijzen et al., 1996, 
Montuschi et al., 2000, MacNee, 2005). Oxidative stress is due to the generation of 
excessive reactive oxygen species (ROS). Under conditions of cellular stress, 
nuclear factor erythroid 2-related factor (Nrf2) is activated to induce a multitude of 
antioxidant genes that protect cells from the oxidative stress (Singh et al., 2009).  
 
The lungs are exposed to environmental- and cellular-derived ROS (MacNee, 2005). 
The major sources of environmental-derived ROS in COPD includes outdoor 
pollution and cigarette smoke (Rahman, 2005). Inhaled cigarette smoke and other 
noxious particles induce acute pulmonary inflammation through activation of pro-
inflammatory redox-sensitive transcription factors, such as NF-B and AP-1 and 
signalling pathways, such as p38 MAPK and PI3K (Rahman, 2005). The bronchial 
epithelium of COPD patients and smokers has been shown to have increased 
expression of p65, a major subunit of NF-B, which is negatively correlated to airflow 
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limitation (Di Stefano et al., 2002). NF-B upregulates the transcription of many 
inflammatory genes which are highly expressed in COPD patients including CXCL8, 
TNF- and IL-6 (Keatings et al., 1996). In an in vitro setting, cigarette smoke 
exposure to alveolar macrophages resulted in increased oxidative metabolism and 
impaired phagocytosis (Drath et al., 1979). 
 
The two mains sources of intracellular ROS are the mitochondria and NADPH 
oxidase (Lee and Yang, 2012, Rahman, 2005). Mitochondria play a crucial role in the 
pathological generation of ROS in disease (Pacher et al., 2007, Kirkham and 
Rahman, 2006). The recognition of the important role of mitochondria in oxidative-
stress related diseases has resulted in the development of experimental techniques 
to analyse mitochondrial O2˙
- production (Kirkham and Rahman, 2006). Traditionally, 
hydroethidine (HE) which is converted into the fluorescent product 2-hydroxy-
ethidium, upon oxidation by O2˙
-, has been used to detect intracellular levels of 
ROS. More recently, a novel derivative of HE, MitoSOX Red was developed to 
specifically detect O2˙
- in the mitochondria of live cells. MitoSOX Red accumulates in 
the mitochondria as a function of mitochondrial membrane potential. Several 
confocal fluorescent microscopy studies in cell lines have validated the use of 
MitoSOX Red for selective detection of mitochondrial O2˙
- production. In human 
coronary artery endothelial cells (HCAECs), confocal microscopy showed oxidised 
MitoSOX Red co-localised with GFP targeted to the mitochondria. Furthermore, the 
specific detection of the O2˙
- by MitoSOX Red was demonstrated with pre-treatment 
with a cell-permeable superoxide dismutase that scavenges superoxide (SOD-PEG) 
or a nitric oxide donor that promptly reacts with superoxide (DETANONOate). Both 
  
102 
 
SOD-PEG and DETANONOate markedly reduced the intensity of MitoSOX 
(Mukhopadhyay et al., 2007).  
 
There is growing evidence that suggests oxidative stress may contribute to 
corticosteroid insensitivity in patients with COPD (Barnes, 2010a). In peripheral 
blood mononuclear cells (PBMCs) of COPD patients, reversal of the effects of 
oxidative stress on the signalling molecule PI3K- resulted in restoration of 
corticosteroid sensitivity (To et al., 2010). The purpose of the next series of 
experiments in this Chapter was to determine whether oxidative stress in the in vitro 
setting could lead to corticosteroid insensitivity. We explored the effects of H2O2 on 
intracellular and mitochondrial ROS. Followed by, its effects on IL-1β-induced-
CXCL8 secretion and, NF-B transactivation. Finally, we assessed whether H2O2 in 
combination with IL-1β leads to corticosteroid insensitivity. 
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4.2 Experimental protocols 
4.2.1 Intracellular ROS 
Starved cells were cultured in RPMI supplemented with CS-FCS (0.5%) and L-
glutamine (1%) in 96 well plates overnight. Cells were washed with KRH buffer, 
followed by incubation with 100μM 2’, 7’-dichlorofluorescin (DCFH-DA) for 30mins. 
Thereafter, cells were again washed with KRH buffer, before treatment with H2O2 
(50-200μM) for 2h. The maximal concentration of H2O2 used was 200μM as this 
concentration had no effect on cell viability at 18h (Fig. 4.2.1 & Fig. 4.2.2). 
Fluorescence with an excitation filter set at 485nM (and emission filter set at 530nM) 
was read immediately. The acetate ester of DCFH-DA is a membrane permanent 
molecule that passes across the cell membrane. Once inside the cell, intracellular 
esterases convert DCFH-DA into the non-fluorescent ionic moiety H2DCF-DA, 
causing it to be trapped inside the cell. Upon oxidation by ROS, H2DCF-DA is 
converted into 2, 7-dichlrodihydroflurescein (DCF), which is highly fluorescent.  
 
 
 
 
 
Fig. 4.2.1 Effect of hydrogen peroxide (H2O2) on cell viability. Serum-starved U937 
monocytes were stimulated with H2O2 at 200 and 800µM for 18h, followed by 15min 
incubation with phycoerythrin (PE), a fluorogenic dye that detects early apoptosis. *p<0.05 
vs. basal. 
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Fig 4.2.2 Effect of hydrogen peroxide (H2O2) on cell viability. Serum-starved U937 
monocytes were stimulated with H2O2 at 200 and 800µM for 18h, followed by 15min 
incubation with phycoerythrin (PE), a specific flurogenic dye for detection of early apoptosis, 
in the dark. Levels of PE fluorescence were detected by flow cytometry at the PE channel. 
Dot-plots represent basal (a), 800μM H2O2 (b) and 200μM H2O2 (c). Dots-plots are 
accompanied with their corresponding histogram plots showing level of alive and dead cells. 
These are representative of three independent experiments.  
a1) a2) 
b1) b2) 
c1) c2) 
Early  
Apoptosis Viable 
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4.2.2 Mitochondrial ROS 
Starved cells were cultured in 6 well plates at a seeding density of 0.5x106 cell/ml. 
Cells were treated with H2O2 (50-200μM) for a period of 2h, followed by MitoSOX 
Red (5μM) incubation for 30min at 37°C in the dark. Mitochondrial superoxide levels 
were measured using a novel highly selective fluorogenic dye, MitoSOX Red 
superoxide detector. MitoSOX Red is oxidised by superoxide which leads to 
fluorescence of the dye. Levels of MitoSOX Red fluorescence were detected by flow 
cytometry, using the 488nm argon laser and emission through the PE filter (575nm). 
 
4.2.3 Involvement of oxidative stress in cytokine synthesis and secretion 
Starved cells were cultured in 96-well plates at a seeding density of 0.5x106 cell/ml. 
Cells were treated with H2O2 (200μM) for 90min, followed by IL-1β (1ng/ml) for 
30min. Cells were then stimulated with varying concentrations of BUD, FP and FF. 
16h post IL-1β stimulation, supernatant was collected and stored at -20°C for future 
cytokine/chemokine analyses. 
  
4.2.4 NF-B DNA-binding 
Starved cells were cultured in flasks at a seeding density of 0.5x106 cell/ml. Cells 
were treated with H2O2 (200μM) for 90min, followed by IL-1β (1ng/ml) for 30min. 
Post IL-1β stimulation, nuclear extraction was conducted immediately and p65 (NF-
B) activation was measured.  
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4.2.5 Oxidative stress on corticosteroid activity and function 
Starved cells were either cultured in flasks or 96-well plates at a seeding density of 
0.5x106 cell/ml for intracellular GR detection and pro-inflammatory mediator 
secretion respectively. Cells were treated with H2O2 (200μM) for 90mins followed by 
IL-1β (1ng/ml) for 30min. Cells were then challenged with BUD, FP and FF 2 and 
16h post IL-1β stimulation cells and supernatant were collected for immediate 
detection of intracellular GR and pro-inflammatory mediator secretion. In the 
absence of corticosteroid, H2O2 (200µM) and IL-1β (1ng/mL) alone had no effect on 
GR subcellular localisation (Fig. 4.2.5).  
 
 
 
 
 
Fig 4.2.5 Effect of hydrogen peroxide (H2O2) and IL-1β on glucocorticoid receptor (GR) 
subcellular localisation in resting cells. Serum-starved U937 monocytes were stimulated 
with either H2O2 (200µM) or IL-1β (1ng/ml) to determine effects on GR subcellular 
localisation. 
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4.3 Results 
4.3.1 H2O2 causes oxidative stress 
4.3.1.1 H2O2 induces Intracellular ROS 
In order to establish an in vitro model that characterises the oxidative stress and 
heightened inflammation observed in the in vivo setting of COPD patients, we first 
explored the effects of H2O2, an oxidant that is elevated in COPD patients, on 
intracellular ROS, a marker of oxidative stress. H2O2 (50-200µM) induced 
intracellular ROS in a concentration-dependent manner at 2h. Specifically, H2O2 at 
100 and 200µM increased intracellular ROS by 2.4±0.34- and 2.3±0.1-fold 
respectively relative to basal levels (*p<0.05) (Fig. 4.3.1.1). 
 
 
 
 
 
 
 
 
 
Fig 4.3.1.1 Effect of hydrogen peroxide (H2O2) on intracellular ROS. Serum-starved 
U937 monocytes were treated with 100μM of 2’, 7’-dichlorofluorescin, followed by stimulation 
with H2O2 (50-200μM) for 2h. Fluorescence with an excitation filter set at 485nM was read 
immediately. Results represent the mean±SEM of 3 independent experiments. *p<0.05 vs. 
basal. 
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4.3.1.2 H2O2 induces mitochondrial oxidative stress 
Next we investigated the effects of H2O2 on mitochondrial superoxide levels using a 
flurogenic dye, MoSOX Red. An increase in mean fluorescence intensity, a shift in 
the histogram towards the right represents an increase in mitochondrial superoxide 
levels. H2O2 at 100µM (blue histogram) caused a slight increase in mean 
fluorescence intensity; however this was not significant, relative to basal levels (red 
histogram) (Fig. 4.3.1.2). However, H2O2 at 200µM (red histogram) caused a 2.5-fold 
shift towards the right in mean fluorescence intensity in comparison to basal levels 
(p<0.05). Based upon the effects of a range of concentrations of H2O2 on 
intracellular and mitochondrial ROS, we decided to use the concentration of 200μM 
for all future experiments. 
 
 
 
 
 
 
  
109 
 
 
Fig 4.3.1.2 Effect of H2O2 on mitochondrial superoxide levels. Serum-starved U937 
monocytes were stimulated with H2O2 for 2h. After 2h, cells were incubated with MitoSOX 
Red, a specific flurogenic dye for detection of superoxide levels in live mitochondrial cells, for 
30min. Levels of MitoSOX Red fluorescence were detected by flow cytometry at the PE 
channel. Red, blue and green histograms represent basal, 100 and 200μM H2O2 induced 
superoxide levels. Results represent the mean±SEM of 3 independent experiments. 
 
4.3.2 Nrf2 activation 
In the presence of cellular stress, Nrf2, a transcription factor, upregulates the 
transcription of antioxidant genes. We next explored the effects of H2O2 on Nrf2 
transactivation, measured as binding of Nrf2 to anti-oxidant response elements 
(AREs). H2O2 (200μM induced a significant increase in Nrf2 transactivation 
compared with basal levels at both 1h (1.9±0.40-fold increase, *p<0.05 vs. basal) 
and 2h (1.6±0.12-fold increase, *p<0.05 vs. basal).  
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Fig 4.3.2 Effect of H2O2 on Nrf2 transactivation. Serum-starved U937 monocytes were 
treated with H2O2 (200M) for 2 h. After the various time points indicated nuclear extraction 
was performed. Results represent the mean±SEM of 4 independent experiments. *p<0.05 
vs. basal. 
 
4.3.3 H2O2 enhances markers of inflammation 
4.3.3.1 H2O2 enhances-IL-1β induced CXCL8 
So far, we have established an in vitro model of oxidative stress, where H2O2 
induces intracellular and mitochondrial oxidative stress. Next we explored whether 
H2O2 would enhance the inflammatory response in U937 monocyte cells. We used 
IL-1 to stimulate CXCL8 secretion. As seen previously (Fig. 3.2.2), IL-1 (1-
100ng/ml) significantly increased CXCL8 levels in a concentration-dependent 
manner with a submaximal concentration of 1ng/ml. The combination of H202 (25-
200µM) with IL-1β (1ng/ml) enhanced IL-1β-induced CXCL8 levels in a 
concentration-dependent manner, with the highest concentration of H202 (200µM) 
increasing CXCL8 secretion 10 fold, (2900±110 vs. 290±28 pg/ml, #p<0.05) (Fig. 
4.3.3.1). H2O2 (25-200µM) alone had no effect on IL-1β-induced CXCL8 levels. 
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Fig. 4.3.3.1 Effect of H2O2 on IL-1β-induced CXCL8. Serum-starved U937 monocytes 
were firstly stimulated with varying concentrations of H2O2 for 90 min followed by IL-1β 
(1ng/ml) for a further 16h. Thereafter supernatant was collected and CXCL8 levels were 
measured. Results represent the mean±SEM of 3 independent experiments. #p<0.05 vs. IL-
1β alone. 
 
4.3.3.2 H2O2 enhances-IL-1β induced NF-B activation 
IL-1β-induced secretion of extracellular CXCL8 is mediated by NF-B (Patel et al., 
2002). We therefore examined whether H2O2 could enhance IL-1β-induced p65 
transactivation. As expected IL-1β (1ng/ml) significantly increased p65  
transactivation by 1.9±0.12-fold (*p<0.05). This was significantly enhanced when 
cells were pre-treated with H2O2 (200μM) (2.6±0.10 vs. 1.9±0.12, 
#p<0.05). In 
contrast, H2O2 alone (200μM) alone had no effect on p65 transactivation. 
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Fig 4.3.3.2 Effect of H2O2 on IL-1β-induced NF-B transactivation. Serum-starved U937 
monocytes were firstly stimulated with H2O2 (200μM) for 90min followed by IL-1β (1ng/ml) for 
a further 30min. Thereafter nuclear extractions were performed and NF-B binding to DNA 
was assessed. Results represent the mean±SEM of 3 independent experiments. *p<0.05 vs. 
basal.  #p<0.05 vs. IL-1β alone. 
 
4.3.4 Oxidative stress impairs BUD- and FP-driven suppression of IL-1β-
induced CXCL8  
So far, we have shown that oxidative stress leads to a heightened inflammatory 
response in U937 monocytes. Next we wanted to determine whether this would lead 
to corticosteroid insensitivity, as observed in COPD. We therefore explored the 
effects of our in vitro oxidative stress model on corticosteroid-driven suppression of 
IL-β-induced CXCL8. As shown in Fig. 3.3.2.1, in the absence of H2O2, BUD, FP and 
FF all suppressed IL-β-induced CXCL8 secretion, with FF and FP being more potent 
than BUD. However, in the presence of H2O2 (200μM), BUD- and FP-mediated 
suppression of IL-1β-induced CXCL8 was significantly impaired particularly at higher 
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concentrations (Fig. 4.3.5.2). Pre-treatment with H2O2 significantly impaired FP-
mediated suppression of IL-1β-induced CXCL8 by 11±1.5% (10-9M) and 23±2.3% 
(10-7M), respectively. The effect of H2O2 on suppression of CXCL8 release by BUD 
was similar with a 16±8.7% and 24±7.7% attenuation of BUD effects at 10-9 and 10-
7M respectively. Although there was an effect on the maximal inhibition seen, there 
were no differences in IC50 values for either BUD or FP in the presence and absence 
of H2O2 (Fig. 4.3.4.1).  Suppression of IL-1β-induced CXCL8 at lower concentrations 
of both BUD and FP (10-12-10-10M), were not affected by pre-treatment with H2O2.  
 
In contrast, H2O2 had no effect on FF-mediated suppression of IL-1β-induced CXCL8 
at any concentration tested. These set of results clearly demonstrate our in vitro 
model of oxidative stress associated with heightened inflammatory response causes 
relative corticosteroid insensitivity, at least for two out of three corticosteroids tested.  
 
 Corticosteroid-mediated suppression 
of IL-1β-induced CXCL8 (IC50) 
 Without H2O2 With H2O2 
BUD 3.3 ± 4.7 x10
-10 5.4 ± 3.0 x10-10 
FP 7.2 ± 1.9 x10
-11 1.2 ± 3.0 x10-10 
FF 1.8 ± 4.2 x10
-11 2.3 ± 3.1 x10-11 
 
Fig. 4.3.4.1 Effect of H2O2 (200M) on IC50 values for corticosteroid-driven suppression 
of IL-1β-induced CXCL8.  
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Fig. 4.3.4.2 Effect of H2O2 on corticosteroid suppression of IL-1β-induced CXCL8. 
Serum-starved U937 monocytes were stimulated with H2O2 (200μM) for 90min followed by 
IL-1β (1ng/ml) for a further 30min. Cells were then incubated with varying concentrations of 
(a) BUD, (b) FP and (c) FF. Supernatant was collected 16h post IL-1β stimulation. Results 
represent the mean±SEM of a minimum of 3 independent experiments. *p<0.05 vs. without 
H2O2. 
* 
* * 
* * * 
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4.3.5 Oxidative stress impairs BUD and FP induced GR nuclear localisation 
In our in vitro model, oxidative stress was associated with a heightened inflammatory 
response and resulted in corticosteroid insensitivity, with reduced suppression of IL-
1β-induced CXCL8 by both BUD and FP. We next assessed whether this 
corticosteroid insensitivity could be due to impaired GR nuclear localisation. Cells 
were incubated with BUD, FP or FF (all at 10-9M) for 2h following H2O2 and IL-1β 
pre-treatment. Both BUD- and FP-induced GR nuclear localisation was significantly 
reduced in the presence of H2O2 and IL-1β (Fig. 4.3.5.2). In the absence of H2O2 and 
IL-1β, BUD- and FP-induced GR nuclear localisation by 3.0±0.43- and 5.7±0.85-fold 
respectively (both *p<0.05). In the presence of H2O2 and IL-1β, BUD- and FP-
induced GR nuclear localisation was attenuated with a reduced 1.7±0.15-fold and 
3.4±0.51-fold increase seen respectively (both #p<0.05 compared to no H2O2 and IL-
1β). Pre-treatment with H2O2 alone or IL-1β alone had no effect on FP- and FF-
induced GR nuclear import (Fig. 4.3.5.1). 
 
In contrast, FF-induced GR nuclear localisation was not affected by pre-treatment 
with H2O2 and IL-1β (6.6±1.5 fold increase vs. 7.3±1.5 fold increase, p = ns). This 
corresponded with the observed failure of H2O2 to modify FF suppression of IL-1β-
induced CXCL8 release.   
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Fig. 4.3.5.1 Effect of H2O2 or IL-1β alone on corticosteroid-induced GR nuclear 
localisation. Serum-starved U937 monocytes were stimulated with either H2O2 (200μM) for 
2 h or IL-1β (1ng/ml) for 30min. Cells were then incubated with FP or FF (all at 10-9M) for 2h. 
Nuclear extraction and determination of GR levels by Western blotting was performed 
immediately. Results represent the mean±SEM of 3 independent experiments. p=ns. 
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Fig. 4.3.5.2 Effect of H2O2 in combination with IL-1β on corticosteroid-induced GR 
nuclear localisation. Serum-starved U937 monocytes were stimulated with H2O2 (200μM) 
for 90min followed by IL-1β (1ng/ml) for a further 30min. Cells were then incubated with 
BUD, FP and FF (all at 10-9M) for 2h. Nuclear extraction and determination of GR levels by 
Western blotting was performed immediately. Results represent the mean±SEM of 3 
independent experiments. *p<0.05 vs. basal. #p>0.05 vs. corticosteroid without H2O2 and IL-
1β. 
 
4.3.6 Oxidative stress impairs FP-induced GR-GRE binding 
GR nuclear translocation is essential for activated GR to bind to promoter regions of 
corticosteroid-inducible genes. We explored whether a reduction in FP-induced GR 
nuclear translocation would result in reduced GR-GRE binding. Corticosteroid FP 
(10-9M) enhanced GR-GRE binding by 1.6±0.05-fold (*p<0.05). The combination of 
H2O2 and IL-1β, in the absence of FP, had no effect on GR-GRE binding, relative to 
basal levels. But, in the presence of H2O2 and IL-1β, FP-induced GR-GRE binding 
was significantly attenuated resulting in a 1.3±0.06-fold increase only (#p<0.05 vs. 
FP-induced GR-GRE binding without H2O2 and IL-1β). 
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Fig. 4.3.6 Effect of H2O2 and IL-1β on FP-induced GR-GRE binding. Serum-starved U937 
monocytes were stimulated with H2O2 (200μM) for 90min followed by IL-1β (1ng/ml) for a 
further 30min. Then cells were incubated with FP (10-9M) for 2h. Nuclear extraction was 
performed immediately. Results represent the mean±SEM of 3 independent experiments. 
*p<0.05 vs. basal. #p>0.05 vs. FP (10-9M) alone. 
 
4.3.7 Oxidative stress on BUD- and FP-induced DUSP1 expression 
Finally, we determined the effect of H2O2 on BUD- and FP-induced DUSP1 mRNA 
expression. In the absence of H2O2 and IL-1β, BUD and FP significantly induced 
DUSP1 mRNA expression (Fig. 3.3.3). Interestingly, we found that H2O2 in 
combination with IL-1β also induced DUSP1 mRNA expression by 7.2±1.8-fold in the 
absence of corticosteroid (Fig 4.3.7). This was similar to levels seen with BUD, FP 
and FF alone. However, in the presence of H2O2 and IL-1β, BUD and FP did not 
cause a further increase in DUPS1 mRNA expression compared to H2O2 and IL-1β 
(Fig. 4.3.7). 
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Fig. 4.3.7 Effect of H2O2 and IL-1β on corticosteroid-induced DUSP1 mRNA 
expression. Serum-starved U937 monocytes were stimulated with H2O2 (200μM) for 90min 
followed by IL-1β (1ng/ml) for a further 30min. Then cells were incubated with BUD or FP 
(both at 10-9M) for 3h PCR. Results represent the mean±SEM of 3 independent experiments. 
*p<0.05 vs. basal.  
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4.4 Discussion 
In this Chapter we explored the effects of oxidative stress on the inflammatory 
response, on corticosteroid-mediated suppression of CXCL8 and, on corticosteroid-
induced GR nuclear localisation. We found H2O2 in a concentration-dependent 
manner induced intracellular and mitochondrial ROS. This demonstrated the 
importance of H2O2, which is elevated in COPD patients (Dekhuijzen et al., 1996), in 
further propagating ROS generation by targeting key intracellular sources of ROS. In 
addition, pre-treatment with H2O2 also significantly enhanced IL-1β-induced CXCL8 
extracellular secretion and NF-B transactivation, pro-inflammatory markers that are 
elevated in COPD (Keatings et al., 1996, Di Stefano et al., 2002). This is consistent 
with findings that suggest oxidative stress drives the inflammatory response in 
COPD (Dekhuijzen et al., 199, Rahman et al., 2005, Lee et al, 2012). Therefore, 
further investigations of the signalling pathways in our in vitro model of oxidative 
stress may reveal novel therapeutic targets for COPD.   
 
This increase in oxidative stress was associated with an increase in Nrf2 
transactivation, an important transcription factor that upregulates the expression of 
antioxidant genes under cellular stress. Gene expression of several Nrf2-regulated 
antioxidant genes was markedly reduced in COPD lungs compared to non-COPD 
lungs (Malhotra et al., 2008). This depletion in Nrf2-regulated antioxidant genes 
correlated to disease severity. Measurement of the temporal response to H2O2 on 
Nrf2 activation in our model may identify whether Nrf2 levels fall in our model. The 
importance of Nrf2 in corticosteroid insensitivity was recently demonstrated in 
alveolar macrophages from patients with COPD (Malhotra et al., 2011). 
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Sulphoraphane, an activator of Nrf2, was able to reverse nitrosylation of histone 
deacetylase (HDAC)-2, which resulted in restoration of dexamethasone sensitivity in 
alveolar macrophages. Acetylation of Nrf2 also reduces its ability to switch on anti-
oxidant gene expression (Mercado et al., 2012).  The effect of H2O2 on Nrf2 
acetylation status over time may also prove useful.   
 
Under oxidative stress conditions, both BUD (10-9M)- and FP (10-9M)-induced GR 
nuclear localisation and suppression of IL-1β-induced CXCL8 were severely 
reduced. A full concentration-response curve of BUD- and FP-induced GR nuclear 
localisation would identify the extent of corticosteroid insensitivity. This reduction in 
corticosteroid sensitivity in our in vitro model is consistent with findings reported in 
sputum macrophages from COPD patients whereby BUD was unable to suppress 
pro-inflammatory mediators (Keatings et al, 1997). This loss in GR nuclear 
translocation observed in our model mimics the reduced GR ligand-binding affinity in 
the nucleus observed in peripheral blood mononuclear cells (PBMCs) of severe 
asthmatics (Irusen et al., 2002). These findings support the use of our model as an in 
vitro representation of COPD.  
 
Irusen and colleagues also demonstrated that this loss in nuclear GR ligand-binding 
affinity was blocked by SB203580, a p38 mitogen-activated kinase (p38 MAPK) 
inhibitor. Under separate conditions, activation of p38 MAPK was demonstrated to 
phosphorylate GR, which was associated with reduced dexamethasone suppression 
of granulocyte-macrophage colony-stimulating factor (GM-CSF) release (Irusen et 
al., 2002). Recent data from Kent and colleagues has shown that p38 MAPK 
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inhibitors can restore corticosteroid responsiveness in BAL macrophages from 
patients with COPD (Kent et al., 2009). It has also been demonstrated that oxidative 
stress directly inhibits GR nuclear translocation (Okamoto et al., 1999). In this study 
in human GR-expressing CHOpMTGR cells, H2O2 inhibited GR nuclear 
translocation, in addition to partially inhibiting ligand-dependent dissociation of 
Hsp90 from GR. GR nuclear translocation was reversed with N-acetyl-L-cysteine.  
 
This reduction in GR nuclear translocation may also be due to impaired nuclear 
receptors that govern GR nucleocytoplasmic shuttling (Kodiha et al., 2004). In HeLa 
cells, several components of the classical nuclear import pathway, importin-β, were 
affected by extremely high concentrations of H2O2. Importin-β belongs to the same 
family of receptors as importin-7 which has been reported to bind and facilitate 
nuclear import of the GR (Freedman and Yamamoto, 2004). Treatment with H2O2 
also resulted in the redistribution and degradation of nuclear RanGTP, essential for 
nuclear import of cargo proteins, and relocalisation of importin-β (Kodiha et al., 
2004). Additionally, in growing yeast Saccharomyces cerevisiae cells, heat, shock 
and H2O2 significantly impaired classical nuclear import of NLS fused to green 
fluorescent protein (NLS-GFP). This was associated with a redistribution of the small 
GTPase, Gsp1p, from the nucleus into the cytoplasm (Stochaj et al., 2000).  
 
In contrast to BUD and FP, FF maintained its level of GR nuclear translocation and 
suppression of IL-1β-induced CXCL8 under oxidative stress. This resistance to 
oxidative stress may be partly explained by its enhanced affinity for GR (Valotis and 
Hogger, 2007, Valotis et al., 2004). We also found FP-induced GR-GRE binding was 
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significantly impaired under oxidative stress conditions. Corticosteroid-inducible 
genes include DUSP1 and SLP1, which are essential for counteracting the pro-
inflammatory signalling pathways that are heightened in COPD (Shipp et al., 2010). 
DUSP1 codes for mitogen-activated protein kinase phosphatase (MKP)-1, which 
inhibits p38 and JNK MAPK activity and can indirectly modulate NF-B function by 
altering p65 phosphorylation status (Perkins, 2007).  We found, H2O2 in combination 
with IL-1β induced DUSP1 mRNA expression levels similar to what was seen with 
corticosteroids alone (Fig. 3.3.3). This is consistent with data reported in HeLa cells, 
where IL-1β induced DUSP1 mRNA expression in a p38 MAPK-dependent manner 
(Lasa et al., 2002). In order to verify whether H2O2 and IL-1β impair corticosteroid-
induced GR-GRE binding on corticosteroid-inducible genes we would need to 
undertake these experiments on genes that are not upregulated by H2O2 and IL-1β.  
 
Taken together, these findings support that our in vitro model of oxidative stress-
induced corticosteroid insensitivity represents some aspects of the disease 
pathology in COPD. As COPD is characterised by a multitude of inflammatory cells 
and mediators, it would be crucial to determine the effects of H2O2 alone and in 
combination with a cocktail of inflammatory stimuli on inflammatory marker secretion 
to further validate our model. Stimulation of our cells with more than one 
inflammatory stimulus may better represent the multiple signalling pathways that 
contribute to inflammation in COPD (Lee et al., 2009, Wang et al., 2008). 
Furthermore, H2O2 is amongst a number of oxidants that are found elevated in 
COPD (Kirkham and Rahman, 2006, Lee and Yang, 2012). The role of other ROS on 
corticosteroid insensitivity needs to be assessed and modelled in combination with 
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H2O2. It would be important to compare the inflammatory signalling pathways that 
are activated in our model to cigarette smoke-induced inflammation to determine 
how well H2O2 reflects the numerous molecular signalling pathways activated by 
cigarette smoke, the major cause of environmental-derived ROS in COPD. In 
addition, it would be important to confirm our findings in primary cells from patients 
with COPD. In the next Chapter we will explore the role of nuclear transport 
receptors in corticosteroid-induced GR nuclear localisation. Hopefully this will allow 
us to identify potential nuclear transport receptors that govern GR 
nuclecocytoplasmic shuttling that may be implicated in reduced GR nuclear 
translocation under conditions of oxidative stress. 
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CHAPTER 5 
IMPORTIN-7-MEDIATED GR NUCLEAR IMPORT 
 
5.1 Introduction 
In Chapter 4, we demonstrated that H2O2 induces oxidative stress and enhances IL-
1β-induced NF-B (p65 transactivation) and CXCL8 in monocytes, pathological 
changes that are characteristic of COPD. Additionally, in our in vitro model of 
oxidative stress, fluticasone propionate (FP)- and budesonide (BUD)-mediated 
suppression of IL-1β-induced CXCL8 were significantly reduced. Further 
experiments showed that GR nuclear translocation, essential for corticosteroid 
function, was dramatically reduced. The purpose of this Chapter is to investigate 
whether reduced corticosteroid-induced GR nuclear translocation is due to impaired 
mechanisms that may regulate GR nucleocytoplasmic shuttling in our in vitro model 
of oxidative stress associated with a heightened inflammatory response. 
 
Nucleocytoplasmic shuttling of proteins across the nuclear pore complex (NPC) is 
governed by several sequential steps. They are (i) retrograde movement through the 
cytoplasm, (ii) recognition by nuclear import proteins, (iii) docking to the nuclear 
pore, (iv) translocation across the nuclear compartment, (v) binding to and release 
from nuclear sites of action, (vi) recognition by nuclear export proteins and finally, 
(vii) anteretrograde cytoplasmic movement (Galigniana et al., 2010). The signalling 
pathways that regulate GR nucleocytoplasmic shuttling remain largely unknown. 
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Several in vitro studies have suggested importin proteins-α, -β, -7, -8 and -13 may 
govern GR nucleocytoplasmic shuttling.  
 
Of these, importin-7 has been shown to bind and mediate GR nuclear translocation 
in an in vitro import nuclear assay (Freedman and Yamamoto, 2004). However, the 
role of importin-7 in corticosteroid-induced GR nucleocytoplasmic shuttling in 
inflammatory cells and under oxidative stress associated with heightened 
inflammatory response has not been studied. Importin-7 belongs to the karyopherin 
family of nuclear receptors that mediate RanGTPase-dependent transport across the 
NPC. RanGTPases regulate interactions between the nuclear transport receptors of 
the importin family and their cargo proteins. Interestingly, Importin-β, a member of 
the same family of nuclear receptors as importin-7, has been shown to be degraded 
under exceptionally high concentrations of H2O2 (Kodiha et al., 2004). Moreover, 
H2O2 at 500μM, also caused degradation of nuclear RanGTP, which is essential for 
the dissociation of nuclear importin receptors from their cargo proteins. We therefore 
investigated the role of importin-7 in corticosteroid-induced GR nuclear translocation 
and under conditions of oxidative stress (Fig. 5.1).  
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Fig. 5.1 Proposed mechanism of reduced corticosteroid-induced GR nuclear 
translocation. Corticosteroid-induced GR nuclear translocation is essential for 
corticosteroid-mediated suppression of pro-inflammatory mediators. Importin-7 binds to and 
mediates nuclear translocation of the glucocorticoid receptor (GR). Once in the nucleus, 
nuclear RanGTP binds to importin-7 resulting in the dissociation of the importin-7 and GR 
complex. Consequently, the GR is able to move through the nucleus and either binds to 
glucocorticoid response elements on corticosteroid-inducible genes or recruits histone 
deacetylase (HDAC)-2 to prevent the gene transcription of pro-inflammatory mediators. 
Activated GR may also prevent gene transcription by binding as a monomeric unit to other 
transcription factors. Under conditions of oxidative stress, importin-7 or nuclear RanGTP 
levels may be reduced leading to reduced GR nuclear translocation and consequently 
corticosteroid insensitivity. 
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5.2 Experimental protocol 
5.2.1 Importin-7 knockdown 
Please see section 2.10 for full details. Briefly, U937 cells in full media were 
transfected with either 200nM of human importin-7 ON-TARGETplus SMARTpool 
siRNA or 200nM of ON-TARGETplus Non-Targeting pool (negative control) for 36h 
in either 6- or 96-well plates. Fig. 5.2.1 clearly shows that transfection with importin-7 
siRNA had no significant effect on cell viability compared to untransfected cells as 
determined by the MTT assay. 
 
 
 
 
 
 
Fig. 5.2.1 Effect of electroporation with siRNA on cellular activity. U937 cells were 
transfected via electroporation for 36h with siRNA, followed by incubation with MTT to 
determine the effects of electroporation and siRNA on cellular activity. Results represent the 
mean±SEM of 3 independent experiments. 
 
5.2.2 The role of importin-7 on corticosteroid-induced GR nuclear translocation 
Following 36h transfection with importin-7 siRNA, U937 cells were serum starved for 
3h and then incubated with FP for 2h. Protein extracts were obtained and GR was 
detected by Western blotting. 
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5.2.3 The role of importin-7 on corticosteroid-mediated suppression of CXCL8 
Following 36h transfection with importin-7 siRNA, U937 cells were serum starved for 
3h and then incubated with IL-β (1ng/ml) for 30min. Cells were then stimulated with 
FP (10-9M) and the supernatant was collected 16h after IL-1β stimulation. 
 
5.2.4 Importin-7 & RanGTP subcellular localisation under oxidative stress 
Serum starved cells were cultured in large T175 flasks. Cells were treated with H202 
(200μM) for 90min followed by IL-β (1ng/ml) stimulation for 30 min. Post IL-1β 
stimulation, nuclear extraction was performed and protein levels of importin-7 were 
determined by Western blotting. RanGTP was detected by immunoprecipitation with 
agarose beads bound to RanBP1. In Fig. 5.2.4 we clearly demonstrated that 
importin-7 predominantly resides in the cytoplasm in resting U937 cells, therefore the 
effects of H2O2 and IL-1β were determined on cytoplasmic importin-7. 
 
             Sample number 
 
 
 
 
 
 
 
 
Fig. 5.2.4 Intracellular localisation of Importin-7. Cytoplasmic and nuclear extraction was 
carried out on serum-starved U937 monocytes. Western blot indicates importin-7 subcellular 
localisation from three different samples. 
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5.2.5 Corticosteroid-induced GR nuclear localisation under nuclear export 
inhibition 
Serum starved cells were cultured in large flasks with leptomycin B (10nM) for 30min 
followed by corticosteroids for varying time points. Several in vitro studies have 
established LMB as a potent inhibitor of nuclear exportin 1 at nanomolar 
concentrations (Wolff et al., 1997, Menendez et al., 2003, Kudo et al., 1999). To 
ensure LMB had no effect on cell viability, we incubated cells with LMB for 4h 
followed by incubation with R-phycoerythrin (PE), a fluorogenic detector of early 
apoptosis. LMB had no significant effect on cell viability at 4h (Fig. 5.2.5.1 & Fig. 
5.2.5.2) treatment relative to untreated cells.  
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Fig. 5.2.5.1 Effects of 4 h Leptomycin B (LMB) treatment on cell viability. Serum-
starved U937 monocytes were stimulated with LMB  at 10nM for 30min followed by 
incubation with PE, a specific fluorogenic dye for detection of early apoptosis, for 15min in 
the dark. Levels of PE fluorescence were detected by flow cytometry using the PE channel. 
The effects of 800M H2O2 are shown as a positive control. *p<0.05 vs. basal. 
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Fig. 5.2.5.2 Effect of 4 h leptomycin B (LMB) treatment on cell viability. Serum-starved 
U937 monocytes were stimulated with LMB (10 nM) for 4h followed by incubation with PE, a 
specific fluorogenic dye for detection of early apoptosis, for 15min in the dark. Levels of PE 
fluorescence were detected by flow cytometry at the PE channel, where a) represents a dot-
plot of PE vs. forward scatter (FSC) for each cell and b) represents the distribution of those 
cells as either viable or apoptotic, as a histogram. Red and blue dot plots and histograms 
represent untreated cells and LMB at 10nM for 4h, respectively. These are representative of 
three experiments. 
   
 
 
 
 
 
 
Early  
Apoptosis Viable a) b) 
  
132 
 
5.3 Results 
5.3.1 Importin-7 siRNA reduces both cytosolic and nuclear levels of Importin-7 
In order to determine the role of importin-7 on corticosteroid-induced GR nuclear 
import in U937 monocytes, we first assessed the effects of electroporation of 
importin-7 siRNA on importin-7 protein levels. We used ON-TARGET SMARTpool 
siRNA against human importin-7 (L-012255-00-001, Dharmacon, Lafayette, CO, 
USA). The siRNA pool contained four ON-TARGETplus SMARTpool siRNAs: 
CAAUUGCAGCUUUGUAUUA, UAAGCAGGCUGGUGAAGAU, 
GAAGAUCGCCAUUGUAUUC and CAACACUGCUCCAGAUUAC. The non-
silencing negative siRNA control used in this study was ON-TARGETplus non-
targeting siRNA. We found that both cytosolic (38.4±11.5%) and nuclear 
(42.7±16.5%) importin-7 levels were greatly reduced to a similar extent relative to 
non-targeting siRNA negative control 36h after importin-7 siRNA transfection 
(*p<0.05 vs. non-targeting siRNA negative control). For all future experiments 
exploring the role of importin-7 knockdown on corticosteroid-induced GR nuclear 
translocation, we used the above conditions.  
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Fig 5.3.1 Effect of importin-7 siRNA transfection. Nuclear and Western blotting was 
carried out on serum-starved U937 monocytes 36h after eelctroporation with importin-7 
siRNA or control. Results represent the mean±SEM of 3 independent experiments. *p<0.05 
vs. non-targeting siRNA negative control. 
 
5.3.2 Importin-7 siRNA reduces corticosteroid-induced GR nuclear localisation 
After optimising in vitro conditions for importin-7 knockdown, we next explored the 
role of importin-7 on FP-induced GR nuclear localisation. FP (10-9M)-induced GR 
nuclear localisation was markedly reduced in the importin-7 knockdown model by 
39.3±8.7%, relative to non-targeting siRNA negative control (*p<0.05). Interestingly, 
the percentage reduction in FP-induced GR nuclear localisation was similar to the 
level of importin-7 knockdown achieved in the cytoplasm (39.3±8.71% vs. 
38.4±11.5). 
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Fig. 5.3.2 Effect of importin-7 siRNA transfection on FP-induced GR nuclear 
localisation. 36h post importin-7 siRNA transfection, cells were serum starved for 3h, 
followed by incubation with FP (10-9M) for 2h. Results represent the mean±SEM of 3 
independent experiments. *p<0.05 vs. non-targeting siRNA negative control. 
 
5.3.3 Importin-7 siRNA reduces corticosteroid-induced suppression of CXCL8 
We have shown that importin-7 knockdown impairs corticosteroid-induced GR 
nuclear translocation. Next, we investigated whether importin-7 knockdown would 
also have an impact on corticosteroid-mediated suppression of IL-1β-induced 
CXCL8 secretion. Following 36h transfection, the non-targeting siRNA had no 
significant effect on FP (10-9M)-induced suppression of IL-1β-induced CXCL8 in 
comparison to the non-transfected cells (76.8±2.6 vs. 68.4±3.0% stimulated levels, 
p=ns). Whereas, in the importin-7 knockdown model, FP was only able to suppress 
IL-1β-induced CXCL8 by 40.2±16.1% which was significantly less than that seen in 
control untransfected cells (68.4±3.0%, *p<0.05). The percentage reduction in FP 
function (~40%) reflects the degree of importin-7 knockdown achieved. 
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Fig. 5.3.3 Effect of importin-7 siRNA transfection on FP-mediated suppression of IL-
1β-induced CXCL8. 36 h post importin-7 siRNA transfection, cells were serum starved and 
stimulated with IL-1β (1ng/ml) for 30min followed by incubation with FP (10-9M). 16h post IL-
1β stimulation the supernatant was collected and CXCL8 levels were analysed by ELISA. 
Results represent the mean±SEM of 3 independent experiments. *p<0.05 vs. FP mediated 
suppression of IL-1β-induced CXLC8. #p<0.05 vs. non-targeting siRNA.  
 
5.3.4 Effects of oxidative stress on cytoplasmic importin-7 
Having established that importin-7 was involved in corticosteroid-induced GR nuclear 
translocation, we next explored whether the impaired corticosteroid-induced GR 
nuclear translocation observed under conditions of oxidative stress and heightened 
inflammatory response (Chapter 4), was due to impaired importin-7-mediated GR 
nuclear transport. In our in vitro model of oxidative stress, pre-treatment with 200μM 
of H2O2 and 1ng/ml of IL-1β had no effect on cytosolic levels of importin-7 (Fig. 
5.3.4). 
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Fig. 5.3.4 No effect of H2O2 and IL-1β alone or in combination on cytoplasmic importin-
7 levels. Serum-starved U937 cells were stimulated with H2O2 (200M) for 90min followed 
by stimulation with IL-1β (1ng/ml) for 30min. Nuclear extraction and Western blotting were 
performed immediately. Results represent the mean±SEM of 3 independent experiments.  
 
5.3.5 Oxidative stress reduces nuclear RanGTP levels 
Importin-7 mediated transport of cargo proteins is RanGTP-dependent. We next 
explored whether impaired corticosteroid-induced GR nuclear translocation in our in 
vitro model of oxidative stress was due to degradation of nuclear RanGTP. Levels of 
nuclear RanGTP were detected by pull down using RanBP1 Agarose beads.  Pre-
treatment with H2O2 (200μM) and IL-1β (1ng/ml) caused a significant reduction in 
nuclear Ran GTP levels by 61.2±12.6% relative to basal levels (*p<0.05 vs. basal). 
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Fig. 5.3.5 Effect of H2O2 and IL-1β on nuclear RanGTP levels. Serum-starved U937 cells 
were stimulated with H2O2 (200M) for 90min followed by stimulation with IL-1β (1ng/ml) for 
30min. Immunoprecipitation of nuclear RanGTP was performed immediately. Results 
represent the mean±SEM of 3 independent experiments. *p<0.05 vs. basal nuclear levels.  
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5.4 Discussion 
Nucleocytoplasmic shuttling of proteins across the NPC is governed by nuclear 
receptors. Over the last decade, several members of the karyopherin family of 
nuclear receptors have been shown to facilitate GR nucleocytoplasmic shuttling 
(Freedman and Yamamoto, 2004, Tao et al., 2006). In an in vitro nuclear import 
assay, importins-β, -7 and -8 bound to and facilitated the nuclear import of the NL1 
fragment of GR, with importins-7 and -8 additionally facilitating nuclear import of the 
NL2 fragment of GR (Freedman and Yamamoto, 2004). We found knockdown of 
importin-7 by siRNA in a human monocyte cell line, considerably reduced FP-
induced GR nuclear localisation and FP-mediated suppression of IL-1β-induced 
CXCL8 (Figures. 5.3.1, 5.3.2 and 5.3.3). Our experiments provide evidence that 
importin-7 plays a vital role in corticosteroid-induced GR nuclear import and 
corticosteroid-mediated suppression of inflammatory markers in human monocyte 
cells.    
 
After establishing the potential role of importin-7 in corticosteroid-mediated GR 
nuclear translocation, we next explored (in our in vitro model of oxidative stress 
associated with heightened inflammatory response) whether reduced BUD and FP 
function maybe partly due to impaired importin-7 mediated GR nuclear import. We 
found H2O2 (200μM) in combination with IL-1β (1ng/ml) significantly reduced nuclear 
RanGTP levels, however cytoplasmic levels of importin-7 were not affected. As 
reported previously, importin-7 mediated transport of cargo proteins is RanGTP 
dependent (Jakel et al., 1999). The RanGTPase system is composed of a Ran 
gradient across the NPC, where RanGDP is predominantly found in the cytoplasm, 
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whereas RanGTP mainly resides in the nucleus (Poon and Jans, 2005, Wagstaff and 
Jans, 2009, Gorlich and Kutay, 1999). Hydrolysis of RanGTP to RanGDP releases a 
sufficient degree of energy to facilitate the dissociation of importin-7 and its cargo 
protein (for example a transcription factor) in the nucleus.  This subsequently allows 
the transcription factor to progress through the nucleus and regulate gene 
transcription. Based upon our findings that nuclear RanGTP is degraded in our in 
vitro model of oxidative stress and that knockdown of importin-7 reduces 
corticosteroid function we suggest that BUD and FP insensitivity may be partly due 
to abnormal degradation of nuclear RanGTP.   
 
Kodiha and colleagues showed importin-β, a member of the same family of nuclear 
transport receptors as importin-7, underwent significant degradation post H2O2 
treatment in HeLa cells (Kodiha et al., 2004). A closer examination of the findings 
revealed that the group used a concentration of H2O2 at 10mM, which is far greater 
than 800μM, where we observed a significant level of apoptosis in U937 cells at 4h 
and 18h (see Fig. 5.2.5.2 and Fig. 4.2.2). Further in-depth studies by this group 
revealed that inhibition of caspases, a key apoptotic signalling mechanism, reduced 
the loss of importin-β. One therefore would assume the observed loss in importin-β 
reported by this group was most probably due to apoptosis induced by oxidative 
stress.  
 
In this Chapter we have been able to demonstrate that importin-7 is crucial for 
corticosteroid-induced GR nuclear import. In addition, under conditions of oxidative 
stress-induced corticosteroid insensitivity, nuclear RanGTP, an essential co-factor 
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for importin-7, was markedly less. In the next Chapter we would like to confirm 
whether corticosteroid insensitivity in cells extracted from severe asthmatics and 
COPD patients is also associated with reduced GR nuclear localisation, as observed 
in our in vitro model of oxidative stress-induced corticosteroid insensitivity.       
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CHAPTER 6 
CORTICOSTEROID SENSITIVITY IN MONOCYTES 
FROM SEVERE ASTHMATICS AND COPD PATIENTS 
 
6.1 Introduction 
Corticosteroids are widely used in the treatment of asthma and COPD, however in 
sharp contrast to their use in patients with asthma, they are less effective in 
controlling the underlying inflammation and reversing the decline in lung function in 
patients with COPD (Keatings et al., 1997, Suissa and Barnes, 2009). In Chapter 3, 
we compared three corticosteroids, budesoinde (BUD), fluticasone propionate (FP) 
and fluticasone furoate (FF), which have different physiochemical and structural 
properties, and found FF had a greater effect on glucocorticoid receptor (GR) activity 
and on suppression of the pro-inflammatory mediator, CXCL8, compared to BUD. 
Furthermore, FF was able to sustain its effect on GR nuclear translocation and 
CXCL8 suppression following a 20h washout, whereas BUD was unable to achieve 
this. This clear difference in activity and function between BUD and FF was also 
explored under conditions of oxidative stress associated with heightened 
inflammatory response. We observed FF was resistant to the effects of oxidative 
stress associated with heightened inflammatory response. In contrast, BUD-induced 
GR nuclear import and BUD-mediated suppression of IL-1β-induced CXCL8 were 
greatly reduced. Based upon these differences between BUD and FF at the in vitro 
level, the aim of this Chapter was to compare BUD and FF activity and function ex 
vivo in monocytes from healthy volunteers, severe asthmatics and COPD patients. 
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We also observed in Chapter 3 that the addition of long-acting 2-agonists (LABA), 
formoterol (FORM) and vilanterol trifenatate (VI), to BUD and FF, respectively 
(combinations that are used in clinical practice) reduced CXCL8 to a greater extent 
than the corticosteroid treatment alone. This probably reflected the additional 
contribution of the anti-inflammatory effect of the corticosteroid in the combination 
formulations over-and-above the single-agent LABA treatment (Adcock et al., 2002). 
Indeed, there is growing evidence for the molecular rationale of the complementary 
interactions and effects between corticosteroids and LABA both in vitro (Mak et al., 
1995, Eickelberg et al., 1999, Papakonstantinou et al., 2012) and in vivo (Usmani et 
al., 2005b, Orsida et al., 2001, Li et al., 1999), where studies have shown that 
corticosteroids up-regulate β2-receptors and LABA’s increase GR nuclear 
translocation. This molecular basis may explain the improvement in lung function, 
symptoms, disease exacerbations in both asthma and COPD achieved with the 
combination treatment than either drug alone in large patient clinical trials (Woolcock 
et al., 1996, Greening et al., 1994, Pauwels et al., 1997, Juniper et al., 1999, 
Calverley et al., 2007). The use of corticosteroids in combination with LABA is well 
established in national and international guidelines for treating patients with asthma 
and also those with COPD. Experimental evidence suggests there is a 
complementary action between corticosteroids and LABA (Mak et al., 1995, 
Eickelberg et al., 1999, Papakonstantinou et al., 2012, Usmani et al., 2005b, 
Baraniuk et al., 1997). In an asthmatic study, the combination of low-dose FP and 
SLM was as effective as high-dose FP on GR activation, gene transactivation and 
gene transrepression (Usmani et al., 2005b). Based upon these previous findings, 
the additional aim of this Chapter was to determine whether the complementary 
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effect of the LABA, FORM and VI, on their respective corticosteroids used in clinical 
practice, BUD and FF, could have a beneficial effect in primary monocytes from 
severe asthmatics and COPD patients who are characterised by corticosteroid 
insensitivity.       
 
6.2 Experimental protocols 
6.2.1 Screening visit  
Subjects attended a screening visit at the Asthma Lab of the Royal Brompton 
Hospital and underwent a medical history, assessment of current medications and 
smoking history and, if required, a medical examination. They also underwent 
spirometry testing to determine eligibility to enter the study. A review of the inclusion 
and exclusion criteria were carried out and written informed consent was obtained 
from each patient.  
 
Patients were allowed to use their current short-acting 2 agonists (SABA) and short-
acting muscarinic-antagonists (SAMA), and were asked to refrain for 12h from their 
LABAs, inhaled corticosteroid (ICS) and long-acting muscarinic-antagonists (LAMA) 
prior to the study visit. Theophylline (an oral tablet bronchodilator) was required to be 
stopped at least 3 days prior to the study visit. 
 
6.2.2 Study design 
Six healthy volunteers, 8 mild-to-moderate COPD patients and 4 severe asthmatics 
participated in this study. There was only one study visit per subject that lasted 
approximately 30min. Clinical assessment and lung function were measured and 
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80ml of venous blood taken during this visit. This study had Ethical approval 
(Research Ethics Committee Number: 11/SC/0037).  
 
The primary outcome of this study was to compare BUD- and FF-induced GR-GRE 
binding in blood monocytes from healthy volunteers, severe asthmatics and COPD 
patients. Secondary endpoints included the effects on inflammatory markers, CXCL8 
and IL-6, alone and in combination with LABA, FORM and VI. 
 
6.2.3 Monocytes from blood 
A sample of 80ml of venous blood was taken during the patient’s visit. The blood was 
separated by centrifugation using Ficoll-Paque (400xg for 30min at 22°C). The 
peripheral blood mononuclear cell (PBMC) monolayer was collected and washed with 
HANKS buffered solution at 300xg for 5min at 4°C. PBMCs were resuspended in 
RPMI-1640 complete media and seeded as 100µl of 2x106 cells/ml or 3ml of 2x106 
cells/ml in 96 and 6 well-plates respectively for 90min to allow monocyte adherence. 
Following 90min incubation, the supernatant was removed and monocytes forming a 
layer on the flask were resuspended in RPMI-1640 minimal media. 
 
6.2.4 Corticosteroid-induced GR activation 
Nuclear protein was extracted from blood monocytes using a nuclear protein 
extraction kit (Active Motif, Carlsbad, CA, USA). GR-GRE binding was detected using 
a TransAM-GR kit (Active Motif). We decided to use a concentration of 10-9M for 
each corticosteroid based on experimental data in U937 cells, as shown in Fig. 6.2.3.  
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Fig. 6.2.3 Fluticasone furoate (FF)-induced GR-GRE binding. U937 mononcytes were 
treated with FF for 2h. Nuclear extraction was carried out immediately and activated 
glucocorticoid receptor (GR) binding to glucocorticoid response elements (GRE) was 
determined by GR-GRE assay. Results are based on 3 independent experiments. *p<0.05 
vs. basal. 
 
6.2.5 Enzyme-linked immunosorbent assay (ELISA) 
Extracellular concentrations of CXCL8 and IL-6 were measured with the human 
Duoset ELISA kits (R&D Systems Europe, UK), according to the manufacturer’s 
instructions. 
  
6.2.6 Statistical methods 
All statistical comparisons were conducted using a multiplicative analysis of variance 
(ANOVA) model. P-values less than 5% were considered statistically significant. 
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6.3 Results 
6.3.1 Patient demographics 
Age-matched patients with mild-to-moderate COPD, severe asthma and healthy 
patients were studied. Eight patients with mild-to-moderate COPD (GOLD 1 and 2 
guidelines) and four patients with severe asthma defined according to the GINA 
guidelines were recruited. COPD patients had significantly lower mean FEV1 (% 
pred.) compared to their healthy age-matched counterparts (*p<0.05).  
 
 Healthy 
(n=6) 
Severe Asthma 
(n=4) 
COPD 
(n=8) 
Age  55 ± 6.7 60 ± 2.5 68 ± 8.0 
Gender (M/F) 3/3 2/2 4/4 
FEV1 (% pred.)  100 ± 15 54 ± 16 67 ± 22* 
FVC (% pred.)  100 ± 16 76 ± 14 90 ± 22 
FEV1/FVC (% pred.)  99 ± 5.5 72 ± 9.1 76 ± 18 
 
Table 6.1 Patient demographics. 6 healthy volunteers, 4 severe asthmatics and 8 COPD 
patients were recruited. Age, gender and several parameters of lung function were recorded. 
Definition of abbreviation: FEV1 = forced expiratory volume in 1 second; FVC = forced vital 
capacity. 
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6.3.2 Corticosteroid-induced GR activation in blood monocytes 
6.3.2.1 Comparison of BUD- and FF-induced GR-GRE binding  
We first compared BUD- and FF-induced GR-GRE binding in blood monocytes from 
healthy volunteers. As expected, BUD and FF at 10-9M, significantly induced GR-
GRE binding by 1.4±0.18- and 1.6±0.35-fold increase respectively relative to basal 
levels.  No significant difference was observed between FF- and BUD-induced GR-
GRE binding (Fig. 6.3.2.1). 
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Fig. 6.3.2.1 Comparison of budesonide (BUD)- and fluticasone furoate (FF)-induced 
GR-GRE binding blood monocytes derived from blood of healthy volunteers.  
Monocytes were isolated from peripheral blood mononuclear cells from 6 healthy volunteers. 
Following isolation, monocytes were stimulated with BUD or FF (both at 10-9M) for 2h. 
Immediately after 2h corticosteroid stimulation, nuclear extraction and GR-GRE binding was 
performed. *p<0.05 vs. basal.   
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6.3.2.2 BUD and FF-induced GR-GRE binding in severe asthma and COPD 
It has been previously reported that corticosteroid-induced GR activation in severe 
asthmatics is impaired (Irusen et al., 2002, Mercado et al., 2012). As a subpopulation 
of patients with severe asthma and COPD patients show a degree of corticosteroid 
insensitivity, we compared BUD- and FF-induced GR-GRE binding in blood 
monocytes from healthy volunteers, severe asthmatics and COPD patients. 
Following a 2h stimulation, BUD (10-9M) significantly induced GR-GRE binding by 
1.4±0.18 (healthy volunteers) and 1.9±0.2 (COPD) in blood monocytes, relative to 
basal levels (Fig. 6.3.2.2.1). Whereas in severe asthmatics, BUD (10-9M) was unable 
to induce GR-GRE binding relative to basal levels. There was no significant 
difference in BUD-induced GR-GRE binding between the treatment groups (Fig. 
6.3.2.2.1). FF (10-9M) also induced GR-GRE binding in COPD patients to a similar 
extent to that seen in healthy volunteers (2.4±0.77- vs. 1.6±0.35-fold increase, p = 
ns) (Fig. 6.3.2.2.2). In severe asthmatics, FF was also unable to cause a significant 
increase in GR-GRE binding compared to basal levels. There was also no significant 
difference in FF-induced GR-GRE binding between the treatment groups studied. 
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Fig. 6.3.2.2.1 Comparison of budesonide (BUD)-induced GR-GRE binding in blood 
monocytes from 6 healthy volunteers, 4 severe asthmatics and 8 COPD patients. 
Monocytes were isolated from peripheral blood mononuclear cells and stimulated with BUD 
at 10-9M for 2h. Immediately after this nuclear extraction and GR-GRE binding assays were 
performed.  Results represent mean±SEM. 
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Fig. 6.3.2.2.2 Comparison of fluticasone furoate (FF)-induced GR-GRE binding in 
blood monocytes from 6 healthy volunteers, 4 severe asthmatics and 8 COPD 
patients. Monocytes were isolated from peripheral blood mononuclear cells from subjects 
and stimulated with FF (10-9M) for 2h and nuclear extraction and GR-GRE assays 
performed. Results are presented as mean±SEM.  
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6.3.3 Pro-inflammatory cytokine secretion in monocytes 
Following corticosteroid-induced GR activation, activated nuclear GR dampens down 
gene transcription of pro-inflammatory genes, such as IL-8 and IL-6, which 
respectively encode for the pro-inflammatory mediators, CXCL8 and IL-6 (Barnes, 
2006b). The neutrophil chemoattractant, CXCL8, and the pro-inflammatory mediator, 
IL-6, are found in elevated levels in COPD and asthmatic patients (Keatings et al., 
1996, Barnes, 2008). We compared basal levels and IL-1β-induced CXCL8 and IL-6 
release from blood monocytes from 6 healthy volunteers, 4 severe asthmatics and 8 
COPD patients. We observed that IL-1β-induced a significant increase in CXCL8 and 
IL-6 levels in blood monocytes derived from all three subject groups (Fig. 6.3.3.1 & 
Fig. 6.3.3.2). We also noted basal levels of CXCL8 from COPD patients were 
significantly higher than in healthy volunteers (1940±277 vs. 808±191pg/ml, 
*p<0.05). Although, severe asthmatics had similar basal levels of CXCL8 compared 
to COPD patients, this did not quite reach statistical significance when compared to 
healthy volunteers (2304±810 vs. 808±191pg/ml, p=0.17) (Fig. 6.3.3.1a). 
Furthermore, after monocytes were stimulated for 16h with IL-1β (1ng/ml), CXCL8 
was markedly higher in monocytes from both severe asthmatics (10900±2600 vs. 
4670±667pg/ml, *p<0.05) and COPD patients (11500±1630 vs. 4670±667pg/ml, 
*p<0.05), compared to healthy volunteers. There was no significant difference in 
CXCL8 secretion between severe asthmatics and COPD patients.  
 
We also observed that basal levels of IL-6 were significantly higher in severe 
asthmatics compared to (i) COPD patients (2300±811 vs. 216±125pg/ml, #p<0.05) 
and (ii) healthy volunteers (2300±811 vs. 12.3±5.90pg/ml, *p<0.05). Although there 
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was a substantial difference in IL-6 basal levels between COPD and healthy 
volunteers, this did not reach statistical significance (216±125 vs. 12.3±5.90pg/ml, 
p=0.9).  
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Fig. 6.3.3.1 Basal and IL-1β-induced CXCL8 secretion from monocytes. Monocytes 
were isolated from peripheral blood mononuclear cells of 6 healthy, 4 severe asthmatic and 
8 COPD patients. Following isolation, monocytes were stimulated with IL-1β (1ng/ml) for 16h 
and CXCL8 levels were determined by ELISA. *p<0.05 vs. Healthy.   
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Fig. 6.3.3.2 Basal and IL-1β-induced IL-6 secretion from monocytes. Monocytes were 
isolated from peripheral blood mononuclear cells of 6 healthy, 4 severe asthmatic and 8 
COPD patients. Following isolation, monocytes were stimulated with IL-1β for 16 h and IL-6 
levels were determined by ELISA. *p<0.05 vs. Healthy. #p<0.05 vs. COPD.  
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Similarly, IL-1β-induced IL-6 was substantially higher in blood monocytes from 
severe asthmatics compared to (i) COPD patients (10900±2610 vs. 1520±592pg/ml, 
#p<0.05) and (ii) healthy volunteers (10900±2610 vs. 536±180pg/ml, *p<0.05). IL-1β-
induced IL-6 levels were not statistically different between COPD and healthy 
volunteers (1520±592 vs. 536±179pg/ml, p=0.29) even though mean levels were 
almost 3 times higher in COPD patients.   
 
6.3.4 Corticosteroid-mediated suppression of CXCL8  
So far, we have shown that IL-1β induces CXCL8 and IL-6 secretion in blood 
monocytes from severe asthmatics and COPD patients, compared with that of 
healthy volunteers. We next explored the suppressive effects of BUD and FF, alone 
and in combination with FORM and VI, respectively, on these pro-inflammatory 
mediators.  
 
6.3.4.1 Comparison of BUD and FF in monocytes from healthy volunteers 
Both BUD and FF reduced IL-1β-induced CXCL8 release in blood monocytes from 
healthy volunteers in a concentration-dependent manner with IC50 values of 
7.7±2.5x10-9 and 2.4±2.2x10-9M respectively. At the highest concentration (10-7M), 
BUD and FF suppressed CXCL8 by 59.1±5.1 and 64.0±7.4% respectively. Thus, 
there was no difference in the concentration-response curves for BUD- and FF-
mediated suppression of IL-1β-induced CXCL8 (Fig. 6.3.4.1.1).  
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Fig. 6.3.4.1.1 Comparison of budesonide (BUD)- and fluticasone furoate (FF)-mediated 
suppression of IL-1β-induced CXCL8 secretion from monocytes. Monocytes were 
isolated from peripheral blood mononuclear cells from 6 healthy subjects and stimulated with 
IL-1β (1ng/ml) for 16h in the presence and absence of BUD or FF. CXCL8 levels were 
determined and results shown as means±SEM of percent suppression of IL-1-stimulated 
levels.  
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Fig. 6.3.4.1.2 Comparison of Budesonide (BUD) and fluticasone furoate (FF)-mediated 
suppression of IL-1β-induced IL-6 secretion from monocytes. Monocytes were isolated 
from 6 healthy volunteers and stimulated with IL-1β for 16h and with varying concentrations 
of BUD and FF. IL-6 levels were determined and results shown as means±SEM of percent 
suppression of IL-1-stimulated levels. #p<0.05 vs. BUD (10-9M).  
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BUD and FF also suppressed IL-1β-induced IL-6 in a concentration dependent 
manner. The highest concentration (10-7M) of BUD and FF achieved similar levels of 
IL-6 suppression (62±3.7 vs. 64±3.4%, p=NS) with IC50 values of 1.0±1.6x10
-8 and 
1.4±2.0x10-9M respectively. In contrast, FF (10-9M) was more effective in 
suppressing IL-1β-induced IL-6 than the corresponding concentration of BUD 
(59±6.7 vs. 39±3.7% suppression, #p<0.05).  
 
6.3.4.2 Corticosteroid suppression of CXCL8 in severe asthma and COPD  
So far, we have shown that BUD and FF suppress IL-1β-induced CXCL8 to a similar 
extent in blood monocytes from healthy volunteers. We next explored the anti-
inflammatory effects of BUD and FF in severe asthmatics and COPD patients. In 
blood monocytes from severe asthmatics 10-11M BUD was as effective in 
suppressing CXCL8 as observed in healthy volunteers (19.8±11.8 vs. 23.1±5.4% 
suppression). In contrast, BUD-mediated suppression of IL-1β-induced CXCL8 in 
blood monocytes from COPD patients was completely abolished at the lowest 
concentration of BUD (10-11M) compared to that seen in healthy volunteers (-5.9±9.2 
vs. 23.1±5.4%, p<0.05). Additionally, BUD-mediated suppression of IL-1β-induced 
CXCL8, at the highest concentration of 10-7M, was reduced in COPD patients by 11 
% compared to healthy volunteers (48.1±6.6 vs. 59.1±5.1%) although this did not 
reach statistical significance (p=0.23). We observed an almost 15-fold increase in the 
concentration of BUD required to obtain a 50% inhibition of CXCL8 in blood 
monocytes from severe asthmatics compared to healthy volunteers. Again, this did 
not reach statistical significance (1.2±7.6 x10-7 vs 7.7±2.6 x10-9M, p=ns) (Fig. 
  
155 
 
6.3.4.2.3). There was no significant difference in IC50 values between COPD patients 
and healthy volunteers (5.0±2.7 x10-8 vs. 7.7±2.6 x10-9M, p=0.23).  
 
Next, we examined FF-mediated suppression of CXCL8 in severe asthmatics and 
COPD patients compared to healthy volunteers. We found FF (10-11-10-7M) was as 
effective in reducing IL-1β-induced CXCL8 in severe asthmatics as observed in 
healthy volunteers for each corresponding concentration measured (Fig. 6.3.4.2.2a). 
The IC50 values were 4.5±2.2x10
-9 and 2.4±2.2x10-9M in severe asthmatics and 
healthy volunteers, respectively (Fig. 6.3.4.2.2a). In COPD patients, FF-mediated 
suppression of IL-1β-induced CXCL8 was similar to that in healthy volunteers, with 
IC50 values of 9.8±2.6x10
-9 and 2.4±2.2x10-9M respectively (Fig. 6.3.4.2.2a). There 
were no significant differences at each corresponding concentration of FF between 
healthy volunteers, and severe asthmatics and COPD patients. 
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Fig. 6.3.4.2.1 Budesonide (BUD)-mediated suppression of IL-1β-induced CXCL8 in 
blood monocytes from healthy volunteers, severe asthmatics and COPD patients. 
Monocytes were isolated from peripheral blood mononuclear cells from 6 healthy, 4 severe 
asthmatics and 8 COPD patients. Cells were stimulated with IL-1β (1ng/ml) for 16h with 
varying concentrations of BUD. a) compares BUD-mediated CXCL8 suppression between 
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healthy volunteers and severe asthmatics; b) compares BUD-mediated suppression of 
CXCL8 between healthy volunteers and COPD patients. CXCL8 levels were determined by 
ELISA.  Results expressed as means±SEM of percent inhibition of the IL-1 response. 
lo g  [F F ], M
C
X
C
L
8
 s
e
c
r
e
ti
o
n
(r
e
la
ti
v
e
 t
o
 I
L
-1

)
-1 4 -1 2 -1 0 -8 -6
0
5 0
1 0 0
H e a lthy S e ve re  A s th m a
lo g  [F F ], M
C
X
C
L
8
 s
e
c
r
e
ti
o
n
(r
e
la
ti
v
e
 t
o
 I
L
-1

)
-1 4 -1 2 -1 0 -8 -6
0
5 0
1 0 0
H e a lthy C O P D
a ) b )
Fig. 6.3.4.2.2 Fluticasone furoate (FF)-mediated suppression of IL-1β-induced CXCL8 
in blood monocytes from 6 healthy volunteers, 4 severe asthmatics and 8 COPD 
patients. Monocytes were isolated from peripheral blood mononuclear cells and stimulated 
with IL-1β (1ng/ml) for 16h and varying concentrations of FF. a) compares FF-mediated 
CXCL8 suppression between healthy volunteers and severe asthmatics and b) compares 
FF-mediated suppression of CXCL8 between healthy volunteers and COPD patients. 
CXCL8 levels were determined by ELISA.  Results expressed as means±SEM of percent 
inhibition of the IL-1 response. 
 
 
 
 
 
 
 
  
157 
 
Corticosteroid-mediated suppression of IL-1β-induced CXCL8 
  IC50 
 
FF 
Healthy 2.4 ± 2.2 x10-9 
Severe Asthma 4.5 ± 2.2 x10-9 
COPD 9.8 ± 2.6 x10-9 
 
BUD 
Healthy 7.7 ± 2.6 x10-9 
Severe Asthma 1.2 ± 7.6 x10-7 
COPD 5.0 ± 2.7 x10-8 
 
Fig. 6.3.4.2.3 Comparison of Budesonide (BUD)- and fluticasone furoate (FF)-mediated 
suppression of IL-1β-induced CXCL8 from peripheral blood monocytes isolated from 
6 healthy volunteers, 4 severe asthmatics and 8 COPD patients.  
 
6.3.5 Corticosteroid-mediated suppression of IL-6 secretion 
We next compared BUD- and FF-induced suppression of IL-1β-induced IL-6 in blood 
monocytes from the three patient groups. BUD (10-11M) suppressed IL-1β-induced 
IL-6 to a similar extent in cells from severe asthmatics as compared to those from 
healthy volunteers (30±9.7 vs. 17±5.2%, p=ns) with IC50 values of 1.2±5.3x10
-8 and 
1.0±1.6 x10-8M respectively (Fig. 6.3.5.1a). Furthermore, although BUD (10 -7M)-
mediated suppression of IL-1β-induced IL-6 secretion was 13% less in monocytes 
from severe asthmatics compared to healthy volunteers, this did not reach statistical 
significance (p=0.29). BUD was equally effective at suppressing IL-6 release from 
cells isolated from severe asthmatics at 10-9M and 10-7M (45±6.0 vs 48±12%, p=ns). 
This is in contrast to the situation in cells from healthy volunteers where there was a 
significant additional reduction in IL-6 secretion between the two BUD concentrations 
(38.7±4.5 vs. 61.7±3.7% repression, p<0.05) (Fig. 6.3.5.1a). In cells from COPD 
patients, all BUD concentrations (10-11 to 10-7M) were all equally as effective in 
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suppressing IL-6 secretion as observed in healthy volunteers with IC50 values of 
1.0±2.1x10-8 and 1.0±1.6x10-8M respectively (Fig. 6.3.5.1b). 
 
Finally, each corresponding concentration of FF suppressed IL-1β-induced IL-6 to a 
similar extent in all three patient groups, with IC50 values of 1.4±2.0x10
-9 (Healthy 
volunteers), 5.3±2.5x10-9 (severe asthmatics) and 1.7±1.8x10-9M (COPD) 
respectively. The effects of BUD and FF reached a maximum at 10-9M with respect 
to suppression of IL-1β-induced IL-6 secretion in severe asthmatics.  In COPD 
patients, FF also suppressed IL-1β-induced IL-6 in a concentration-dependent 
manner (Fig. 6.3.5.2). 
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Fig. 6.3.5.1 Budesonide (BUD)-mediated suppression of IL-1β-induced IL-6 in blood 
monocytes from 6 healthy volunteers, 4 severe asthmatics and 8 COPD patients. 
Monocytes were isolated from peripheral blood mononuclear cells and stimulated with IL-1β 
(1ng/ml) for 16h and varying BUD concentrations. Graphs show a) BUD-mediated IL-6 
suppression between healthy volunteers and severe asthmatics and b) BUD-mediated IL-6 
suppression between healthy volunteers and COPD patients. IL-6 levels were determined 
and results expressed as means±SEM of percent inhibition of the IL-1 response.   
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Fig. 6.3.5.2 Fluticasone furoate (FF)-mediated suppression of IL-1β-induced IL-6 in 
blood monocytes from 6 healthy volunteers, 4 severe asthmatics and 8 COPD 
patients. Monocytes were isolated and stimulated with IL-1β for 16h and varying 
concentrations of FF. Graphs show a) FF-mediated IL-6 suppression between healthy 
subjects and severe asthmatics and b) FF-mediated suppression of IL-6 between healthy 
subjects and COPD patients. IL-6 levels were determined and results expressed as 
means±SEM of percent inhibition of the IL-1 response.   
 
Corticosteroid-mediated suppression of IL-1β-induced IL-6 
  IC50 
 
FF 
Healthy 1.4 ± 2.0 x10-9 
Severe Asthma 5.3 ± 2.5 x10-9 
COPD 1.7 ± 1.8 x10-9 
 
BUD 
Healthy 1.0 ± 1.6 x10-8 
Severe Asthma 1.2 ± 3.3 x10-8 
COPD 1.1 ± 2.1 x10-8 
 
Fig. 6.3.5.3 Comparison of Budesonide (BUD)- and fluticasone furoate (FF)-mediated 
suppression of IL-1β-induced IL-6 from peripheral blood monocytes isolated from 6 
healthy volunteers, 4 severe asthmatics and 8 COPD patients.  
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6.3.6 LABA effects on corticosteroid-mediated suppression of CXCL8 
The combination of LABA with low dose corticosteroids is more effective in 
dampening down inflammation than monotherapy with high dose corticosteroids in 
mild-to-moderate asthmatics (Usmani et al., 2005b, Papakonstantinou et al., 2012, 
Woolcock et al., 1996). In Chapter 3, we showed low concentrations of the LABA 
FORM and VI significantly enhanced corticosteroid-mediated suppression of IL-1β-
induced CXCL8 in a monocyte cell line. As observed in our ex vivo study (section 
6.2) and consistent with other investigations, CXCL8 is highly expressed in COPD 
patients (Keatings et al., 1996). Several studies in cells extracted from COPD 
patients have shown high dose corticosteroids fail to reduce pro-inflammatory 
markers (Culpitt et al., 1999, Keatings et al., 1997, Pauwels et al., 1997). In sputum 
macrophages of COPD patients, high doses of budesonide (800 mg twice daily) 
failed to suppress inflammatory markers (Keatings et al., 1997). We therefore 
explored whether FORM and VI in combination with their respective corticosteroids 
used in clinical practice, BUD and FF, could enhance corticosteroid-mediated 
suppression of CXCL8. Secondly, in COPD patients, where there is an element of 
corticosteroid insensitivity, whether LABA (10-9M) could restore corticosteroid 
sensitivity.  
 
We observed FORM and VI both at 10-9M, had no significant effect on IL-1β-induced 
CXCL8 (Fig. 6.3.6.1 & Fig. 6.3.6.2). In healthy volunteers, BUD at 10-11M in 
combination with FORM (10-9M) caused a greater suppression of IL-1β-induced 
CXCL8 than BUD (10-11M) alone, but this did not reach statistical significance 
(40.0±7.0 vs. 23.0±5.4%, p=0.09) (Fig. 6.3.6.1a). Importantly, BUD at 10-11M in 
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combination with FORM (10-9M) was as effective as the higher concentration of BUD 
at 10-9M alone (40.0±7.0 vs. 44.4±11.4%, p=ns). Whereas in COPD patients, a lower 
concentration of BUD (10-11M) in combination with FORM (10-9M) was not as 
effective in reducing CXCL8 levels as the higher concentration of BUD (10-9M) alone 
(7.4±11.0 vs. 40.2±6.4%, p<0.05) (Fig. 6.3.6.1b). Importantly in COPD patients, 
FORM at 10-9M was unable to restore BUD (10-11M) responsiveness (7.4±11.0 vs. -
5.9±9.2%, p = ns).  
 
In cells from healthy volunteers, VI (10-9M) did not enhance FF (10-11M)-mediated 
suppression of IL-1β-induced CXCL8 (40.0±7.0 vs. 24.4±6.1%, p=0.19). However, a 
lower concentration of FF (10-11M) in combination with VI (10-9M) was as effective as 
a higher concentration of FF (10-9M) (40.0±7.0 vs. 51.0±8.3%, p=ns) (Fig. 6.3.6.2a). 
Whereas in COPD patients, FF (10-11M) in combination with VI (10-9M) was not as 
effective as the higher concentration of FF (10-9M) in suppressing CXCL8 (22.7±7.7 
vs. 50.8±4.5%, *p<0.05) (Fig. 6.3.6.2b).  
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Fig. 6.3.6.1 Comparison of Budesonide (BUD) alone and in combination with 
formoterol (FORM). Blood monocytes from healthy volunteers and COPD patients were 
stimulated with IL-1β (1ng/ml) followed by BUD alone and in combination with FORM. 16h 
following IL-1β stimulation the supernatant was collected and CXLC8 levels were 
determined. Results are expressed as means±SEM of percent inhibition of the IL-1 
response. *p<0.05 vs. BUD (10-11M) and FORM (10-9M). 
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Fig. 6.3.6.2 Comparison of Fluticasone furoate (FF) alone and in combination with 
vilanterol trifenatate (VI). Blood monocytes from healthy volunteers and COPD patients 
were stimulated with IL-1β (1ng/ml) followed by FF alone and in combination with VI. 16h 
following IL-1β stimulation the supernatant was collected and CXLC8 levels were 
determined. Results are expressed as means±SEM of percent inhibition of the IL-1 
response. *p<0.05 vs. FF (10-11M). 
  
163 
 
6.4 Discussion 
In Chapter 4, we showed that in an in vitro model of oxidative stress associated with 
heightened inflammatory response that replicated the key pathological changes in 
severe asthma and COPD, BUD-induced GR nuclear localisation and suppression of 
CXCL8 were reduced. Based upon these results, we undertook an ex vivo study 
involving patients with severe asthma and COPD, both corticosteroid insensitive 
diseases, and used healthy volunteers as a control group to further investigate our 
findings. As expected, COPD patients had significant airway obstruction, deemed by 
a reduced FEV1 percentage of predicted values, compared to healthy volunteers 
(Table 6.1). The pro-inflammatory profile in blood monocytes from severe asthmatics 
and COPD patients was consistent with previous studies (Daldegan et al., 2005, 
Morjaria et al., 2011).  
 
Corticosteroids dampen down inflammation via activation of the GR, which then binds 
to GRE on corticosteroid-inducible genes (Barnes, 2006b). We observed no 
significant difference in BUD- and FF-induced GRE binding between healthy 
volunteers and COPD patients. Whereas in severe asthmatics, both BUD and FF 
were unable to induce GR-GRE binding, consistent with data reported in PBMCs of 
corticosteroid-insensitive severe asthmatics, where GR ligand-binding affinity in the 
nucleus was significantly reduced (Irusen et al., 2002).  
 
We next compared BUD and FF suppression of IL-1β-induced CXCL8 and IL-6 
between all three patient groups. In COPD patients, BUD-mediated suppression of 
IL-1β-induced CXCL8 was significantly reduced at 10-11M, whereas FF retained its 
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sensitivity. This experimental finding was consistent with our previous experiments in 
our in vitro model (Chapter 4). However, there were no significant differences in IC50 
values for BUD in severe asthmatics and in COPD patients compared to healthy 
volunteers. This is in contrast to recent findings, where corticosteroid mediated 
suppression of pro-inflammatory mediators was severely reduced in PBMCs 
extracted from severe asthmatics and COPD patients (Mercado et al., 2012, To et al., 
2010). This difference in corticosteroid sensitivity observed between our results and 
the aforementioned studies in severe asthmatics and COPD patients may be due to 
several reasons. Firstly, evidence suggests that the extent of corticosteroid 
insensitivity may correlate to the severity of disease (To et al., 2010). Patients with 
COPD enrolled in our study had milder airway obstruction compared to those 
enrolled by Ito and colleagues, where moderate-to-severe COPD patients were 
recruited. Secondly, Ito and colleagues demonstrated corticosteroid insensitivity in 
PBMCs, whereas we explored corticosteroid sensitivity in monocytes. Thirdly, a 
multitude of pro-inflammatory mediators are involved in driving the pathology in 
COPD, besides IL-1β, CXCL8 and IL-6 (Barnes, 2008). It may be that corticosteroid 
suppression of other pro-inflammatory mediators may be reduced in our patient 
groups. This can be assessed by the use of gene expression arrays or deep 
sequencing of RNA samples obtained from our patients. In addition, the use of 
different inflammatory stimuli may result in differences in corticosteroid sensitivity. For 
example, Mercado and colleagues showed that TNF--induced CXCL8 was 
significantly less sensitive to dexamethasone in PBMCs of patients with severe 
asthma than healthy controls (Mercado et al., 2012).    
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In mild-to-moderate asthmatics, low doses of inhaled corticosteroids in combination 
with LABA have been shown to be more effective in suppressing pro-inflammatory 
mediators than high dose corticosteroids alone (Woolcock et al., 1996, Usmani et al., 
2005b, Eickelberg et al., 1999). In U937 monocytes, Rossios and colleagues showed 
that the LABA FORM, but not SLM, was able to reverse corticosteroid insensitivity, 
via inhibition of the PI3K pathway, suggesting FORM may be able to partially reverse 
corticosteroid insensitivity in COPD (Rossios et al., 2012). We observed that BUD 
(10-11M) in combination with FORM (10-9M) suppressed CXCL8 to a similar extent as 
a higher concentration of BUD (10-9M) alone in healthy volunteers (Fig. 6.3.6.1a). 
Similar results were observed for the combination of FF with VI (Fig. 6.3.6.2a). 
However, in COPD patients, both FORM and VI were unable to enhance BUD- and 
FF-mediated suppression of CXCL8 (Fig. 6.3.6.1b & Fig. 6.3.6.2b). This is 
inconsistent with the data reported by Rossios and colleagues, where FORM was 
able to restore dexamethasone sensitivity in PBMCs from COPD patients (Rossios et 
al., 2012). In this study, Rossios and colleagues used TNF- to stimulate CXCL8 
release, whereas we used IL-1β. At the molecular level, differences in the signalling 
pathways activated by these two inflammatory mediators may explain our results  
(Nee et al., 2004). Therefore, examination of the gene profiles and signalling 
pathways between these two stimuli may indicate key relative corticosteroid resistant 
targets. In subsequent studies using an in vitro model of H2O2–induced corticosteroid 
insensitivity, Rossios and colleagues noted that FORM was able to partially inhibit 
PI3K-δ-dependent Akt phosphorylation, whereas SLM had no effect. Pre-treatment 
with IC87114, a PI3K inhibitor, restored the complementary effect of SLM on the 
corticosteroid (Rossios et al., 2012).  
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Finally, the inability of BUD and FF to induce GR-GRE binding in patients with severe 
asthma and the failure of BUD at a low concentration to suppress CXCL8 in COPD 
patients support our findings in our in vitro model of oxidative stress-induced 
corticosteroid insensitivity (Chapter 4). Some aspects of corticosteroid insensitivity 
observed in our in vitro model, not seen in blood monocytes, better reflect patterns of 
corticosteroid insensitivity observed in monocytes/macrophages obtained from the 
airways of patients with severe asthma and COPD (Culpitt et al., 2003). In Chapter 5, 
we were able to demonstrate that reduced GR nuclear import, under conditions of 
oxidative stress and heightened inflammatory response, was associated with 
degradation of nuclear RanGTP, an essential co-factor for importin-7 mediated GR 
nuclear import. This does suggest that the inability of BUD and FF to induce GR-GRE 
binding in patients with severe asthma may be due to impairment of pathways that 
regulate GR nuclear import. It would be essential to characterise the role of the 
importin-7 pathway in these patient samples, as a potential novel mechanism of 
corticosteroid insensitivity. 
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CHAPTER 7 
GENERAL DISCUSSION & FUTURE DIRECTIONS 
 
General Discussion 
Corticosteroids are widely used in the treatment of chronic inflammatory diseases. 
However in COPD, cystic fibrosis and severe asthma, corticosteroids fail to improve 
the underlying inflammation (Suissa and Barnes, 2009, Vestbo et al., 1999, Balfour-
Lynn and Welch, 2009, Davies and Richeldi, 2002). Recent advances in the cellular 
and molecular basis of pathology in asthma and COPD have revealed several 
biological targets that may contribute to the relative corticosteroid insensitivity 
observed in the disorders severe asthma and COPD (Barnes, 2008). These targets 
include impaired GR nuclear translocation, reduced HDAC-2 activity and heightened 
pro-inflammatory transcription factor activity. 
 
Although in vitro and in vivo data support a role for impaired GR nuclear 
translocation as a potential mechanism of corticosteroid insensitivity in asthma 
(Irusen et al., 2002, Mercado et al., 2012, Okamoto et al., 1999), as of yet, no 
published data has confirmed this in COPD patients. Furthermore, the mechanisms 
that govern GR nuclear translocation are mostly unknown. Subsequently, not much 
is known about the mechanisms under conditions of corticosteroid insensitivity. 
There is growing evidence that excess reactive oxygen species (ROS) generated by 
inflammatory and immune cells of the lung leads to oxidative stress  (Kirkham and 
Rahman, 2006), which plays a crucial role in the amplification of redox-sensitive pro-
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inflammatory transcription factors that leads to corticosteroid insensitivity (Lee and 
Yang, 2012, Barnes, 2008). In this Discussion Chapter, I summarise my novel 
findings concerning the role of GR nuclear translocation under conditions of oxidative 
stress associated with a heightened inflammatory response. 
 
In Chapter 3, we demonstrated that fluticasone furoate (FF) suppressed IL-1β-
induced CXCL8 to a greater extent than budesonide (BUD) in U937 monocytes (Fig. 
3.3.2.1). This was associated with a greater induction of GR nuclear translocation by 
FF compared to BUD (section 3.3.1). There were no observed differences between 
FF and fluticasone propionate (FP). The combination of BUD and formoterol (FORM) 
and, FF and vilanterol trifenatate (VI) caused a greater reduction in CXCL8 release 
than each corticosteroid alone (Fig. 3.3.2.2). There was no difference in CXCL8 
suppression between the combination of FP and salmeterol (SLM) and FP alone. In 
the 20h corticosteroid washout experiments, FF maintained its ability to induce GR 
nuclear localisation and to suppress IL-1β-induced CXLC8, whereas BUD and FP 
were unable to maintain these outputs (section 3.3.4). These differences between 
the corticosteroids may be partly explained by FF’s greater affinity for the GR 
(Valotis and Hogger, 2007, Valotis et al., 2004). 
 
In Chapter 4, we demonstrated that hydrogen peroxide (H2O2) caused a significant 
increase in intracellular and mitochondrial oxidative stress (section 4.3.1). 
Specifically, the significant increase in mitochondrial superoxide anion levels in our 
U937 model of oxidative stress mirrored data that has been shown by other 
investigators ex vivo in diaphragmatic muscle biopsies from COPD patients, where 
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superoxide anion levels in the mitochondria and membrane compartments was 
significantly greater than in healthy control subjects (Marin-Corral et al., 2009). We 
also observed, H2O2 significantly enhanced IL-1β-induced NF-B activity (Fig. 
4.3.4.2) and CXCL8 secretion (Fig. 4.3.4.1), key inflammatory markers that have 
been observed to be elevated in COPD (Barnes, 2008).  This provides further 
experimental evidence of the relevance of our oxidative stress-driven inflammatory 
model as an in vitro model of COPD.  
 
Subsequently, we showed that H2O2 significantly reduced BUD- and FP-mediated 
suppression of IL-1β-induced CXCL8, consistent with data reported in peripheral 
blood mononuclear cells (PBMCs) of COPD patients and severe asthmatics, and in 
sputum macrophages of COPD patients (Mercado et al., 2012, To et al., 2010, 
Keatings et al., 1997). In Chapter 4, we were also able to demonstrate that oxidative 
stress-induced corticosteroid insensitivity was associated with impaired GR nuclear 
import (Fig. 4.3.6).  This was consistent with experimental data reported in PBMCs of 
corticosteroid-insensitive asthmatics, where ligand-binding to GR was severely 
reduced (Irusen et al., 2002). In addition, we found FF-mediated suppression of 
CXCL8 and FF-induced GR nuclear localisation was resistant to the effects of H2O2. 
This highlights the relative nature of this corticosteroid insensitivity and raises the 
potential that novel corticosteroids may be able to reverse this effect (Crim et al., 
2001, Valotis and Hogger, 2007, Rossios et al., 2012). Greater occupation of the 
lipophilic 17- α alpha pocket of the GR by FF over FP may contribute to FF’s 
resistance to oxidative stress (Biggadike et al., 2008).  
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In Chapter 5, we demonstrated that members of the importin (section 5.3.2) and 
exportin (section 5.3.6) family of nuclear transport receptors are essential in the 
regulation of GR nucleocytoplasmic shuttling which is necessary for corticosteroid 
function. Specifically, for the first time in the literature we demonstrated that importin-
7 knockdown significantly reduced FP-mediated suppression of IL-1β-induced 
CXCL8 and impaired FP-induced GR nuclear localisation. In parallel, we were also 
able to see that leptomycin B (LMB), a potent inhibitor of exportin-1, enhanced BUD- 
and FF-induced GR nuclear localisation at 2h, although, it was unable to reverse the 
loss of BUD-induced GR nuclear localisation following a 20h washout. It is likely that 
different mechanisms regulate GR nucleocytoplasmic shuttling in the presence and 
absence of the ligand, and that they are time-dependent. Savory and colleagues 
showed that rapid nuclear import of GR (4 to 6 minutes) was mediated through the 
NL1 fragment of GR, whereas slow GR nuclear import (45 to 60 min) was NL2-
mediated (Savory et al., 1999).  
 
We also showed in subsequent experiments in U937 monocytes that nuclear 
RanGTP, an essential co-factor for importin-7 mediated nuclear import of cargo 
proteins, was significantly degraded in our in vitro model of oxidative stress-induced 
corticosteroid insensitivity (Fig. 5.3.5). These findings support the notion that 
impaired corticosteroid-induced GR nuclear import leads to corticosteroid 
insensitivity, which may be partly due to degradation of the importin-7 pathway. 
Furthermore, these findings also suggest that the importin-7 pathway, in particular 
nuclear RanGTP, is potentially a novel therapeutic target for restoring corticosteroid 
insensitivity.            
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In Chapter 6, we assessed corticosteroid insensitivity in blood monocytes from 
severe asthmatics and mild-to-moderate COPD patients, compared to healthy 
volunteers. In both asthmatics and COPD patients, we were unable to detect any 
significant difference in IC50 values for BUD- and FF-mediated suppression of 
CXCL8 (Fig. 6.3.4.2.3) and IL-6 (Fig. 3.5.3), compared to their healthy counterparts. 
In addition, we observed no difference in BUD or FF-induced GR-GRE binding 
between all three groups. However, BUD was unable to suppress CXCL8 at a low 
concentration in COPD patients, compared to healthy volunteers, suggesting relative 
corticosteroid insensitivity. Previously, it has been reported that at the cellular level, 
macrophages, T-cells, epithelial cells and PBMCs obtained from severe asthmatics 
and COPD patients are corticosteroid insensitive (Keatings et al., 1997, Rossios et 
al., 2012, To et al., 2010, Mercado et al., 2012). In the process of extraction of 
monocytes from PBMCs, we may have lost vital cellular components in PBMCs that 
give rise to corticosteroid insensitivity, which may explain why we did not observe a 
significant loss in anti-inflammatory effects of corticosteroids in our patients although 
there were some changes in the magnitude of the effects seen. 
 
Secondly, the patients enrolled in our study had milder airway obstruction compared 
to those enrolled by Keatings and colleagues (67 vs. 35 mean FEV1 (% pred.)) 
(Keatings et al., 1997). Data reported from Ito and colleagues suggests that severity 
of disease correlates to the extent of corticosteroid insensitivity (To et al., 2010). 
Corticosteroids downregulate a multitude of pro-inflammatory mediators and 
therefore it would be important to assess corticosteroid suppression of other pro-
inflammatory mediators, in addition to CXCL8 and IL-6. Furthermore, Mercado and 
  
172 
 
colleagues used TNF- as the inflammatory stimuli, whereas in our study we used 
IL-1β (Mercado et al., 2012). Variations in the signaling pathways activated by TNF-
 and IL-1β may also contribute to differences in corticosteroid sensitivity (Nee et al., 
2004). Nee and colleagues demonstrated that the differential effects of TNF- and 
IL-1β on matrix metalloproteinase-9 (MMP-9) are mediated through the TNF-receptor 
I (TNF-RI) and IL-1-receptor (IL-1-R) and the various signaling pathways PKC, 
extracellular signal-regulated protein kinase (ERK1/2) and p38MAPK.  
 
Finally, the number of severe asthmatic patients we recruited was fewer than the 
number of subjects recruited by Mercado and colleagues. This may also have 
contributed to our inability to detect statistical significance in corticosteroid-mediated 
suppression of pro-inflammatory mediators (Mercado et al., 2012). Surprisingly, 
although we observed no significant reduction in BUD- or FF-mediated suppression 
of CXCL8 or IL-6 in blood monocytes from severe asthmatics, compared to healthy 
volunteers, both corticosteroids were unable to induce GR-GRE binding. This loss in 
GR-GRE binding is consistent with findings in PBMCs of severe asthmatics, where 
dexamethasone-induced GR nuclear translocation, was severely reduced (Irusen et 
al., 2002).  
 
In summary, I have shown that importin-7 is important in ligand-mediated GR nuclear 
import and that this process is affected by oxidative stress in a cell line.  Modulation 
of this mechanism may affect GR function in cells from patients with severe asthma 
and more severe COPD (Fig 7.1).  Confirmation of this effect in patient samples from 
the site of disease is essential. 
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Fig. 7.1 Potential role of importin-7-RanGTP complex in oxidative stress-induced 
corticosteroid insensitivity. Corticosteroid-induced GR nuclear translocation is essential 
for corticosteroid-mediated of pro-inflammatory mediators. Importin-7 binds to and mediates 
nuclear translocation of the glucocorticoid receptor (GR). Once in the nucleus, nuclear 
RanGTP binds to importin-7 resulting in the dissociation of the importin-7 and GR complex. 
Consequently, the GR is able to move through the nucleus and either binds to glucocorticoid 
response elements on corticosteroid-inducible genes or recruits histone deacetylase 
(HDAC)-2 to prevent the gene transcription of pro-inflammatory mediators. Under conditions 
of oxidative stress, nuclear RanGTP is reduced, which consequently prevents the 
dissociation of importin-7 and GR leading to corticosteroid insensitivity. 
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Future directions 
We need to show our novel findings concerning the role of importin-7 in our in vitro 
model can also be observed in primary cells and in vivo in airway or blood cells from 
patients with severe asthma and COPD. Several members of the nuclear importin 
family, besides importin-7, have been shown to interact and mediate GR nuclear 
translocation, using GR purified from rat liver and S-methionine-labelled fragments of 
GR in reticulocyte lysate (Freedman and Yamamoto, 2004, Vandevyver et al., 2012). 
It will be important to identify the role of other nuclear import in receptors in GR 
nucleocytoplasmic shuttling. More importantly, nuclear RanGTP levels need to be 
quantified in corticosteroid insensitive and sensitive individuals to determine if there 
is a difference in these states so as to further validate this biological entity as a 
potential novel therapeutic target to reverse corticosteroid insensitivity.  
 
Indeed, nuclear RanGTP is maintained by 2 enzymes, cytoplasmic RanGTPases-
activating protein (RanGAP), which hydrolyses RanGTP to RanGDP, and the 
nuclear RanGDP/GTP-activating protein (RANGEF), which hydrolyses RanGDP to 
RanGTP (Poon and Jans, 2005, Wagstaff and Jans, 2009). It will be important to 
determine whether reduced nuclear RanGTP levels seen under conditions of 
oxidative stress is due to an imbalance of these enzymes. A combination of in vitro 
enzymatic assays along with siRNA-mediated knockdown or overexpression of each 
enzyme may more closely define a role for these enzymes in GR nuclear import.  In 
addition, immunoprecipitation assays and site-directed mutagenesis of GR and 
importin-7 may identify key interaction sites between these two proteins to allow 
better understanding of the mechanisms of GR nuclear import. The use of SILAC 
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analysis may also determine whether other proteins are involved in GR nuclear 
import.  Genome-wide analysis using gene arrays or deep sequencing of the effect 
of ROS-stress on GR function would also be of interest and could be linked to 
alterations in GR function in primary monocytes from patients with COPD or severe 
asthma. 
 
As we were unable to show corticosteroid insensitivity in blood monocytes from 
severe asthmatics and COPD patients, it will be necessary to extract PBMCs and 
alveolar macrophages which have been reported to be corticosteroid insensitive, and 
determine whether this loss in corticosteroid insensitivity is associated with impaired 
GR nuclear translocation. Indeed, recruiting further numbers of severe asthmatic 
patients may validate our initial results in blood monocytes and enable us to apply 
statistical analyses. We measured GR-GRE binding in this study as fewer cells are 
required for quantification. However measurement of nuclear GR levels, which 
directly impact on downregulation of pro-inflammatory genes by corticosteroids, will 
be useful as well as a readout of GR-transactivation such as DUSP1 or GILZ 
expression. 
 
Use of gene expression arrays or deep sequencing may be applied to RNA samples 
obtained from monocytes isolated in this study under the various conditions 
examined.  Statements regarding corticosteroid function on the expression of 1 gene 
may not hold true for a host of other genes.  It will be important to establish a 
genome-wide measure of Bud and FF function in these cells regarding both 
transactivation and transrepression functions. 
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There is much interest in the role of epigenetic control of GR function and in 
particular GR interaction with the DNA-chromatin backbone.  Genome-wide analysis 
of GR-nucleosome interaction using ChIP-seq analysis in ROS-treated cells or 
primary cells from patients with disease may further elucidate mechanisms important 
for ROS-mediated changes in GR function. 
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